%PDF-1.3
%
11 0 obj
<>>>/BBox[0 0 612 792]/Length 133>>stream
xA0}O1K]('@J)}@n/̟{:UunRLSzfuyIAяnmM)Ɍ3|ږ}yt[[%tJCb8WS+n{;'G
endstream
endobj
7 0 obj
<>>>/BBox[0 0 612 792]/Length 133>>stream
xA0}O1K]('@J)}@n/̟{:UunRLSzfuyIAяnmM)Ɍ3|ږ}yt[[%tJCb8WS+n{;'G
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 133>>stream
xA0}O1K]('@J)}@n/̟{:UunRLSzfuyIAяnmM)Ɍ3|ږ}yt[[%tJCb8WS+n{;'G
endstream
endobj
9 0 obj
<>>>/BBox[0 0 612 792]/Length 133>>stream
xA0}O1K]('@J)}@n/̟{:UunRLSzfuyIAяnmM)Ɍ3|ږ}yt[[%tJCb8WS+n{;'G
endstream
endobj
10 0 obj
<>>>/BBox[0 0 612 792]/Length 133>>stream
xA0}O1K]('@J)}@n/̟{:UunRLSzfuyIAяnmM)Ɍ3|ږ}yt[[%tJCb8WS+n{;'G
endstream
endobj
3 0 obj
<>>>/BBox[0 0 612 792]/Length 133>>stream
xA0}O1K]('@J)}@n/̟{:UunRLSzfuyIAяnmM)Ɍ3|ږ}yt[[%tJCb8WS+n{;'G
endstream
endobj
4 0 obj
<>>>/BBox[0 0 612 792]/Length 133>>stream
xA0}O1K]('@J)}@n/̟{:UunRLSzfuyIAяnmM)Ɍ3|ږ}yt[[%tJCb8WS+n{;'G
endstream
endobj
8 0 obj
<>>>/BBox[0 0 612 792]/Length 133>>stream
xA0}O1K]('@J)}@n/̟{:UunRLSzfuyIAяnmM)Ɍ3|ږ}yt[[%tJCb8WS+n{;'G
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 133>>stream
xA0}O1K]('@J)}@n/̟{:UunRLSzfuyIAяnmM)Ɍ3|ږ}yt[[%tJCb8WS+n{;'G
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 133>>stream
xA0}O1K]('@J)}@n/̟{:UunRLSzfuyIAяnmM)Ɍ3|ږ}yt[[%tJCb8WS+n{;'G
endstream
endobj
13 0 obj
<>stream
2018-09-18T16:25:59+05:30
Arbortext Advanced Print Publisher 9.0.114/W
2018-09-28T04:37:30-07:00
Atypon Systems, Inc.; modified using iText 4.2.0 by 1T3XT
application/pdf
ACM-2018-0175-ver9-Frenkel_4P 862..871
uuid:de2e7a66-6bb3-448a-9e77-5bb381ed97a2
uuid:e93c5e3b-e611-4d01-87b4-2db50af2ba82
endstream
endobj
14 0 obj
<>stream
x+ |
endstream
endobj
15 0 obj
<>stream
xS**T0T0 Bi yw*
endstream
endobj
16 0 obj
<>stream
x+ |
endstream
endobj
17 0 obj
<>stream
xS**T0T0 Bi ye(
endstream
endobj
18 0 obj
<>stream
x+ |
endstream
endobj
19 0 obj
<>stream
xS**T0T0 Bi yn)
endstream
endobj
20 0 obj
<>stream
x+ |
endstream
endobj
21 0 obj
<>stream
xS**T0T0 Bi y\'
endstream
endobj
22 0 obj
<>stream
x+ |
endstream
endobj
23 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
24 0 obj
<>stream
x+ |
endstream
endobj
25 0 obj
<>stream
xS**T0T0 Bi yS&
endstream
endobj
26 0 obj
<>stream
x+ |
endstream
endobj
27 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
28 0 obj
<>stream
x+ |
endstream
endobj
29 0 obj
<>stream
xS**T0T0 Bi y,
endstream
endobj
30 0 obj
<>stream
x+ |
endstream
endobj
31 0 obj
<>stream
xS**T0T0 Bi y+
endstream
endobj
32 0 obj
<>stream
x+ |
endstream
endobj
33 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
35 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 59.7543 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(review)-332.4(addresses)-329.6(the)-327.1(main)-323.7(questi)-7.8(ons)-325.6(and)-321.2(challenges)-332.5(related)]TJ
0 -1.1174 TD
[(to)-273(the)-269.5(use)-275(of)-272.9(CIM,)-267.8(in)-273(its)-274.1(various)-273.7(forms,)-269.1(in)-273(patients)-270.5(with)-276.2(lung)]TJ
0 -1.1116 TD
[(cancer.)-354.5(The)-351.2(authors)-348.6(anticipate)-350.2(that)-351.4(this)-344.3(information)-354.7(will)-345.5(be)]TJ
T*
[(helpful)-400.8(to)-394(clinicians)-395(seeking)-401.6(to)-394(counsel)-395.9(their)-398.6(patients)-397.2(with)]TJ
T*
[(lung)-252.2(cancer)-253.1(using)-247.3(a)-249.9(patient-centered)-255.4(and)-246.4(informed)-253.2(approach.)]TJ
/F4 1 Tf
8.9663 0 0 8.9663 59.7543 659.3384 Tm
(Nutrition)Tj
/F5 1 Tf
9.843 0 0 9.843 69.7323 642.8975 Tm
[(One)-408.5(of)-405.3(the)-407.8(main)-410.1(issues)-404.7(that)-409(patients)-408.8(affected)-410.9(by)-405.4(cancer)]TJ
-1.0137 -1.1116 TD
[(request)-413.1(an)-412.3(integrative)-419.3(oncology)-407.5(consultation)-419.1(relates)-414.4(to)-405.5(the)]TJ
0 -1.1174 TD
[(issue)-403.8(of)-405.3(nutrition.)]TJ
7.3823 0 0 6.5614 132.0945 625.3794 Tm
(69)Tj
9.843 0 0 9.843 147.1181 620.9573 Tm
[(Although)-401.6(few)-402.7(studies)-406.2(have)-404.2(evaluated)]TJ
-8.8757 -1.1116 TD
[(nutritional)-307.6(interventions)-304.9(in)-301.8(patients)-305.1(with)-305(active)-304.1(lung)-304(cancer,)]TJ
T*
[(many)-381.2(studies)-377.4(have)-375.4(examined)-382.3(which)-376.3(foods)-379.7(and)-378.8(dietary)-378.9(pat-)]TJ
T*
[(terns)-461.6(affect)-453.7(the)-459.6(risk)-453.6(of)-457.2(developing)-457.1(the)-453.8(disease.)-457.9(The)-460.7(2007)]TJ
0 -1.1174 TD
[(World)-272.8(Cancer)-270.3(Research)-279.2(Fund/American)-273.4(Institute)-270.5(for)-268.2(Cancer)]TJ
0 -1.1116 TD
[(Research)-250.4(\(WCRF/AICR\))-255.4(Report,)-248.5()50.8(Food,)-244.9(Nutrition,)-245.1(Physical)]TJ
T*
[(Activity)-431.8(and)-424.9(the)-425.1(Prevention)-428.1(of)-422.6(Cancer:)-427(a)-428.5(Global)-423.6(Perspec-)]TJ
0 -1.1174 TD
[(tive,)47.3()-358.2(which)-364.8(was)-356.5(rst)-361.2(published)-362.5(in)-353.7(1997,)-359.2(updated)-361.5(in)-359.4(2007,)]TJ
0 -1.1116 TD
[(and)-424.9(updated)-424.9(again)-422.7(in)-422.8(2018,)-422.5(provides)-424.6(a)-422.7(comprehensive)-423.3(re-)]TJ
T*
[(view)-438.5(of)-428.4(the)-436.6(relationship)-436.3(between)-432.7(certain)-437.6(food)-430.6(groups)-432.6(and)]TJ
0 -1.1174 TD
[(lung)-402(cancer,)-400.6(in)-394(prevention)-399.5(as)-400.6(well)-398.4(as)-400.6(survivorship.)-396.6(In)-399.6(that)]TJ
0 -1.1116 TD
[(document,)-355.8(the)-350.2(authors)-348.6(cited)-353.7(studies)-354.3(that)-345.6(discuss)-354(the)-350.2(role)-351.2(of)]TJ
T*
[(fruits,)-539.9(vegetables,)-537.5(carotenoids,)-537.5(avonoids,)-538.4(red)-534.3(meat,)-535.7(and)]TJ
0 -1.1174 TD
(others.)Tj
7.3823 0 0 6.5614 86.3433 482.9101 Tm
(11)Tj
9.843 0 0 9.843 98.9291 478.4881 Tm
[(The)-529.8(main)-525.3(possible)-528.2(benecial)-533(foods,)-527.1(as)-527.3(well)-530.8(as)]TJ
-3.98 -1.1116 TD
[(foods)-276(that)-270.8(have)-271.7(a)-273(possible)-274.8(detrimental)-270.8(effect)-275.1(as)-273.9(hinted)-273(in)-267.3(the)]TJ
T*
[(research)-341.5(arena,)-334.9(are)-333.9(listed)-336.3(in)-336.4(Table)-331.7(1.)]TJ
/F12 1 Tf
8.9663 0 0 8.9663 59.7543 434.6078 Tm
[(Fruits)-334.7(and)-335.7(vegetables)]TJ
/F5 1 Tf
9.843 0 0 9.843 69.7323 418.1668 Tm
[(A)-387.9(recent)-384.6(systematic)-390.1(review)-390(and)-384.6(meta-analysis)-394.6(evaluated)]TJ
-1.0137 -1.1116 TD
[(the)-275.3(impact)-275.4(of)-272.9(fruit)-270.6(and)-275.2(vegetable)-274(consumption)-273.8(on)-272.9(the)-275.3(risk)-269.2(of)]TJ
T*
[(lung)-344.4(cancer.)-343(Across)-348(the)-338.7(18)-342(studies)-342.8(included,)-348.9(high)-338.6(intake)-343.3(of)]TJ
0 -1.1174 TD
[(fruits)-254.3(and)-252.1(vegetables)-257.6(reduced)-253.1(the)-252.3(risk)-252(of)-249.8(lung)-252.2(cancer)-253.1(by)-255.6(14%)]TJ
25.5097 34.5294 TD
[(\(relative)-457.2(risk)-453.6([RR])]TJ
/F10 1 Tf
7.9254 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.86;)-451.5(95%)-453.6(condence)-457.9(interval)-455([CI])]TJ
/F10 1 Tf
14.9234 0 TD
(=)Tj
/F5 1 Tf
-23.5687 -1.1174 TD
(0.780.94\).)Tj
7.3823 0 0 6.5614 355.9747 718.5825 Tm
(12)Tj
9.843 0 0 9.843 368.3338 714.1605 Tm
[(A)-503.1(doseresponse)-512.5(association)-510.9(was)-506.2(observed,)]TJ
-5.8403 -1.1116 TD
[(although)-367.3(consumption)-365.9(of)-365(more)-363.9(than)-368.6(400)-164.6(g)-364(\(about)-365(1)-364(pound\))]TJ
T*
[(per)-298.2(day)-304(did)-302.9(not)-297.2(confer)-302.6(additional)-307.6(protection.)-305.1(This)-299.3(benecial)]TJ
T*
[(effect)-332.7(was)-333.5(signicant)-335.9(in)-336.4(current)-332.6(smokers,)-335.7(but)-331.7(not)-331.7(in)-330.6(former)]TJ
0 -1.1174 TD
[(or)-330.5(never)-336.1(smokers.)]TJ
7.3823 0 0 6.5614 382.7905 674.7021 Tm
(12)Tj
9.843 0 0 9.843 320.8251 659.3951 Tm
[(In)-514.8(terms)-520.4(of)-514.8(lung)-517.1(cancer)-523.8(prevention,)-449(fruits)-444.3(had)-442.2(a)-445.8(more)]TJ
-1.0137 -1.1116 TD
[(benecial)-193.2(effect)-188.7(than)-190(vegetables,)-192(with)-189.8(a)-186.6(risk)-188.6(reduction)-191(of)-186.5(18%)]TJ
0 -1.1174 TD
[(\(95%)-281.9(CI)]TJ
/F10 1 Tf
3.6171 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
(0.760.89;)Tj
/F13 1 Tf
4.5674 0 TD
(n)Tj
/F10 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(29)-284.4(studies)-285.2(and)-280.9(15,599)-285.4(cases\))-286.1(when)]TJ
-10.2811 -1.1116 TD
[(comparing)-416.7(the)-413.5(highest)-417.9(intake)-418.1(of)-411.1(fruits)-415.5(with)-420.2(the)-413.5(lowest)-417.7(in-)]TJ
T*
(take.)Tj
7.3823 0 0 6.5614 329.7826 619.9368 Tm
(12)Tj
9.843 0 0 9.843 339.7038 615.5715 Tm
[(A)-255.4(15%)-252(reduction)-254.4(in)-255.7(lung)-252.2(cancer)-258.9(risk)-252(\(95%)-253.1(CI)]TJ
/F10 1 Tf
18.3907 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.78)Tj
-22.0424 -1.1174 TD
(0.93;)Tj
/F13 1 Tf
2.4191 0 TD
(n)Tj
/F10 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(15)-388.1(studies)-388.9(and)-390.4(12,021)-389.1(cases\))-395.6(was)-391(observed)-391.1(when)]TJ
-3.8072 -1.1116 TD
[(examining)-296(citrus)-301.5(fruits)-300.4(in)-296.1(isolation,)-297.1(and)-298.2(a)-296(doseresponse)-305.2(re-)]TJ
T*
[(lationship)-260.2(was)-264.3(observed)-264.3(with)-259(intakes)-263.5(up)-261.4(to)-261.5(70)-163.5(g.)]TJ
7.3823 0 0 6.5614 500.5416 587.0549 Tm
(12)Tj
9.843 0 0 9.843 320.8251 571.7479 Tm
[(Vegetable)-188.5(intake)-193.5(is)-186.4(also)-189.8(helpful)-193.4(for)-187.5(lung)-188.8(cancer)-195.5(prevention,)]TJ
-1.0137 -1.1174 TD
[(with)-339.6(a)-342.1(summary)-345.2(RR)-344.1(estimate)-342(of)-342(0.92)-340.8(\(95%)-339.5(CI)]TJ
/F10 1 Tf
19.2893 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.870.97;)Tj
/F13 1 Tf
-20.0092 -1.1116 TD
(n)Tj
/F10 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(25)-445.7(studies)-446.5(and)-448(19,095)-446.7(cases\))-447.4(between)-449.9(the)-448.1(highest)-446.7(and)]TJ
-1.3823 -1.1116 TD
[(lowest)-273.7(intake,)-277.6(although)-275.2(this)-275.2(association)-280.6(was)-270.1(statisticall)-11.5(y)-271.8(sig-)]TJ
0 -1.1174 TD
[(nicant)-303.9(only)-304(for)-302.7(current)-309.6(smokers.)-306.9(A)-301.5(doseresponse)-311(associa-)]TJ
0 -1.1116 TD
[(tion)-292.6(was)-293.1(observed)-298.9(for)-291.2(vegetables;)-299.2(the)-292.6(risk)-292.3(was)-293.1(decre)-9(ased)-294.5(by)]TJ
T*
[(18%)-344.2(for)-348.8(intakes)-349.9(of)-347.7(up)-347.8(to)-347.9(300)-170.3(g)-346.7(\(two-thirds)-347.2(of)-347.8(a)-347.8(pound\))-352.2(per)]TJ
0 -1.1174 TD
(day.)Tj
7.3823 0 0 6.5614 327.5716 499.4077 Tm
(12)Tj
9.843 0 0 9.843 339.5338 494.9857 Tm
[(The)-460.7(2018)-465.2(report)-468.6(suggests)-464.5(that)-466.6(there)-462.9(is)-468.7(limited)-465.6(but)]TJ
-2.9144 -1.1116 TD
[(generally)-341.9(consistent)-341.7(that)-345.6(lung)-338.6(cancer)-345.3(risk)-338.4(is)-342(decreased)-343.8(with)]TJ
T*
[(increased)-244.9(intake)-239.6(of)-238.3(nonstarchy)-243.6(vegetables)-246.1(\(specically)-242.5(green)]TJ
0 -1.1174 TD
[(leafy)-445.7(vegetables\))-443(and)-442.2(nonstarchy)-445.2(root)-442.2(vegetables,)-451.1(such)-443.1(as)]TJ
0 -1.1116 TD
[(tubers)-428.1(and)-424.9(beets,)-425.9(carrots,)-428(artichokes,)-432.7(asparagus,)-425.4(avocados,)]TJ
T*
[(beans,)-310.6(and)-315.5(others.)-310.6(Data)-313(extracted)-320.1(from)-310.8(10)-313.2(studies)-314(showed)-308(a)]TJ
T*
[(signicant)-422.3(inverse)-430.4(association)-424.5(per)-424.9(80)-163.5(g)-421.6(o)0(f)-422.6(veget)-8(ables)-422.5(con-)]TJ
0 -1.1174 TD
[(sumed)-370.6(per)-367.3(day,)-365(but)-372.1(this)-367.3(was)-368(a)-370.9(nonlinear)-369.6(dose)-368.2(response)-373.6(for)]TJ
0 -1.1116 TD
[(intakes)-257.8(of)-255.6(up)-255.6(to)-255.7(300400)-169(g/day.)]TJ
7.3823 0 0 6.5614 435.118 411.7038 Tm
(11)Tj
9.843 0 0 9.843 445.0392 407.3385 Tm
[(Regarding)-261(particular)-256.7(types)]TJ
-13.6332 -1.1116 TD
[(of)-192.2(vegetables,)-197.7(green)-197.9(leafy)-198(vegetables)-200(reduced)-195.5(the)-194.7(risk)-200.1(by)-192.3(15%)]TJ
0 -1.1174 TD
[(\(95%)-304.9(CI)]TJ
/F10 1 Tf
3.6344 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.750.96;)Tj
/F13 1 Tf
4.5905 0 TD
(n)Tj
/F10 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(9)-306.4(studies)-308.2(and)-304(5783)-303.9(cases\),)-312.6(slightly)]TJ
ET
59.754 348.151 490.167 .28345 re
f
59.754 68.485 490.167 .28348 re
f
59.754 329.386 490.167 .22675 re
f
BT
/F7 1 Tf
9.845 0 0 9.845 75.2882 353.8204 Tm
(Table)Tj
/F5 1 Tf
3.0002 0 TD
(1.)Tj
/F7 1 Tf
1.2496 0 TD
[(Foods)-338.1(and)-332(Supplements)-338.7(That)-334.4(May)-331.7(Be)-331.2(Benecial)-340.1(or)-330(Harmful)-339.1(in)-331.6(Patients)-337(with)-334.7(Lung)-329.8(Cancer)]TJ
/F13 1 Tf
12.2599 -1.837 TD
[(Recommended)-18215.4(Avoid)]TJ
/F5 1 Tf
-18.0876 -1.9118 TD
[(Foods)-4605.7(Fruits)]TJ
7.3837 0 0 6.5625 152.107 321.2787 Tm
(11,12)Tj
9.845 0 0 9.845 129.0897 306.992 Tm
[(Nonstarchy)-341.3(vegetables)-337.2(\(green)-336.5(leafy)-335.7(vegetables,)-334.9(nonstarchy)-334.7(root)]TJ
0 -1.0135 TD
[(vegetables,)-340.6(tubers,)-333(and)-338.1(carrots\))]TJ
7.3837 0 0 6.5625 254.0976 301.3795 Tm
[(11,)-9.2(12)]TJ
9.845 0 0 9.845 129.0897 287.0361 Tm
[(Foods)-338.6(high)-332.4(in)-330.4(carotenoids)-337.1(\(carrots,)-336.1(cantaloupe,)-340.8(sweet)-336.4(potatoes,)]TJ
T*
[(tomatoes,)-337.5(pumpkins,)-334.9(spinach,)-335.1(apricots\))]TJ
7.3837 0 0 6.5625 285.6188 281.4802 Tm
(11,13)Tj
9.845 0 0 9.845 129.0897 267.137 Tm
[(Foods)-338.6(high)-332.4(in)-330.4(selenium)-339.8(\(Brazil)-333.1(nuts,)-335.6(cremini)-339(mushrooms,)-331(tuna,)]TJ
T*
[(halibut,)-340.2(salmon,)-334.1(scallops,)-336.1(organic)-331.9(eggs,)-336.6(shiitake)-333.1(mushrooms,)-336.7(barley,)]TJ
T*
[(grass-fed)-339.2(beef,)-337.9(turkey\))]TJ
7.3837 0 0 6.5625 219.7417 251.5464 Tm
(11)Tj
9.845 0 0 9.845 129.0897 237.2031 Tm
[(Foods)-338.6(high)-332.4(in)-330.4(quercetin)-341(\(capers,)-336.1(dill,)-330.3(kale,)-338.1(buckwheat,)-333.5(sweet)]TJ
0 -1.0077 TD
[(potatoes,)-336.3(apples\))]TJ
7.3837 0 0 6.5625 196.2708 231.6472 Tm
[(14,1)-8.3(5)]TJ
9.845 0 0 9.845 129.0897 217.3039 Tm
[(Green)-336.4(tea)]TJ
7.3837 0 0 6.5625 168.0944 221.6693 Tm
(83)Tj
9.845 0 0 9.845 129.0897 207.3259 Tm
[(Spices:)-337.5(turmeric,)]TJ
7.3837 0 0 6.5625 196.8944 211.6913 Tm
(84)Tj
9.845 0 0 9.845 207.5527 207.3259 Tm
[(black)-335.7(cumin)]TJ
7.3837 0 0 6.5625 256.9889 211.6913 Tm
(85)Tj
9.845 0 0 9.845 129.0897 197.4047 Tm
(Soy)Tj
7.3837 0 0 6.5625 144.3968 201.7701 Tm
(86)Tj
9.845 0 0 9.845 129.0897 187.4267 Tm
(Garlic)Tj
7.3837 0 0 6.5625 153.8078 191.7921 Tm
(87)Tj
9.845 0 0 9.845 129.0897 177.4488 Tm
(Pomegranate)Tj
7.3837 0 0 6.5625 180.6803 181.8141 Tm
(88)Tj
9.845 0 0 9.845 422.4755 316.9133 Tm
[(Red)-333.4(meat)]TJ
7.3837 0 0 6.5625 460.9133 321.2787 Tm
(11,16)Tj
9.845 0 0 9.845 422.4755 306.992 Tm
[(Processed)-334.4(meat)]TJ
7.3837 0 0 6.5625 484.3841 311.3574 Tm
[(11,1)-8.3(6)]TJ
9.845 0 0 9.845 422.4755 297.0141 Tm
[(Diets)-335.4(high)-332.4(in)-330.4(Glycemic)-342(Index)]TJ
7.3837 0 0 6.5625 542.551 301.3795 Tm
(89)Tj
9.845 0 0 9.845 59.7543 164.5228 Tm
[(Supplements)-1868.6(Astragalus)]TJ
7.3837 0 0 6.5625 171.2692 168.8881 Tm
(47,48)Tj
9.845 0 0 9.845 129.0897 154.5448 Tm
[(Omega)-337.5(3)-335(\(EPA:DHA)]TJ
/F10 1 Tf
9.0524 0 TD
()Tj
/F5 1 Tf
.5528 0 TD
(4:1\))Tj
7.3837 0 0 6.5625 239.5842 158.9102 Tm
(3641)Tj
9.845 0 0 9.845 129.0897 144.5669 Tm
(Curcumin)Tj
7.3837 0 0 6.5625 168.6047 148.9323 Tm
(84)Tj
9.845 0 0 9.845 129.0897 134.5889 Tm
(Ginseng)Tj
7.3837 0 0 6.5625 161.9149 139.011 Tm
(90)Tj
9.845 0 0 9.845 129.0897 124.6677 Tm
[(Sun)-336.8(soup)]TJ
7.3837 0 0 6.5625 166.2236 129.0331 Tm
(91)Tj
/F13 1 Tf
9.845 0 0 9.845 129.0897 114.6897 Tm
[(Trametes)-339(versicolor)]TJ
/F5 1 Tf
7.3837 0 0 6.5625 209.0267 119.0551 Tm
(49,50)Tj
9.845 0 0 9.845 129.0897 104.7118 Tm
[(Homeopathic)-339.2(remedies)]TJ
7.3837 0 0 6.5625 221.3291 109.0771 Tm
(73,7882)Tj
9.845 0 0 9.845 129.0897 94.7339 Tm
(Melatonin)Tj
7.3837 0 0 6.5625 169.7385 99.1559 Tm
(4246)Tj
9.845 0 0 9.845 129.0897 84.8126 Tm
-.0271 Tc
[(Vit)6.3(a)-.5(m)5.3(i).5(n)-327.5(D)-334.1(\(e)5.3(ar)6.5(ly)-333.3(s)6.6(t).5(ag)6.5(e\))]TJ
7.3837 0 0 6.5625 219.1747 89.1779 Tm
-.0393 Tc
[(30)-7.7(34)]TJ
9.845 0 0 9.845 129.0897 74.8346 Tm
-.0284 Tc
[(Pro)5.2(b)-.6(io)5.2(tics)]TJ
7.3837 0 0 6.5625 166.1669 79.2 Tm
-.0393 Tc
(6871)Tj
9.845 0 0 9.845 422.4755 164.5228 Tm
0 Tc
(Selenium)Tj
7.3837 0 0 6.5625 459.7794 168.8881 Tm
(11)Tj
9.845 0 0 9.845 422.4755 154.5448 Tm
[(Vitamin)-333.1(A)]TJ
7.3837 0 0 6.5625 465.2219 158.9102 Tm
(11)Tj
/F14 1 Tf
9.845 0 0 9.845 422.4755 144.5669 Tm
(b)Tj
/F5 1 Tf
.5528 0 TD
(-carotene)Tj
7.3837 0 0 6.5625 464.7117 148.9323 Tm
(11,22)Tj
9.845 0 0 9.845 422.4755 134.5889 Tm
[(Vitamin)-333.1(D)-335.8(\(advanced)-336.1(stage\))]TJ
7.3837 0 0 6.5625 535.9747 139.011 Tm
(35)Tj
8.7511 0 0 8.7511 67.748 56.6929 Tm
[(Adapted)-332.1(with)-332(permission)-336.2(from)-333.4(the)-333.3(Integrative)-333.9(Oncology)-329.7(Consultants)-333.6(website:)-333.2(www.moshefrenkelmd.com)-336.8(\(2018\).)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(INTEGRATIVE)-339.7(MEDICINE)-335.4(IN)-335.1(LUNG)-336.8(CANCER)-31974.3(863)]TJ
ET
endstream
endobj
50 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 62.022 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(more)-242.9(than)-247.6(the)-246.5(13%)-240.5(reduction)-248.6(seen)-242.7(for)-245.1(cruciferous)-245.8(vegetables)]TJ
0 -1.1174 TD
[(\(95%)-258.9(CI)]TJ
/F10 1 Tf
3.5941 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.790.97;)Tj
/F13 1 Tf
4.5386 0 TD
(n)Tj
/F10 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(11)-261.4(studies)-262.2(and)-257.9(11,467)-262.4(cases\).)]TJ
7.3823 0 0 6.5614 278.192 718.5825 Tm
(12)Tj
/F12 1 Tf
8.9663 0 0 8.9663 62.022 692.277 Tm
(Carotenoids)Tj
/F5 1 Tf
9.843 0 0 9.843 72 675.8361 Tm
[(A)-405.1(substantial)-406.2(amount)-406.6(of)-405.3(evidence)-411(shows)-403.4(that)-409(food)-401.8(con-)]TJ
-1.0137 -1.1174 TD
[(taining)-354.8(carotenoids)-355.5(\(e.g.,)-354.6(sweet)-354.2(potatoes,)-354.5(carrots,)-358.9(tomatoes,)]TJ
0 -1.1116 TD
[(pumpkins,)-370.5(spinach,)-376.3(cantaloupe,)-370.7(and)-373.1(apricots\))-375.1(has)-372.9(a)-370.9(protec-)]TJ
T*
[(tive)-305.3(effect)-309.7(against)-309.6(lung)-304(cancer.)]TJ
7.3823 0 0 6.5614 185.2724 647.3195 Tm
(11)Tj
9.843 0 0 9.843 195.6472 642.9542 Tm
[(Fruits)-306(and)-304(vegetables)-309.5(high)]TJ
-13.5756 -1.1174 TD
(in)Tj
/F14 1 Tf
1.1404 0 TD
(b)Tj
/F5 1 Tf
.5472 0 TD
[(-carotene)-366(provide)-354.6(a)-359.4(23.2%)-354.5(reduced)-362.5(risk)-355.6(of)-359.3(lung)-355.9(cancer)]TJ
-1.6876 -1.1116 TD
[(\(95%)-247.3(CI)]TJ
/F10 1 Tf
3.5825 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.6750.874;)Tj
/F13 1 Tf
5.5236 0 TD
(n)Tj
/F10 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(18)-244.1(studies)-250.6(and)-246.4(9372)-252.1(cases\))-245.8(when)]TJ
-11.2141 -1.1116 TD
[(comparing)-445.5(the)-436.6(highest)-446.7(with)-437.5(the)-442.3(lowest)-440.7(dietary)-448(intake,)-438.8(ac-)]TJ
0 -1.1174 TD
[(cording)-423.7(to)-428.5(a)-422.7(2015)-424.9(meta-analysis.)]TJ
7.3823 0 0 6.5614 197.4614 603.4959 Tm
(13)Tj
9.843 0 0 9.843 209.0267 599.0739 Tm
[(A)-422.4(clear)-429.6(doseresponse)]TJ
-14.9349 -1.1116 TD
[(relationship)-419(is)-416.8(evident)-413.5(from)-414.5(cohort)-416.8(studies.)-415.4(The)-414.6(more)-415.7(one)]TJ
T*
[(consumes)-415.2(dietary)-419.2(carotenoids,)-416.5(the)-419.3(more)-415.7(the)-413.5(risk)-413.2(of)-416.9(devel-)]TJ
T*
[(oping)-391.5(lung)-390.4(cancer)-397.1(is)-393.8(reduced.)-394.7(Data)-393.6(extracted)-400.7(from)-391.5(several)]TJ
0 -1.1174 TD
[(studies)-337(with)-333.8(a)-336.3(total)-335.4(of)-336.2(400,000)-332.6(participant)-10.3(s,)-332.6(including)-334(3100)]TJ
0 -1.1116 TD
[(lung)-286.8(cancer)-287.7(patients,)-291.2(with)-287.8(a)-284.5(follow-up)-287.4(period)-290.1(of)-284.4(716)-286.6(years,)]TJ
T*
[(suggest)-244.8(that)-247.7(those)-242.7(who)-240.3(consumed)-248.3(the)-246.5(most)-241.7(carotenoids)-246(had)-246.4(a)]TJ
0 -1.1174 TD
[(24%)-332.7(decreased)-338(risk)-338.4(of)-330.5(developing)-336.1(lung)-332.8(cancer.)]TJ
7.3823 0 0 6.5614 251.433 526.7337 Tm
(11)Tj
9.843 0 0 9.843 72 511.4266 Tm
[(Supplements)-902.6(of)]TJ
/F14 1 Tf
7.8102 0 TD
(b)Tj
/F5 1 Tf
.5529 0 TD
[(-carotene,)-905.1(however,)-907.1(are)-898.3(not)-901.9(re-)]TJ
-9.3768 -1.1116 TD
[(commended.)-243.9(Findings)-239.1(from)-236(the)-240.7(new)-241.5(edition)-239.6(of)-238.3(WCRF/AICR)]TJ
0 -1.1174 TD
[(document)-392.6(reveal)-390.3(that)-386(high-dose)-391.1(beta)-387(carotene)-393.7(supplements)]TJ
0 -1.1116 TD
[(are)-293.6(a)-284.5(convincing)-295.8(cause)-291(of)-284.4(lung)-292.5(cancer)-293.5(in)-284.6(current)-292.3(and)-292.4(former)]TJ
T*
(smokers.)Tj
7.3823 0 0 6.5614 97.285 471.9684 Tm
(11)Tj
9.843 0 0 9.843 108.17 467.603 Tm
[(The)-351.2(protective)-360.4(effect)-355.7(of)-353.5(dietary)-355.8(intake)-354.8(of)-353.5(carot-)]TJ
-4.6884 -1.1174 TD
[(enoids)-480(may)-483.8(be)-481.4(lost)-482.5(or)-480.2(reversed)-484.3(by)-480.3(the)-476.9(higher)-485.9(doses)-478.6(that)]TJ
0 -1.1116 TD
[(pharmacologic)-337.2(supplementation)-338.4(provides.)]TJ
7.3823 0 0 6.5614 229.096 450.0282 Tm
(11)Tj
/F12 1 Tf
8.9663 0 0 8.9663 62.022 423.7227 Tm
(Flavonoids)Tj
/F5 1 Tf
9.843 0 0 9.843 72 407.2818 Tm
[(Flavonoids,)-424.5(which)-422.4(are)-426.1(phytochemicals)-430.4(in)-422.8(food)-424.8(products)]TJ
-1.0137 -1.1116 TD
[(derived)-493.9(from)-489.4(plants,)-495.1(often)-490.6(contribute)-497.5(to)-486.1(the)-494.2(color)-490.6(of)-491.7(the)]TJ
T*
[(foods.)-423.4(Foods)-414.1(such)-425.8(as)-417.9(berries,)-422.3(dill,)-422.9(buckwheat,)-421(red)-419.1(onions,)]TJ
0 -1.1174 TD
[(kale,)-304(cranberries,)-308(sweet)-308.1(potatoes,)-302.6(apples,)-306(and)-298.2(others)-307.2(contain)]TJ
0 -1.1116 TD
[(avonoids.)-377.2(Flavonoid)-379.8(intake)-377.8(has)-378.7(been)-375.4(shown)-380.6(to)-376.7(be)-377.7(associ-)]TJ
T*
[(ated)-404.3(with)-408.7(a)-405.4(decreased)-407.2(risk)-407.5(of)-399.6(lung)-407.7(cancer,)-406.3(particularly)-408.8(for)]TJ
0 -1.1174 TD
[(current)-321.1(smokers.)-318.4(A)-318.7(2013)-315.4(meta-analysis)-325.4(of)-313.2(dietary)-321.3(avonoid)]TJ
0 -1.1116 TD
[(intake)-493(showed)-498(a)-491.8(marginally)-498.7(signicant)-491.4(reduction)-496.3(in)-491.9(lung)]TJ
T*
[(cancer)-454.7(risk)-453.6(of)-451.4(16%)-453.6(\(95%)-454.7(CI)]TJ
/F10 1 Tf
12.3834 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.711.00;)Tj
/F13 1 Tf
4.7345 0 TD
(n)Tj
/F10 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(8)-450.4(studies\),)]TJ
7.3823 0 0 6.5614 293.7259 323.9999 Tm
(14)Tj
9.843 0 0 9.843 62.022 308.6928 Tm
[(wh)20(ic)19.5(h)-369.7(d)0(i)20.7(f)0(f)20.9(e)0(r)14(s)-363.8(fr)20.9(om)-360.5(a)-370.9(p)0(r)20.9(i)0(o)20.7(r)-369.7(me)18.4(ta)19.6(-a)19.7(na)19.7(ly)20.7(si)20.9(s)-369.5(t)0(h)20.7(a)0(t)-360.6(s)0(h)21(o)0(w)20(e)0(d)-360.5(a)-365.1(st)15.1(a-)]TJ
0 -1.1174 TD
[(ti)20.6(st)15.1(ic)19.6(al)19.5(ly)-261.5(si)15.1(gn)20.8(i)20.9(ca)18.5(nt)-261.5(24)15.1(%)-272.9(r)0(i)20.7(s)0(k)-266.9(r)0(e)19.7(d)0(u)20.8(c)0(t)19.5(i)0(o)20.7(n)-277.6(wi)19.8(th)-261.5(a)-278.7(d)0(o)20.8(s)0(e)19.9()0(r)20.9(e)0(s)19.9(p)0(o)15.1(n)0(s)21(e)]TJ
0 -1.1116 TD
[(as)19.9(so)15.3(ci)19.5(at)19.5(io)20.7(n.)]TJ
7.3823 0 0 6.5614 107.2063 291.118 Tm
-.0162 Tc
(15)Tj
9.843 0 0 9.843 118.0346 286.7527 Tm
0 Tc
[(Fo)21(r)-358.2()0(a)19.8(v)0(o)20.8(n)0(o)20.8(i)0(d)-353.7(s)0(u)21(b)0(c)19.7(l)0(a)19.6(s)0(s)21.2(e)0(s)14.1(,)-354.8(lu)15(ng)-347.8(ca)18.5(nc)19.7(er)-348.9(ri)20.7(sk)-353.3(ap)19.7(-)]TJ
-5.6906 -1.1116 TD
.0187 Tc
[(pe)-6.6(ars)-448.7(t)-5.6(o)-448.9(b).3(e)-450.1(m)-.9(os)-5.2(t)-449.1(s).5(i)-5.6(gni)-5.6(ca)-6.6(n).3(tl)-5.6(y)-448.9(r).4(ed)-5.4(uce)-6.6(d)-443.2(b)-5.4(y)-448.9(the)-450.1()-5.3(avo)-5.4(nol)-5.6(s)]TJ
0 -1.1174 TD
.0227 Tc
[(q)4.3(u)-1.4(er)4.4(cet)4.2(i)-1.6(n)-329.7(\()-1.4(3)4.3(4)4.3(%)-336.6(r)4.4(i)-1.6(s)4.5(k)-335.5(r)4.4(e)3.2(du)4.3(cti)4.2(o)4.3(n;)-329.9(95)4.3(%)-330.8(C)-2.5(I)]TJ
/F10 1 Tf
16.8068 0 TD
0 Tc
(=)Tj
/F5 1 Tf
.7372 0 TD
.0187 Tc
[(0)-5.4(.)-2(47)-5.4(0.92)-5.4(;)]TJ
/F13 1 Tf
4.8209 0 TD
0 Tc
(n)Tj
/F10 1 Tf
.6854 0 TD
(=)Tj
/F5 1 Tf
.743 0 TD
(5)Tj
-23.7933 -1.1116 TD
[(st)20.9(ud)20.8(ie)13.8(s\))-255.4(an)19.7(d)-266(k)0(a)19.7(e)0(m)18.5(p)0(f)20.9(e)0(r)14(o)0(l)-255.8(\()0(2)20.9(2)0(%)-256.7(r)0(i)20.7(s)0(k)-261.2(r)0(e)19.7(d)0(u)20.8(c)0(t)19.5(i)0(o)20.7(n)0(;)-261.5(9)0(5)20.8(%)-267.1(CI)]TJ
/F10 1 Tf
21.3743 0 TD
(=)Tj
/F5 1 Tf
.7084 0 TD
[(0.)18.5(64)20.8()]TJ
-22.0827 -1.1116 TD
[(0.)18.5(95)20.8(;)]TJ
/F13 1 Tf
2.3154 0 TD
(n)Tj
/F10 1 Tf
.6566 0 TD
(=)Tj
/F5 1 Tf
.7084 0 TD
.3236 Tc
[(5s)323.6(t)344.5(u)323.6(d)344.4(i)323.6(e)343.2(s)323.6(\))338.9(.)]TJ
7.3823 0 0 6.5614 138.5574 247.2944 Tm
0 Tc
(15)Tj
/F12 1 Tf
8.9663 0 0 8.9663 62.022 220.9889 Tm
[(Red)-334.1(meat)-336.5(and)-329.4(processed)-332.6(meat)]TJ
/F5 1 Tf
9.843 0 0 9.843 72 204.548 Tm
[(In)-353.5(the)-361.7(2018)-355.7(WCRF)-354.2(report,)-362.6(there)-359.3(was)-356.5(limited)-356.2(but)-360.5(consis-)]TJ
-1.0137 -1.1174 TD
[(tent)-386(evidence)-382.2(that)-386(consumption)-383.2(of)-382.3(red)-378.8(meat)-382.5(and)-384.6(processed)]TJ
0 -1.1116 TD
[(meat)-250(increases)-250.4(risk)-252(of)-244.1(lung)-252.2(cancer.)-250.8(The)-247.6(doseresponse)-253.4(meta-)]TJ
T*
[(analysis)-264.4(showed)-261.9(a)-255.7(signicantly)-263.4(increased)-267.9(risk)-257.7(of)-261.4(lung)-258(cancer)]TJ
T*
[(per)-332.7(100)-170.3(g)-329.4(o)0(f)-336.2(red)-332.7(meat)-336.4(and)-332.8(50)-169.2(g)-335.2(o)0(f)-330.5(processed)-335.5(meat.)]TJ
7.3823 0 0 6.5614 265.0393 165.0897 Tm
(11)Tj
9.843 0 0 9.843 72 149.726 Tm
[(Other)-566.3(studies)-567.4(suggest)-567.3(that)-564.5(among)-566.6(current)-568.8(and)-568.9(former)]TJ
-1.0137 -1.1116 TD
[(smokers)-349.5(\(the)-339.7(COSMOS)-349.8(screening)-347.4(study\),)-344(there)-347.7(is)-342(a)-347.8(signi-)]TJ
T*
[(cant)-369.7(73%)-361.5(increased)-371.6(risk)-361.4(\(CI)]TJ
/F10 1 Tf
11.7613 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(1.152.61;)Tj
/F13 1 Tf
4.6423 0 TD
(p)Tj
/F10 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.002;)Tj
/F13 1 Tf
2.8971 0 TD
(n)Tj
/F10 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(178)Tj
-22.7912 -1.1174 TD
[(cases\))-372.5(of)-365(lung)-373.2(cancer)-368.3(for)-366.1(those)-369.5(with)-374.2(the)-367.5(highest)-366(meat)-371(con-)]TJ
0 -1.1116 TD
(sumption.)Tj
7.3823 0 0 6.5614 101.1968 110.2677 Tm
(16)Tj
/F12 1 Tf
8.9663 0 0 8.9663 62.022 83.9622 Tm
[(Mediterranean)-332.6(diet)]TJ
/F5 1 Tf
9.843 0 0 9.843 72 67.5212 Tm
[(In)-468.7(terms)-474.3(of)-468.7(overall)-471(dietary)-471(patterns,)-475.4(the)-471.1(Mediterranean)]TJ
-1.0137 -1.1116 TD
[(diet)-322.6(is)-318.9(well)-317.7(established)-326.6(for)-320(the)-315.6(prevention)-324.6(of)-319(cardiovascular)]TJ
25.504 67.9242 TD
(disease)Tj
7.3823 0 0 6.5614 341.5747 729.5242 Tm
(17)Tj
9.843 0 0 9.843 353.4235 725.1588 Tm
[(and)-453.7(likewise)-449.9(appears)-454.5(promising)-454.7(for)-452.5(lung)-448(cancer)]TJ
-4.1009 -1.1174 TD
[(prevention.)-414.4(The)-408.8(COSMOS)-407.4(screening)-416.5(study)-408.6(of)-405.3(4336)-407.6(heavy)]TJ
0 -1.1116 TD
[(smokers)-222.8(revealed)-226.7(an)-216.5(80%)-217.5(lower)-220.8(risk)-223.2(of)-215.3(lung)-223.4(cancer)-218.6(diagnosis)]TJ
T*
[(among)-324.7(participants)-322.3(with)-322.3(a)-319(strong)-317.5(adherence)-326.7(to)-319.1(the)-315.6(Mediter-)]TJ
T*
[(ranea)-9(n)-329.4(diet.)]TJ
7.3823 0 0 6.5614 360.0566 685.7006 Tm
(18)Tj
9.843 0 0 9.843 370.7149 681.3352 Tm
[(That)-335.2(study)-333.7(also)-333.8(suggested)-340.3(that)-334.1(a)-330.6(high)-332.8(dietary)]TJ
-5.8576 -1.1174 TD
[(inammato)-9(ry)-157.7(index)-162.3(increases)-169.8(the)-165.9(risk.)-163.2(An)-158.6(earlier)-166.9(casecontrol)]TJ
0 -1.1116 TD
[(study)-425.9(of)-416.9(individual)-427.4(components)-423.5(of)-422.6(the)-419.3(Mediterranean)-430.2(diet)]TJ
T*
[(showed)-290.7(protective)-285.6(effects)-287.5(with)-287.8(high)-281(consumption)-291(of)-284.4(carrots,)]TJ
0 -1.1174 TD
[(tomatoes,)-419.1(and)-419.2(white)-416.7(meat)-417(and)-413.4(statistically)-421.5(signicant)-422.3(pro-)]TJ
0 -1.1116 TD
[(tection)-269.6(with)-270.5(high)-263.7(consumption)-268(of)-267.1(sage)-271.5(and)-263.6(the)-269.5(exclusive)-266.9(use)]TJ
T*
[(of)-261.4(olive)-266.1(oil.)]TJ
7.3823 0 0 6.5614 359.0928 619.9368 Tm
(19)Tj
9.843 0 0 9.843 323.0361 604.5731 Tm
[(Additional)-336.1(benecial)-337.2(foods)-333.6(are)-339.7(listed)-336.3(in)-330.6(Table)-337.5(1.)]TJ
/F4 1 Tf
8.9663 0 0 8.9663 313.0582 577.1337 Tm
[(Nutritional)-341.1(Supplements)]TJ
/F5 1 Tf
9.843 0 0 9.843 323.0361 560.6927 Tm
[(Nutritional)-164.5(supplement)-8.9(s)-156.4(include)-165.8(herbal)-164.5(remedies,)-166.6(minerals,)]TJ
-1.0137 -1.1116 TD
[(vitamins,)-285.5(and)-275.2(certain)-282.1(other)-283.2(substances.)-282.4(Supplements)-280.5(are)-282.1(one)]TJ
0 -1.1174 TD
[(of)-203.8(the)-200.4(easiest)-201.1(type)-201.5(of)-203.8(CIM)-201(therapies)-203.5(for)-199.1(cancer)-201.3(patients)-207.2(to)-198.2(use,)]TJ
0 -1.1116 TD
[(and)-448(20%90%)-447.6(of)-451.4(patients)-449.1(affected)-451.3(by)-445.7(cancer)-449(use)-447.8(supple-)]TJ
T*
[(ments)-7.8(.)]TJ
7.3823 0 0 6.5614 339.1369 521.2345 Tm
(20)Tj
9.843 0 0 9.843 348.3212 516.8691 Tm
[(Patients)-189.7(tend)-190(to)-180.9(use)-188.6(nutritional)-186.7(supplements)-188.3(as)-187.5(a)-186.6(type)]TJ
-3.5825 -1.1174 TD
[(of)-313.2(psychologic)-319.8(support;)-314.1(they)-311(want)-317.6(to)-307.6(feel)-317.9(hopeful)-314.2(or)-313.2(have)-312(a)]TJ
0 -1.1116 TD
[(sense)-266.6(of)-267.1(control)-262.5(in)-267.3(the)-263.8(decision-making)-269.1(process,)-266.5(so)-266.9(that)-265(they)]TJ
T*
[(feel)-243(they)-236.1(are)-241.7(doing)-241.8(everything)-238.2(possible.)]TJ
7.3823 0 0 6.5614 468.2267 488.3526 Tm
[(20,2)-8.6(1)]TJ
9.843 0 0 9.843 487.2188 483.9873 Tm
[(Patients)-241.6(also)-235.9(use)]TJ
-17.6938 -1.1174 TD
[(supple)-7.7(ments)-537.7(to)-543.7(help)-541.3(reduce)-540(side)-541.2(effects)-546.7(of)-537.8(conventional)]TJ
0 -1.1116 TD
[(treatments)-171.4(and)-165.7(enhance)-173.6(their)-162.4(quality)-170.5(of)-163.4(life.)-164.7(Typically)-169.3(patients)]TJ
T*
[(are)-264.8(not)-262.6(seeking)-263.4(a)-261.4(cure)-260.1(for)-262.4(their)-260.3(disease)-264.4(with)-259(supplement)-8.9(s.)]TJ
7.3823 0 0 6.5614 539.8865 455.4707 Tm
(21)Tj
9.843 0 0 9.843 323.0361 440.107 Tm
[(Although)-367.1(foods)-362.4(high)-361.6(in)-359.4(vitamins)-362.7(and)-361.6(minerals)-369.5(appear)-361.4(to)]TJ
-1.0137 -1.1116 TD
[(reduce)-292.3(the)-292.6(risk)-286.5(of)-290.2(lung)-286.8(cancer,)-291.1(studies)-291(of)-290.2(micronutrient)-294.8(sup-)]TJ
T*
[(plements)-191(thus)-188.7(far)-188.7(have)-185.3(not)-187.7(shown)-190.5(convincing)-186.4(evidence)-192.1(for)-187.5(the)]TJ
T*
[(prevention)-313.1(of)-307.4(lung)-309.8(cancer.)-314.2(A)-307.2(2012)-303.9(Cochrane)-312.8(review)-315.2(of)-307.4(ran-)]TJ
0 -1.1174 TD
[(domized)-224.5(controlled)-215.3(trials)-221(of)-215.3(vitamin)-217.8(A,)-218.5(vitamin)-217.8(C,)-218.7(vitamin)-217.8(E,)]TJ
0 -1.1116 TD
[(and)-355.8(selenium)-352.3(supplementation)-355.6(found)-351.1(no)-353.5(signicant)-353.2(risk)-349.9(re-)]TJ
T*
[(duction)-239.5(for)-233.6(the)-235(general)-235.9(population)-237.2(and)-234.9(a)-232.6(small)-238.3(but)-233.8(signicant)]TJ
0 -1.1174 TD
[(increased)-371.6(risk)-361.4(with)]TJ
/F14 1 Tf
8.1615 0 TD
(b)Tj
/F5 1 Tf
.5529 0 TD
[(-carotene)-366(supplement)-8.9(ation)-364(in)-359.4(smokers)]TJ
-8.7144 -1.1116 TD
[(and)-263.7(individuals)-255.5(exposed)-263.3(to)-255.8(asbestos.)]TJ
7.3823 0 0 6.5614 456.6046 356.8251 Tm
(22)Tj
9.843 0 0 9.843 466.5825 352.4597 Tm
[(However,)-257.1(a)-261.5(few)-258.7(other)]TJ
-15.5973 -1.1116 TD
[(studie)-7.8(s)-473.2(suggest)-475.2(that)-472.4(adding)-474.4(nutritional)-480.4(supplements)-476.3(could)]TJ
0 -1.1174 TD
[(reduce)-269.3(the)-263.8(risk)-263.5(of)-267.1(lung)-263.7(cancer)-264.7(or)-261.4(improve)-269.4(the)-263.8(benet)-262.3(of)-267.1(con-)]TJ
0 -1.1116 TD
[(ventional)-266.1(care)-261.3(during)-265.9(and)-257.9(after)-261.3(treatment.)]TJ
7.3823 0 0 6.5614 477.2408 323.9432 Tm
(2329)Tj
9.843 0 0 9.843 323.0361 308.6361 Tm
[(A)-422.4(meta-analysis)-423.4(from)-420.3(2014)-419.1(showed)-423.2(a)-417(17%)-419.1(lung)-419.2(cancer)]TJ
-1.0137 -1.1116 TD
[(risk)-511.2(reduction)-513.6(\(95%)-506.5(CI)]TJ
/F10 1 Tf
10.1544 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.7340.937;)Tj
/F13 1 Tf
5.7885 0 TD
(n)Tj
/F10 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(21)-503.3(studies)-515.6(and)]TJ
-18.0509 -1.1174 TD
[(8938)-396.1(cases\))-395.6(when)-392.3(comparing)-393.7(highest)-394.8(and)-390.4(lowest)-394.6(intake)-395.1(of)]TJ
0 -1.1116 TD
[(vitamin)-384.9(C,)-379.9(with)-379.9(a)-382.4(linear)-383.5(7%)-377.6(doser)-7.5(esponse)-378.3(reduction)-386.8(with)]TJ
T*
[(every)-491.6(100-mg)-485.9(increase)-491.4(per)-488.3(day,)-486(but)-487.3(the)-488.4(analysis)-489.1(did)-487.2(not)]TJ
0 -1.1174 TD
[(distinguish)-450(between)-444.2(dietary)-448(and)-448(supplemental)-444.4(intake.)]TJ
7.3823 0 0 6.5614 532.2329 258.1795 Tm
(23)Tj
9.843 0 0 9.843 543.9683 253.8141 Tm
(In)Tj
-23.4593 -1.1116 TD
[(addition,)-261.5(a)-255.7(2017)-257.8(meta-analysis)-262.1(of)-255.6(vitamin)-258.2(E)-255.7(intake)-256.9(showed)-256.1(a)]TJ
T*
[(16%)-292.4(lung)-292.5(cancer)-299.2(risk)-292.3(reduction)-294.7(\(95%)-287.7(CI)]TJ
/F10 1 Tf
16.6168 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.760.93;)Tj
/F13 1 Tf
4.5732 0 TD
(n)Tj
/F10 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
(11)Tj
-23.2922 -1.1174 TD
[(studie)-7.8(s)-381(and)-384.6(4164)-378.8(cases\),)-387.5(with)-385.7(a)-382.4(doseresponse)-385.8(decrease)-388.8(in)]TJ
0 -1.1116 TD
[(risk)-338.4(of)-336.2(5%)-331.6(for)-337.3(every)-336.1(2-mg)-333.9(increase)-341.7(per)-332.7(day)-332.8(in)-336.4(dietary)-338.6(vita-)]TJ
T*
[(min)-338.7(E)-330.6(intake.)]TJ
7.3823 0 0 6.5614 367.7101 203.4141 Tm
(24)Tj
9.843 0 0 9.843 323.0361 188.0503 Tm
[(Preliminary)-482.4(studies)-475.3(suggest)-480.9(that)-478.1(the)-476.9(use)-476.6(of)-474.5(antioxidant)]TJ
-1.0137 -1.1116 TD
[(vitamins)-408.8(and)-401.9(minerals)-409.8(following)-408.6(a)-399.7(diagnosis)-408.4(of)-405.3(cancer)-402.9(re-)]TJ
T*
[(duces)-600.9(chemotoxicity)-601.3(and)-592(radiotoxici)-9.2(ty)-595.6(during)-594.2(treatment;)]TJ
T*
[(positive)-321.2(ndings)-318.5(were)-318.6(observed)-316.2(in)-319.1(34)-313.2(of)-319(46)-319(trials)-319(in)-313.3(a)-319(2016)]TJ
0 -1.1174 TD
[(systematic)-303.7(review.)]TJ
7.3823 0 0 6.5614 387.0991 148.5921 Tm
(25)Tj
9.843 0 0 9.843 397.4172 144.2267 Tm
[(However,)-297.4(there)-301.7(remains)-299.2(a)-296(concern)-304.9(that)]TJ
-8.5704 -1.1116 TD
[(antioxidant)-510.3(supplementation)-511.2(could)-507.9(reduce)-511.2(the)-505.7(therapeutic)]TJ
T*
[(effects)-506.4(of)-497.5(free)-502(radical-generating)-505.3(radiotherapy)-500.7(or)-497.5(chemo-)]TJ
0 -1.1174 TD
[(therapeutic)-454.9(agents)-452.4(such)-454.6(as)-446.7(the)-453.8(platinum)-449.3(compounds)-449.9(\(e.g.,)]TJ
0 -1.1116 TD
[(cisplatin\),)-535.4(and)-528.6(current)-534.2(evidence)-532(regarding)-536.4(treatment)-533.4(out-)]TJ
T*
[(come)-8(s)-329.2(i)0(s)-336.2(not)-331.7(denitive.)]TJ
7.3823 0 0 6.5614 407.1117 93.8268 Tm
(25)Tj
9.843 0 0 9.843 323.0361 78.463 Tm
[(For)-245(lung)-240.7(cancer)-241.6(specically,)-244.9(two)-246.2(preliminary)-240.6(Mayo)-242.6(Clinic)]TJ
-1.0137 -1.1116 TD
[(cohort)-451.4(studies)-452.2(showed)-446.2(improved)-454.8(survival)-447.8(in)-445.8(patients)-454.8(with)]TJ
T*
[(small)-8(-cell)-428.5(lung)-430.8(cancer)-437.4(\(SCLC;)-430.3(RR)]TJ
/F10 1 Tf
14.716 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(0.65;)-434.2(95%)-430.6(CI)]TJ
/F10 1 Tf
5.8922 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.43)Tj
/F11 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(864)Tj
46.3849 0 TD
[(FRENKEL)-338(ET)-338.7(AL.)]TJ
ET
endstream
endobj
54 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 59.7543 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
(1.00;)Tj
/F13 1 Tf
2.3269 0 TD
(p)Tj
/F10 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.05;)Tj
/F13 1 Tf
2.3212 0 TD
(n)Tj
/F10 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(178\))-292.4(and)-292.4(non-SCLC)-294.1(\(NSCLC;)-299.8(RR)]TJ
/F10 1 Tf
14.117 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.74;)Tj
-22.2613 -1.1174 TD
[(95%)-246.3(CI)]TJ
/F10 1 Tf
3.2427 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.440.65;)Tj
/F13 1 Tf
4.5271 0 TD
(p)Tj
/F10 1 Tf
.6624 0 TD
(<)Tj
/F5 1 Tf
.72 0 TD
(0.01;)Tj
/F13 1 Tf
2.2751 0 TD
(n)Tj
/F10 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(1129\))-241.6(who)-240.3(used)-247.3(vitamin)-240.9(or)]TJ
-13.5353 -1.1116 TD
[(mineral)-299.5(supplements,)-295.5(along)-300.5(with)-293.5(improved)-293.5(quality)-297.2(of)-295.9(life)-293.8(in)]TJ
T*
[(the)-361.7(NSCLC)-355.1(cohort.)]TJ
7.3823 0 0 6.5614 138.274 696.6423 Tm
(26,27)Tj
9.843 0 0 9.843 158.3999 692.277 Tm
[(An)-354.4(early)-359.3(study)-356.8(of)-359.3(18)-353.5(patients)-362.7(with)]TJ
-10.0219 -1.1116 TD
[(SCLC)-404.9(showed)-405.9(improved)-403(survival)-407.4(with)-403(supplementation)-407.5(of)]TJ
0 -1.1174 TD
[(vitamins,)-400.7(trace)-395(elements,)-397.2(and)-396.1(fatty)-398.6(acids,)]TJ
7.3823 0 0 6.5614 227.7354 674.7021 Tm
(28)Tj
9.843 0 0 9.843 239.0172 670.3369 Tm
[(and)-396.1(a)-393.9(random-)]TJ
-18.2122 -1.1116 TD
[(ized)-335.2(controlled)-336.2(trial)-335.3(of)-336.2(136)-331.6(patients)-339.6(with)-333.8(advanced)-336(NSCLC)]TJ
T*
[(showed)-400.1(improved)-403(survival)-395.9(with)-403(supplementation,)-399.4(although)]TJ
0 -1.1174 TD
[(this)-586.2(was)-581.1(not)-585.2(statistically)-582.8(signicant.)]TJ
7.3823 0 0 6.5614 213.5054 641.877 Tm
(29)Tj
9.843 0 0 9.843 226.6015 637.455 Tm
[(More)-588.2(research)-583.4(is)]TJ
-16.9508 -1.1116 TD
[(needed)-269.3(to)-267.3(determine)-268.3(whether)-270.2(antioxidant)-268.4(supplementation)-269.2(is)]TJ
T*
[(appropriate)-401.7(during)-392.6(curative)-392.7(regimens,)-395.8(although)-396.1(use)-395.9(in)-394(pal-)]TJ
0 -1.1174 TD
[(liative)-338.9(settings)-338.3(is)-330.4(likely)-336.5(worth)-334.8(consideration.)]TJ
1.0137 -1.1116 TD
[(Nutritional)-400.7(supplements)-395.7(that)-397.5(have)-398.4(a)-399.7(possible)-395.7(benet)-394.8(are)]TJ
-1.0137 -1.1116 TD
[(listed)-393.9(in)-394(Table)-395.1(1.)-390.4(Leading)-397.3(nutritional)-394(supplements)-395.7(such)-391.3(as)]TJ
T*
[(vitamin)-304.2(D,)-299.1(sh)-296.7(oil,)]TJ
/F13 1 Tf
7.9887 0 TD
(Astragalus)Tj
/F5 1 Tf
4.3313 0 TD
[(,)-297.2(and)-298.2(melatonin)-301.8(are)-299.3(discussed)]TJ
-12.32 -1.1174 TD
[(in)-336.4(more)-335.1(detail.)]TJ
/F12 1 Tf
8.9663 0 0 8.9663 59.7543 538.8093 Tm
[(Vitamin)-341(D)]TJ
/F5 1 Tf
9.843 0 0 9.843 69.7323 522.3683 Tm
[(Three)-337.3(meta-analyses)-338(published)-333.7(in)-330.6(2017)-332.7(examined)-330.4(the)-332.9(re-)]TJ
-1.0137 -1.1116 TD
[(lationship)-214.1(between)-213.8(vitamin)-217.8(D)-209.3(and)-211.8(lung)-211.9(cancer.)-216.3(Regarding)-209.2(the)]TJ
0 -1.1174 TD
[(prevention)-267(of)-261.4(lung)-258(cancer,)-262.3(high)-263.7(serum)-261.1(25-hydroxyvitamin)-263.4(D)]TJ
0 -1.1116 TD
[(levels)-550.4(were)-543.2(associated)-551.2(with)-546.9(a)-543.7(16%)-545.8(risk)-545.7(reduction)-548.1(\(95%)]TJ
T*
(CI)Tj
/F10 1 Tf
1.1692 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.740.95;)Tj
/F13 1 Tf
4.7806 0 TD
(n)Tj
/F10 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(17)-503.3(studies)-504.1(and)-505.6(4368)-499.7(cases\),)-508.4(and)-505.6(each)]TJ
-8.0578 -1.1174 TD
[(10)-169.2(nmol/L)-337.6(increase)-341.7(in)-336.4(25\(OH\)D)-338.6(levels)-337.3(conferred)-341.6(an)-337.4(8%)-331.6(re-)]TJ
0 -1.1116 TD
[(duction)-222.2(in)-215.4(lung)-217.6(cancer)-218.6(risk)-217.4(and)-217.6(a)-221.1(7)0(%)-216.4(reduction)-219.8(in)-215.4(lung)-217.6(cancer)]TJ
T*
(mortality.)Tj
7.3823 0 0 6.5614 98.5322 450.0282 Tm
(30)Tj
9.843 0 0 9.843 108.5669 445.6629 Tm
[(One)-276(meta-analysis)-273.6(showed)-273.4(a)-273(nonsignicant)-275.9(cor-)]TJ
-4.9591 -1.1116 TD
[(relation)-224.6(between)-225.3(overall)-223.4(survival)-223.1(in)-215.4(patients)-224.4(with)-224.4(lung)-217.6(cancer)]TJ
0 -1.1174 TD
[(and)-488.3(low)-488.1(circulating)-494.1(25\(OH\)D)-488.3(levels)-487.1(\(adjusted)-490.3(hazard)-488.1(ra-)]TJ
0 -1.1116 TD
(tio)Tj
/F10 1 Tf
1.2326 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(1.25;)Tj
/F13 1 Tf
2.3672 0 TD
(p)Tj
/F10 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.13;)Tj
/F13 1 Tf
2.373 0 TD
(n)Tj
/F10 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(8)-340.9(studies\),)]TJ
7.3823 0 0 6.5614 194.2866 417.1464 Tm
(31)Tj
9.843 0 0 9.843 205.0582 412.781 Tm
[(and)-338.5(another)-344.2(showed)-342.5(no)]TJ
-14.7621 -1.1116 TD
[(relationship)-223.2(at)-222.4(all)-217.8(\(RR)]TJ
/F10 1 Tf
8.9679 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(1.01;)-221.1(95%)-217.5(CI)]TJ
/F10 1 Tf
5.4717 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
(0.881.16;)Tj
/F13 1 Tf
4.5041 0 TD
(p)Tj
/F10 1 Tf
.6681 0 TD
(<)Tj
/F5 1 Tf
.7142 0 TD
(0.001;)Tj
/F13 1 Tf
-21.7602 -1.1174 TD
(n)Tj
/F10 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(5)-185.4(studies\).)]TJ
7.3823 0 0 6.5614 113.2724 395.2062 Tm
(30)Tj
9.843 0 0 9.843 122.5133 390.8408 Tm
[(Finally,)-185.3(high)-188.8(vitamin)-189(D)-186.3(intake)-187.7(was)-189.5(associated)]TJ
-6.376 -1.1116 TD
[(with)-224.4(a)-221.1(28%)-217.5(reduced)-224.3(risk)-223.2(of)-215.3(lung)-223.4(cancer)-224.3(\(95%)-218.5(CI)]TJ
/F10 1 Tf
19.295 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
(0.610.85;)Tj
/F13 1 Tf
-20.0092 -1.1116 TD
(p)Tj
/F10 1 Tf
.6681 0 TD
(<)Tj
/F5 1 Tf
.72 0 TD
[(0.001\),)-260(particularly)-264.8(in)-261.5(nonsmokers.)]TJ
7.3823 0 0 6.5614 212.3716 373.3228 Tm
(32)Tj
9.843 0 0 9.843 69.7323 357.959 Tm
[(One)-431.6(group)-437.5(of)-428.4(researchers)-437.9(took)-436.5(another)-430.6(approach)-438.5(to)-428.5(the)]TJ
-1.0137 -1.1116 TD
[(question)-321.1(of)-318.9(vitamin)-321.5(D)-318.7(supplement)-8.9(ation:)-319.2(they)-316.7(found)-322.3(that)-316.9(the)]TJ
T*
[(stage)-307.3(of)-301.7(disease)-304.7(was)-298.9(an)-302.9(important)-306.4(factor.)-300.4(In)-301.7(their)-306.4(studies,)-300.2(in)]TJ
0 -1.1174 TD
[(the)-344.4(early)-347.7(stages)-348.5(of)-342(the)-344.4(disease,)-348.4(surgery)-348.4(combined)-346.6(with)-345.4(die-)]TJ
0 -1.1116 TD
[(tary)-581.6(vitamin)-586.5(D)-577.9(intake)-585.2(was)-581.1(associated)-585.7(with)-581.5(signicantly)]TJ
T*
[(improved)-414.5(survival)-418.9(rates)-410.9(in)-417(patients)-414.5(with)-414.5(NSCLC.)]TJ
7.3823 0 0 6.5614 262.5448 307.559 Tm
(33)Tj
9.843 0 0 9.843 273.9968 303.1936 Tm
[(In)-411.1(ad-)]TJ
-21.7659 -1.1116 TD
[(dition,)-315.7(levels)-314.3(of)-313.2(circulating)-315.6(vitamin)-315.8(D)-313(i)0(n)-313.4(the)-315.6(early)-313.2(stages)-313.9(of)]TJ
0 -1.1174 TD
[(disease)-408.4(were)-405(directly)-403.2(correlated)-407.5(with)-408.7(survival)-401.7(in)-399.7(these)-405.2(pa-)]TJ
0 -1.1116 TD
(tients.)Tj
7.3823 0 0 6.5614 83.6787 274.6771 Tm
(34)Tj
9.843 0 0 9.843 94.8472 270.3117 Tm
[(In)-388.1(patients)-391.5(with)-385.7(advanced-stage)-396.7(NSCLC,)-387.3(the)-390.5(situ-)]TJ
-3.5653 -1.1116 TD
[(ation)-461.9(was)-465.9(more)-461.8(complex.)-464.1(The)]TJ
/F13 1 Tf
13.2012 0 TD
(C/C)Tj
/F5 1 Tf
2.0735 0 TD
[(genotype)-466.3(of)-457.2(the)]TJ
/F13 1 Tf
7.1248 0 TD
(Fok)Tj
/F5 1 Tf
1.5609 0 TD
(I)Tj
-23.9604 -1.1174 TD
[(polymorphism,)-359(which)-353.3(is)-359.2(thought)-353.6(to)-353.7(have)-352.3(increased)-360.1(vitamin)]TJ
0 -1.1116 TD
[(D)-318.7(receptor)-323.4(activity,)-320.4(was)-321.9(associated)-326.6(with)-316.6(improved)-322.3(survival.)]TJ
T*
[(However,)-683.3(the)]TJ
/F13 1 Tf
6.5085 0 TD
(G-T-C)Tj
/F5 1 Tf
3.283 0 TD
(\()Tj
/F13 1 Tf
.3341 0 TD
(Cdx-2-Fok)Tj
/F5 1 Tf
4.3428 0 TD
(I)Tj
/F13 1 Tf
.3341 0 TD
(-Bsm)Tj
/F5 1 Tf
2.0505 0 TD
[(I\))-681.8(polymorphism,)]TJ
-16.8529 -1.1174 TD
[(which)-445.4(is)-434.1(thought)-440(to)-440.1(have)-438.7(reduced)-443.1(vitamin)-442.5(D)-439.7(receptor)-438.6(ac-)]TJ
0 -1.1116 TD
[(tivity,)-310.1(was)-310.4(associated)-315(with)-310.8(poor)-309.6(survival.)-307.2(This)-310.8(suggests)-314.8(that)]TJ
T*
[(in)-382.5(patients)-380(with)-379.9(certain)-385.8(types)-375.2(of)-382.3(advanced)-382.1(disease,)-383(supple-)]TJ
0 -1.1174 TD
[(mentation)-566.8(with)-564.2(vitamin)-557.7(D)-566.4(might)-559.9(increase)-566.3(mortality)-560(and)]TJ
0 -1.1116 TD
[(those)-501.9(patients)-500.9(should)-496.1(avoid)-496.4(the)-499.9(use)-493.8(of)-497.5(vitamin)-500.1(D.)-495(Thus,)]TJ
T*
[(caution)-344.4(is)-336.2(needed.)-341.8(Researchers)-341.1(concluded)-341.8(that)-339.9(further)-343(stud-)]TJ
T*
[(ies)-465.2(are)-466.4(needed)-470.9(to)-463.1(conrm)-463.8(vitamin)-465.5(Ds)-470.5(role)-460.7(in)-468.9(improving)]TJ
0 -1.1174 TD
[(outcomes)-340.6(in)-330.6(patients)-339.6(with)-333.8(advanced)-336(lung)-332.8(cancer.)]TJ
7.3823 0 0 6.5614 256.422 143.1496 Tm
(35)Tj
/F12 1 Tf
8.9663 0 0 8.9663 59.7543 116.8441 Tm
[(Fish)-335.3(oil)]TJ
/F5 1 Tf
9.843 0 0 9.843 69.7323 100.4031 Tm
(Multiple)Tj
/F13 1 Tf
3.8014 0 TD
[(in)-342.1(vitro)]TJ
/F5 1 Tf
3.3579 0 TD
[(studies)-342.8(have)-340.8(shown)-346(that)-339.9(omega-3)-345.3(poly-)]TJ
-8.173 -1.1116 TD
[(unsaturated)-390(fatty)-381.3(acids)-382.1(\(sh)-384.2(oil\))-384.8(have)-381.1(activity)-386(against)-384.5(lung)]TJ
0 -1.1174 TD
[(cancer)-552.6(cell)-548.4(lines.)]TJ
7.3823 0 0 6.5614 131.811 82.885 Tm
(3638)Tj
9.843 0 0 9.843 155.6787 78.463 Tm
[(There)-550.4(is)-543.5(also)-546.9(some)-548(evidence)-549.2(that)]TJ
-9.7454 -1.1116 TD
[(adding)-422.6(sh)-411.9(oil)-418.3(in)-417(clinical)-421.8(care)-416.8(carries)-425.8(some)-415.5(benet.)-421.3(Lung)]TJ
T*
[(cancer)-397.1(patients)-397.2(who)-390.1(used)-397(sh)-388.8(oil)-395.2(supplements)-395.7(during)-392.6(che-)]TJ
25.5097 67.9242 TD
[(motherapy)-249.7(showed)-256.1(signicantly)-251.9(higher)-249.8(rates)-255.4(of)-249.8(response)-252.6(and)]TJ
0 -1.1174 TD
[(objectively)-321.4(longer)-324.7(overall)-327.1(survival.)-324.5(These)-319.9(benets)-326.6(were)-324.4(not)]TJ
0 -1.1116 TD
[(accompanied)-336.1(by)-336.3(any)-332.8(increase)-335.9(in)-336.4(dose-limiting)-333.9(toxicities.)]TJ
7.3823 0 0 6.5614 538.3558 707.5841 Tm
(39)Tj
9.843 0 0 9.843 320.8251 692.277 Tm
[(In)-324.7(a)-324.8(double-blind)-325.8(experiment)-332.8(with)-322.3(40)-324.7(patients)-328.1(with)-328.1(stage)]TJ
-1.0137 -1.1116 TD
[(III)-475.5(NSCLC,)-479.5(patients)-477.9(were)-479.9(randomized)-482.4(to)-474.6(receive)-484.8(an)-475.7(oral)]TJ
0 -1.1174 TD
[(nutritional)-330.7(supplement)-337.2(containing)-330.5(n-3)-331.6(polyunsaturated)-337(fatty)]TJ
0 -1.1116 TD
[(acids)-681.7(\(2.02)-169.1(g)-680.7(eicosapentaenoic)-688.3(acid)]TJ
/F10 1 Tf
16.0753 0 TD
(+)Tj
/F5 1 Tf
.5529 0 TD
[(0.92)-168(g)-680.7(docosahex-)]TJ
-16.6283 -1.1116 TD
[(aenoic)-471(acid)-473.4(per)-476.7(day\))-472.1(or)-468.7(an)-469.9(isocaloric)-481.2(control)-469.9(supplement)]TJ
0 -1.1174 TD
[(during)-312(multimodality)-318.2(treatment.)-317.9(Patients)-316.4(in)-313.4(the)-315.6(intervention)]TJ
0 -1.1116 TD
[(group)-258.9(reported)-264.6(a)-261.4(signicantly)-263.4(higher)-261.3(quality)-262.7(of)-261.3(life,)-262.7(physical)]TJ
T*
[(and)-603.5(cognitive)-605.9(function,)-601.1(global)-607(health)-602.4(status,)-604.3(and)-603.5(social)]TJ
0 -1.1174 TD
[(function)-355.8(than)-357(those)-357.9(in)-359.4(the)-355.9(control)-354.7(group.)]TJ
7.3823 0 0 6.5614 475.8235 608.9951 Tm
(40)Tj
9.843 0 0 9.843 486.7085 604.5731 Tm
[(In)-359.3(a)-353.6(small)-359.3(mul-)]TJ
-17.8666 -1.1116 TD
[(ticenter,)-563.3(randomized,)-566.4(double-blind)-567.7(trial)-565.7(with)-558.5(33)-566.7(patients)]TJ
T*
[(diagnosed)-357.8(with)-356.9(advanced)-359.1(inoperable)-360.3(NSCLC)-355.1(and)-361.6(undergo-)]TJ
T*
[(ing)-262.6(chemotherapy,)-264.5(eicosapentaenoic)-273.6(acid)]TJ
/F10 1 Tf
16.7147 0 TD
(+)Tj
/F5 1 Tf
.72 0 TD
(docosahexaenoic)Tj
-17.4346 -1.1174 TD
[(acid)-398.5(supplementation)-401.7(was)-396.8(associated)-407.2(with)-397.2(a)-399.7(signicant)-399.3(in-)]TJ
0 -1.1116 TD
[(crease)-512.1(in)-509.2(weight,)-513.4(as)-515.8(well)-507.8(as)-515.8(anti-inammatory)-513.5(and)-511.3(anti-)]TJ
T*
[(oxidative)-335.2(effects.)]TJ
7.3823 0 0 6.5614 379.729 543.2313 Tm
(41)Tj
/F12 1 Tf
8.9663 0 0 8.9663 310.8472 511.4266 Tm
(Melatonin)Tj
/F5 1 Tf
9.843 0 0 9.843 320.8251 494.9857 Tm
[(Melatonin)-284.2(is)-284.4(a)-284.5(hormone)-286.5(produced)-281.8(within)-290.1(the)-281.1(pineal)-285.7(gland)]TJ
-1.0137 -1.1116 TD
[(from)-230.2(tryptophan,)-234.7(which)-232.3(is)-226.8(conve)-7.8(rted)-230.3(to)-227(5-hydr)-6.5(oxytryptophan)]TJ
0 -1.1174 TD
[(and)-390.4(nally)-399.5(to)-388.2(melatonin.)-397.4(Numerous)-397.8(recent)]TJ
/F13 1 Tf
18.0452 0 TD
[(in)-394(vitro)]TJ
/F5 1 Tf
3.4616 0 TD
(studies)Tj
-21.5067 -1.1116 TD
[(have)-219.8(shown)-213.5(promise)-223.1(for)-216.3(the)-217.7(use)-217.4(of)-215.3(melatonin)-221.2(in)-215.4(the)-217.7(treatment)]TJ
T*
[(of)-336.2(lung)-332.8(cancer.)]TJ
7.3823 0 0 6.5614 371.4518 455.5274 Tm
(4244)Tj
9.843 0 0 9.843 393.2786 451.1621 Tm
[(Earlier)-339.7(human)-336.2(studies)-337(by)-330.5(Lisson)-7.5(i)-329.5(e)0(t)-337.6(al.)]TJ
-8.3746 -1.1174 TD
[(showed)-405.9(signicantly)-413.1(increased)-411.9(survival)-407.4(and)-407.6(quality)-406.7(of)-405.3(life)]TJ
0 -1.1116 TD
[(among)-503.2(lung)-499.9(cancer)-506.6(patients)-500.9(who)-505.3(used)-500.7(melatonin)-503.4(supple-)]TJ
T*
(mentation.)Tj
7.3823 0 0 6.5614 352.8566 422.6456 Tm
(45)Tj
9.843 0 0 9.843 362.5511 418.2802 Tm
[(However,)-239.8(a)-232.6(2014)-234.8(randomized)-234.7(controlled)-238.3(trial)-237.4(of)]TJ
-5.2528 -1.1174 TD
[(151)-325.8(patients)-333.9(with)-333.8(NSCLC)-332(that)-328.4(showed)-331(improved)-333.9(quality)-331.8(of)]TJ
0 -1.1116 TD
[(life)-357.1(with)-356.9(treatment)-360.6(with)-356.9(melatonin)-359.4(\(either)-361.6(10)-353.5(or)-359.3(20)-169.2(mg\))-355.8(re-)]TJ
T*
[(vealed)-263.6(no)-261.4(signicant)-261(difference)-263.4(in)-261.5(median)-263.7(survival.)]TJ
7.3823 0 0 6.5614 514.1479 389.7637 Tm
(46)Tj
/F15 1 Tf
8.9663 0 0 8.9663 310.8472 357.959 Tm
(Astragalus)Tj
/F13 1 Tf
9.843 0 0 9.843 320.8251 341.518 Tm
(Astragalus)Tj
/F5 1 Tf
4.5559 0 TD
[(is)-221(a)-221.1(unique)-226.8(herbal)-222.1(remedy)-229(that)-224.7(has)-223.1(been)-225.6(used)-224.2(in)]TJ
-5.5696 -1.1116 TD
[(Traditional)-448.1(Chinese)-443(Medicine)-451.2(for)-441(thousands)-448.6(of)-439.9(years.)]TJ
/F13 1 Tf
22.9582 0 TD
(As-)Tj
-22.9582 -1.1116 TD
(tragalus)Tj
/F5 1 Tf
3.5134 0 TD
[(is)-180.7(an)-181.9(adaptogenic)-184.1(herb)-184.1(that)-178.6(is)-180.7(thought)-180.8(to)-180.9(play)-184.2(a)-180.8(role)-184.2(in)]TJ
-3.5134 -1.1174 TD
[(protecting)-624.2(the)-615.1(body)-620.7(against)-626.4(various)-619.3(stressors,)-624.3(including)]TJ
0 -1.1116 TD
[(physical,)-193.2(mental,)-198.2(or)-192.2(emotional)-192.4(stress.)-195(The)]TJ
/F13 1 Tf
16.6225 0 TD
(Astragalus)Tj
/F5 1 Tf
4.5271 0 TD
[(root)-194.6(has)]TJ
-21.1496 -1.1116 TD
[(antioxidant)-400.9(effects)-402.7(and)-396.1(also)-402.9(affects)-402.7(the)-396.3(immune)-402(system.)-403.8(It)]TJ
0 -1.1174 TD
[(contains)-230.1(a)-226.9(variety)-229.1(of)-232.6(components,)-231.1(including)-230.3(saponins)-228.6(such)-230(as)]TJ
0 -1.1116 TD
[(astragaloside,)-362.2(polysaccharides,)-365.4(multiple)-363.1(trace)-360.4(minerals,)-361.4(a-)]TJ
T*
[(vonoids,)-258.8(and)-263.6(amino)-261.5(acids.)]TJ
7.3823 0 0 6.5614 413.8582 258.2361 Tm
(47)Tj
9.843 0 0 9.843 320.8251 242.8724 Tm
[(A)-353.3(2016)-355.7(meta-analysis)-365.8(of)]TJ
/F13 1 Tf
10.4942 0 TD
(Astragalus)Tj
/F5 1 Tf
4.6942 0 TD
[(use)-355.6(in)-353.7(patients)-362.7(with)]TJ
-16.202 -1.1116 TD
[(advanced)-226.6(NSCLC)-228.4(showed)-227.3(improved)-230.2(overall)-229.1(survival)-228.9(\(hazard)]TJ
T*
(ratio)Tj
/F10 1 Tf
2.0101 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.61;)-163.5(95%)-165.6(CI)]TJ
/F10 1 Tf
5.3623 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.420.89;)Tj
/F13 1 Tf
4.4465 0 TD
(p)Tj
/F10 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.011;)Tj
/F13 1 Tf
2.6955 0 TD
(n)Tj
/F10 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(17)-163.5(studies)-170(and)]TJ
-18.7306 -1.1116 TD
[(1552)-159.9(patients\),)-165.6(improved)-161.1(performance)-167.7(status)-163.2(\(RR)]TJ
/F10 1 Tf
19.5427 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.43;)-163.5(95%)]TJ
-20.2626 -1.1174 TD
(CI)Tj
/F10 1 Tf
1.1635 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.340.55;)Tj
/F13 1 Tf
4.6596 0 TD
(p)Tj
/F10 1 Tf
.6681 0 TD
(<)Tj
/F5 1 Tf
.7142 0 TD
[(0.001\),)-381(and)-378.8(tumor)-375.5(overall)-378.9(response)-379.3(rate)]TJ
-7.9254 -1.1116 TD
(\(RR)Tj
/F10 1 Tf
1.8316 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.7982;)-453.7(95%)-447.9(CI)]TJ
/F10 1 Tf
6.9347 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.7150.89;)Tj
/F13 1 Tf
5.2298 0 TD
(p)Tj
/F10 1 Tf
.6681 0 TD
(<)Tj
/F5 1 Tf
.72 0 TD
[(0.001\),)-450.1(and)-453.7(fewer)]TJ
-16.8241 -1.1116 TD
[(side)-477.8(effects)-477.6(compared)-480(with)-477.8(platinum-based)-486.9(chemotherapy)]TJ
0 -1.1174 TD
(alone.)Tj
7.3823 0 0 6.5614 334.7149 170.5323 Tm
(48)Tj
/F15 1 Tf
8.9663 0 0 8.9663 310.8472 138.7842 Tm
[(Trametes)-335.5(versicolor)-332.5(\(Coriolus)-336.2(versicolor\))]TJ
/F13 1 Tf
9.843 0 0 9.843 320.8251 122.3433 Tm
(Trametes)Tj
/F5 1 Tf
3.9108 0 TD
(\()Tj
/F13 1 Tf
.3341 0 TD
(Coriolus)Tj
/F5 1 Tf
3.4961 0 TD
(\))Tj
/F13 1 Tf
.5299 0 TD
(versicolor)Tj
/F5 1 Tf
4.2564 0 TD
[(is)-192.2(a)-192.3(mushroom,)-193(also)-195.6(known)]TJ
-13.5411 -1.1174 TD
[(as)-170.2(turkey)-174.9(tail,)-176.4(that)-172.9(contains)-172.5(several)-178.1(polysaccharides,)-181.1(including)]TJ
0 -1.1116 TD
[(polysaccharide)-620.3(peptide)-620.8(and)-615(polysaccharide)-626(krestin,)-617.1(both)]TJ
T*
[(shown)-190.5(to)-192.4(have)-191(antitumor)-197(and)-194.5(immunomodulating)-195.8(effects.)]TJ
7.3823 0 0 6.5614 533.5936 93.8268 Tm
(49)Tj
9.843 0 0 9.843 542.8912 89.4614 Tm
(A)Tj
-23.5745 -1.1174 TD
[(2015)-424.9(systematic)-430.4(review)-430.4(of)-428.4(polysaccharide)-436(K)-428.2(from)]TJ
/F13 1 Tf
21.4779 0 TD
(T.)Tj
/F5 1 Tf
1.2268 0 TD
(\()Tj
/F13 1 Tf
.3341 0 TD
(C.)Tj
/F5 1 Tf
.9158 0 TD
(\))Tj
/F13 1 Tf
-23.9546 -1.1116 TD
(versicolor)Tj
/F5 1 Tf
4.4522 0 TD
[(showed)-394.4(supportive)-392.4(evidence)-393.7(for)-389.1(activity)-391.8(again)-8(st)]TJ
-4.4522 -1.1116 TD
[(lung)-211.9(cancer)-218.6(in)-209.7(15)-215.3(of)-209.5(17)-215.3(preclinical)-218.8(studies,)-213.8(improved)-218.7(survival)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(INTEGRATIVE)-339.7(MEDICINE)-335.4(IN)-335.1(LUNG)-336.8(CANCER)-31974.3(865)]TJ
ET
endstream
endobj
58 0 obj
<>stream
hTR{LSwݖvy⦆!UlCPlZz:Vb72|
0n8r: NP# Bsd?圓}HP5-#3gYVFt*'1=5~9JS0hTUh DAQMTg(.oL1%&/؝6I=R[\Z^tU8]VdŔRܒ*.J$*:ܢUvz_t3NBSr\Ktglnau9$wEWdAfdI#d YFV,Crj#dzBhb RGnaj9w~Eb\ܪ<j,=P",4=fiO1B!aL/x@ *CCLs{Љ4鱺 &H9
4}aS} N=dnU-UyF Qh`pj1+
EPG;X*0#tV>]3jO
%fav=Gk`L؎U>g{U2ۢO=o϶EuMoZ̀c1t}M7癖w^n>_ҺqRG١QaBd1PQ{&oiKS73O(hdYF.gYKÊPcW=h?rcu'M}A_C/aZHDar4}JHc^$٣
LV]1UI{h~`g
~0QC3Alms"OpAZ 3ޖTR\h?TŮrn|FZsF`
"p%C8ќChA{u镨&F[ `PK]
ѵ;kqK߳e_ʕ'' ٳbIn-/ĥض٪_ʕӶ^?O3(`]@nJHŇ+_pM[ Ҁin_L5
֞Koɞs3yN~*WY0jS3:\|ן^=TLTyhRͦ!w̯zDٯZ}a:e` oDZ
endstream
endobj
61 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 62.022 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(in)-255.8(5)-254.5(nonrandomized)-255.3(clinical)-260.5(trials,)-259(and)-252.1(objectively)-258(improved)]TJ
0 -1.1174 TD
[(quality)-176.3(of)-169.2(life)-172.8(and)-171.5(survival)-171.3(in)-175.1(6)-168.1(randomized)-177.1(controlled)-175(trials.)]TJ
7.3823 0 0 6.5614 293.7259 718.5825 Tm
(50)Tj
/F4 1 Tf
8.9663 0 0 8.9663 62.022 692.2203 Tm
[(Physical)-336.1(Activity)]TJ
/F5 1 Tf
9.843 0 0 9.843 72 675.7794 Tm
[(Physical)-201.1(activity)-196(is)-198(known)-196.5(to)-198.2(improve)-200.3(quality)-193.6(of)-198(life)-201.6(during)]TJ
-1.0137 -1.1116 TD
[(and)-407.6(after)-405.3(cancer)-408.6(therapy.)-405.2(These)-412(effects)-408.5(include)-407.7(alleviating)]TJ
T*
[(physical)-483.5(and)-476.8(mental)-482.7(fatigue,)-480.2(reducing)-483.5(anxiety,)-480.3(increasing)]TJ
0 -1.1174 TD
[(cognitive)-202.7(function,)-197.9(improving)-201.4(self-esteem,)-199.8(increasing)-204.6(muscle)]TJ
0 -1.1116 TD
[(tone)-478(and)-471(balan)-8(ce,)-474.5(helping)-475.7(manage)-477.9(weight,)-478.9(enhancing)-474.3(the)]TJ
T*
[(immune)-436.6(system,)-438.4(and)-436.4(even)-432.9(reducing)-437.5(the)-436.6(chances)-438.4(for)-435.2(other)]TJ
0 -1.1174 TD
[(illnesses)-305.8(such)-299.1(as)-302.7(heart)-301.7(disease,)-308.1(adult-onset)-302.6(diabetes,)-303.8(and)-304(os-)]TJ
0 -1.1116 TD
(teoporosis.)Tj
7.3823 0 0 6.5614 104.9952 603.4392 Tm
(11,51)Tj
9.843 0 0 9.843 125.2346 599.0739 Tm
[(In)-365(a)-365.1(systematic)-372.8(review)-367(of)-365(45)-365.1(U.S.)-366.9(National)]TJ
-6.4221 -1.1116 TD
[(Cancer)-598.6(Institute-designated)-597.2(comprehens)-9.8(ive)-592.1(cancer)-598.7(center)]TJ
0 -1.1174 TD
[(websites,)-527.9(researchers)-530.1(found)-523.8(that)-524.2(the)-528.7(most)-523.9(common)-522.9(CIM)]TJ
0 -1.1116 TD
[(therapy,)-261.2(that)-265(is)-261.3(being)-260.2(discussed,)-262.9(is)-261.3(exercise)-266.8(\(97.8%\).)]TJ
7.3823 0 0 6.5614 269.0645 570.5574 Tm
(52)Tj
9.843 0 0 9.843 72 555.2502 Tm
[(Evidence)-393.8(from)-385.7(prospective)-395.8(and)-384.6(casecontro)-10.9(l)-387.1(studies)-388.9(has)]TJ
-1.0137 -1.1116 TD
[(shown)-248.1(that)-247.7(the)-246.5(risk)-246.2(of)-244.1(lung)-246.4(cancer)-253.1(is)-244(reduced)-247.3(with)-247.4(increasing)]TJ
0 -1.1174 TD
[(levels)-435.2(of)-434.1(physic)-7.7(al)-429.7(activity.)-441.3(The)-437.6(2007)-430.6(WCRF/AICR)-443.3(report)]TJ
0 -1.1116 TD
[(mentioned)-514.8(5)-507.9(cohort)-509(studies)-509.8(investigating)-512.4(the)-511.4(relationship)]TJ
T*
[(between)-455.7(total)-456.3(physical)-454.7(activity)-455.2(and)-453.7(lung)-453.8(cancer,)-458.2(2)-456.1(cohort)]TJ
0 -1.1174 TD
[(studies)-302.5(investigating)-299.3(nonrecreational)-304.9(activity,)-303.1(and)-298.2(11)-301.7(cohort)]TJ
0 -1.1116 TD
[(studies)-296.7(and)-298.2(4)-294.8(casecontrol)-300.1(studies)-296.7(investigating)-299.3(recreational)]TJ
T*
[(activity)-236.3(as)-233.6(it)-232.8(relates)-235.9(to)-232.7(lung)-229.2(cancer)-241.6(risk.)-232.4(Overall,)-233.4(most)-236(studies)]TJ
0 -1.1174 TD
[(showed)-342.5(a)-342.1(decre)-9(ased)-340.6(risk)-344.1(with)-339.6(increased)-348.5(physical)-345.3(activity.)]TJ
7.3823 0 0 6.5614 293.7259 471.9684 Tm
(11)Tj
9.843 0 0 9.843 62.022 456.6046 Tm
[(Extrapolating)-214.2(from)-212.9(other)-214.1(studies)-216.1(investigating)-212.9(different)-214(types)]TJ
0 -1.1116 TD
[(of)-388.1(cancer,)-389(clinicians)-395(often)-386.9(suggest)-388.8(150)-164.6(min)-390.6(of)-382.3(walking)-390.1(per)]TJ
T*
[(week)-261(at)-262.7(a)-261.4(speed)-261.1(of)-261.4(22.9)-261.3(miles/h)-263.7(\(3.24.6)-169(km/h\).)]TJ
7.3823 0 0 6.5614 254.7779 439.0865 Tm
(53)Tj
9.843 0 0 9.843 72 423.7227 Tm
[(Exercise)-186.2(training)-183.1(can)-178.4(be)-181.9(benecial)-187.5(at)-176.3(all)-183.3(stages)-181.5(of)-180.7(treatment)]TJ
-1.0137 -1.1116 TD
[(for)-331.5(lung)-332.8(cancer.)-337.2(Before)-332.4(surgery,)-334.6(after)-336.2(surgery,)-334.6(during)-335(treat-)]TJ
T*
[(ment,)-390.5(and)-390.4(even)-392.6(during)-386.8(palliative)-395.3(anticancer)-397.2(therapy)-390.3(in)-388.2(pa-)]TJ
0 -1.1174 TD
[(tients)-520.6(with)-518.1(advanced)-520.3(\(inoperable\))-518(lung)-517.1(cancer)-518.1(who)-516.8(have)]TJ
0 -1.1116 TD
[(compromised)-333.6(lung)-332.8(function,)-330.4(supervised)-335.6(exercise-based)-338.9(pul-)]TJ
T*
[(monary)-193.3(rehabilitation)-198.2(is)-192.2(thought)-192.3(to)-192.4(improve)-194.5(cardiorespiratory)]TJ
0 -1.1174 TD
[(tness)-312.6(and)-309.7(functional)-313.2(capacity.)]TJ
7.3823 0 0 6.5614 186.1228 362.381 Tm
(54)Tj
9.843 0 0 9.843 196.5543 357.959 Tm
[(A)-307.2(recent)-315.5(randomized)-309.6(con-)]TJ
-13.6678 -1.1116 TD
[(trolled)-285.7(study)-281.9(exam)-8(ined)-282.2(the)-286.8(effects)-287.5(of)-278.6(a)-284.5(12-week)-287.3(exercise)-289.8(in-)]TJ
T*
[(tervention)-163.5(on)-163.5(sleep)-163.3(and)-160(quality)-164.8(of)-157.7(life)-167.1(in)-157.8(111)-164.6(patients)-161.1(with)-161(lung)]TJ
0 -1.1174 TD
[(cancer.)-331.4(In)-318.9(that)-328.4(study,)-325.7(the)-327.1(intervention)-327.1(included)-322.4(home-based)]TJ
0 -1.1116 TD
[(walking)-683.9(exercise)-687.3(and)-684.1(weekly)-683.8(exercise)-687.3(counseling.)-685(Re-)]TJ
T*
[(searchers)-296.3(found)-293.5(that)-293.8(sleep)-295.7(in)-296.1(the)-292.6(exercise)-295.6(group)-293.5(was)-298.9(signi-)]TJ
T*
[(cantly)-216.5(improved)-212.9(at)-216.6(3)-208.4(and)-211.8(6)-214.2(months)-215.1(after)-215.2(the)-211.9(intervention.)-215.3(The)]TJ
0 -1.1174 TD
[(researchers)-317(concluded)-307.3(that)-311.1(walking)-309.5(is)-307.4(an)-308.6(effective)-314.3(interven-)]TJ
0 -1.1116 TD
[(tion)-321.4(for)-314.3(improving)-322.4(subjective)-320(and)-315.5(objective)-324.8(sleep)-318.8(quality)-320.3(in)]TJ
T*
[(patients)-212.9(with)-207.1(lung)-211.9(cancer)-212.8(and)-206.1(can)-213(be)-205(considered)-216(an)-204.9(additional)]TJ
0 -1.1174 TD
[(element)-266.1(of)-261.4(lung)-258(cancer)-264.7(rehabilitation.)]TJ
7.3823 0 0 6.5614 210.5007 252.7369 Tm
(55)Tj
/F4 1 Tf
8.9663 0 0 8.9663 62.022 226.4315 Tm
[(MindBody)-340.8(Therapies)]TJ
/F5 1 Tf
9.843 0 0 9.843 72 209.9905 Tm
[(Mindbody)-466(therapies,)-471.9(including)-472.2(stress)-473.8(reduction,)-470.9(medi-)]TJ
-1.0137 -1.1116 TD
[(tation,)-472.4(yoga,)-469.8(massage,)-470.5(and)-471(music)-468.6(therapy,)-474.3(are)-466.4(commonly)]TJ
0 -1.1174 TD
[(used)-431.6(in)-434.3(most)-431.8(comprehensive)-434.8(cancer)-431.7(centers)-437.3(in)-428.5(the)-436.6(United)]TJ
0 -1.1116 TD
[(States.)-300.3(This)-305(increased)-302.5(use)-298(reects)-304.7(the)-298.3(current)-303.8(understanding)]TJ
T*
[(that)-437.8(these)-439.7(therapies)-439.7(have)-438.7(an)-435.3(essential)-439.6(role)-437.6(in)-440.1(approaching)]TJ
T*
[(cancer)-696.6(patients)-691(in)-693.5(general.)]TJ
7.3823 0 0 6.5614 178.2991 159.5905 Tm
(52)Tj
9.843 0 0 9.843 192.4724 155.2252 Tm
[(Stress,)-696.2(when)-691.8(experienced)]TJ
-13.2531 -1.1174 TD
[(chronically,)-341.9(leads)-336.1(to)-330.6(the)-338.7(activation)-337.6(of)-336.2(neuroendocrine)-336.9(path-)]TJ
0 -1.1116 TD
[(ways,)-499.3(including)-501(the)-499.9(sympathetic)-500.8(nervous)-504(system)-498.3(and)-499.8(the)]TJ
T*
[(hypothalamicpituitaryadrenal)-400.5(axis.)-394.8(Biologic)-397.3(mechanisms)]TJ
0 -1.1174 TD
[(identied)-335(as)-331.5(having)-330.4(potential)-335.3(direct)-331.7(carcinogenic)-336.1(effects)-333.6(on)]TJ
0 -1.1116 TD
[(the)-459.6(sympathetic)-466.3(nervous)-463.7(system)-458(include)-465.3(DNA)-460.9(repair,)-461.7(on-)]TJ
T*
[(cogene)-355.7(activation,)-352.5(inammation)-357(and)-350(immune)-350.2(response,)-354(he-)]TJ
0 -1.1174 TD
[(matopoiesis,)-335.9(angiogenesis,)-342.6(survival,)-336(and)-332.8(apoptosis.)]TJ
7.3823 0 0 6.5614 266.3999 82.885 Tm
(56)Tj
9.843 0 0 9.843 72 67.5212 Tm
[(In)-393.8(a)-393.9(recent)-396.1(study,)-389(resear)-9.8(chers)-393.5(found)-391.4(that)-397.5(prolonged)-391.3(em-)]TJ
-1.0137 -1.1116 TD
[(ployment)-426.2(in)-428.5(a)-428.5(stressful)-425.4(job)-429.6(was)-425.6(associated)-430.2(with)-426(increased)]TJ
25.504 67.9242 TD
[(odds)-488(of)-480.2(developing)-485.9(cancers)-490.2(of)-486(the)-482.6(lung.)]TJ
7.3823 0 0 6.5614 482.2298 729.5242 Tm
(57)Tj
9.843 0 0 9.843 494.3621 725.1588 Tm
[(In)-486(addition)-482.7(to)]TJ
-18.4195 -1.1174 TD
[(stress)-427.7(being)-421.5(a)-417(possible)-424.5(etiologic)-421.7(factor)-423.7(in)-422.8(lung)-419.2(cancer)-420.2(de-)]TJ
0 -1.1116 TD
[(velopment,)-328.2(the)-315.6(diagnosis)-327.7(of)-319(lung)-315.6(cancer)-328(by)-319(itself)-319(is)-324.7(a)-319(cause)]TJ
T*
[(for)-377.6(emotional)-371(reactions)-376.3(such)-374(as)-371.8(anxiety,)-376.6(stress,)-373.6(depression,)]TJ
T*
[(and)-257.9(fear.)]TJ
7.3823 0 0 6.5614 347.6975 685.7006 Tm
(58)Tj
9.843 0 0 9.843 357.6188 681.3352 Tm
[(Untreated)-262.2(mood)-253.3(disorders)-258.4(can)-259.1(negatively)-262.6(affect)-257.8(a)]TJ
-4.5271 -1.1174 TD
[(patients)-346.5(quality)-337.6(of)-342(life,)-337.5(level)-342.2(of)-336.2(pain,)-343.2(and)-338.5(response)-339(to)-342.2(che-)]TJ
0 -1.1116 TD
[(motherapy.)-500.8(Reducing)-496.1(negative)-496.4(emotions,)-492.8(such)-494.9(as)-492.7(depres-)]TJ
T*
[(sion,)-336.1(may)-334(increase)-341.7(survival.)]TJ
7.3823 0 0 6.5614 425.4802 652.8187 Tm
(59,60)Tj
9.843 0 0 9.843 323.0361 637.455 Tm
[(Animal)-275.1(studies)-273.7(also)-270.4(support)-272.6(this)-269.4(observation;)-274.9(psychologic)]TJ
-1.0137 -1.1116 TD
[(distress)-234.2(was)-229.8(shown)-225.1(to)-227(be)-228(associated)-234.4(with)-224.4(faster)-233.4(tumor)-225.7(growth)]TJ
T*
[(and)-234.9(spread)-233.3(in)-226.9(mice.)]TJ
7.3823 0 0 6.5614 389.3101 619.9368 Tm
(61,62)Tj
9.843 0 0 9.843 408.1888 615.5715 Tm
[(Because)-237.8(most)-230.2(patients)-230.2(are)-236(diagnosed)]TJ
-9.6648 -1.1174 TD
[(with)-207.1(lung)-206.1(cancer)-207.1(in)-203.9(the)-206.2(advanced)-209.3(stage,)-207(when)-202.3(the)-206.2(prognosis)-205.5(is)]TJ
0 -1.1116 TD
[(poor,)-232.4(the)-235(stress)-231.9(and)-229.1(anxiety)-234.9(that)-230.5(these)-232.4(patients)-236(experience)-235.8(are)]TJ
T*
[(quite)-467.7(high.)-463(Most)-466(CIM)-466(practitioners)-473.1(agree)-464(that)-466.6(integrating)]TJ
T*
[(mindbody)-224.4(therapies)-220.8(in)-221.2(cancer)-224.3(care)-221(is)-221(an)-222.2(essential)-226.5(element)-220(in)]TJ
0 -1.1174 TD
[(caring)-302.8(for)-297(patients)-299.3(with)-299.3(cancer,)-302.6(especially)-303.8(in)-296.1(patients)-299.3(with)-299.3(a)]TJ
0 -1.1116 TD
[(poor)-263.6(prognosis.)]TJ
7.3823 0 0 6.5614 374.3999 554.1731 Tm
(63)Tj
9.843 0 0 9.843 323.0361 538.866 Tm
[(Some)-173.7(argue)-169.1(that)-172.9(current)-177.1(research)-174.5(includes)-172.5(a)-169.3(limited)-171.9(number)]TJ
-1.0137 -1.1174 TD
[(of)-353.5(controlled)-353.5(studies)-354.3(in)-347.9(oncology)-349.9(populations,)-356.7(and)-350(thus,)-347.6(no)]TJ
0 -1.1116 TD
[(clear)-251(conclusions)-250.5(can)-247.5(be)-245.3(drawn.)-252.8(However,)-245.6(the)-246.5(few)-247.2(published)]TJ
T*
[(trials)-342(appear)-332.6(to)-336.4(show)-339.1(that)-334.1(mindbody)-333.8(therapies)-341.7(have)-335(prom-)]TJ
0 -1.1174 TD
[(ising)-247.5(effects)-247.2(on)-249.9(the)-240.7(immune)-246.5(system,)-248.3(health-related)-252.1(quality)-245.4(of)]TJ
0 -1.1116 TD
[(life,)-274.2(functional)-272.9(capacity,)-276.3(and)-275.2(mood.)-268.3(As)-273.6(a)-267.2(result,)-276.2(most)-270.5(cancer)]TJ
T*
[(centers)-235.7(do)-226.8(combine)-236(mindbody)-230.2(therapies)-232.3(into)-229.3(their)-231.5(CIM)-229.8(care)]TJ
0 -1.1174 TD
[(plan.)-372(In)-370.8(a)-370.9(study)-368.3(of)-365(265)-371.9(patients,)-371.9(including)-368.6(those)-369.5(with)-374.2(lung)]TJ
0 -1.1116 TD
[(cancer,)-262.3(conducted)-261.2(at)-256.9(The)-259.1(University)-260.9(of)-255.6(Texas)-256.5(MD)-257.4(Anderson)]TJ
T*
[(Cancer)-224.2(Center,)-215.1(patients)-219.8(distress)-217(was)-218.3(shown)-219.3(to)-215.4(be)-216.5(relieved)-214.1(by)]TJ
T*
[(using)-212.8(a)-209.6(patient-centered)-215.1(communication)-210.7(style)-208.3(and)-211.8(integrating)]TJ
0 -1.1174 TD
[(mindbody)-264.7(therapies)-266.9(into)-258.1(the)-263.8(patients)-260.1(care.)]TJ
7.3823 0 0 6.5614 486.992 422.6456 Tm
(64)Tj
9.843 0 0 9.843 323.0361 407.3385 Tm
[(A)-209.3(recent)-211.8(review)-205.7(of)-209.5(the)-206.2(literature)-210.8(suggested)-213.6(that)-207.4(mindbody)]TJ
-1.0137 -1.1116 TD
[(modalities)-349(as)-348.7(part)-345.5(of)-347.7(a)-342.1(multidisciplinary)-351.3(approach)-352.1(can)-345.5(help)]TJ
0 -1.1174 TD
[(reduce)-407.5(anxiety,)-405.4(mood)-403.1(disturbance,)-405(pain,)-406.6(nausea,)-405(vomiting,)]TJ
0 -1.1116 TD
[(sleep)-428.2(disturbance,)-428(and)-424.9(general)-426(well-being)-429.3(in)-422.8(patients)-431.8(with)]TJ
T*
[(lung)-281(cancer.)]TJ
7.3823 0 0 6.5614 361.7007 367.8802 Tm
(54)Tj
9.843 0 0 9.843 371.8487 363.5149 Tm
[(Most)-276(of)-284.4(the)-275.3(resear)-9.8(ch)-279.8(on)-278.7(mindbody)-282(therapies)]TJ
-5.9728 -1.1174 TD
[(such)-189.7(as)-181.7(meditation,)-191.3(mindfulness-based)-190.1(stress)-185.8(reduction,)-182.9(yoga,)]TJ
0 -1.1116 TD
(massage,)Tj
/F13 1 Tf
4.1355 0 TD
[(tai)-482.7(chi)]TJ
/F5 1 Tf
3.1102 0 TD
(,)Tj
/F13 1 Tf
.7372 0 TD
(qigong)Tj
/F5 1 Tf
2.7819 0 TD
[(,)-481.5(and)-488.3(others)-485.7(suggests)-487.6(that)-489.6(these)]TJ
-10.7649 -1.1116 TD
[(therapies)-226.6(are)-224.5(safe)-225.4(and)-217.6(benecial)-227.8(for)-222.1(patients)-224.4(with)-224.4(lung)-217.6(cancer)]TJ
T*
[(if)-405.5(performed)-405(by)-405.4(skilled)-406.5(practitioners.)]TJ
7.3823 0 0 6.5614 464.2015 324.0566 Tm
(54)Tj
9.843 0 0 9.843 475.5967 319.6913 Tm
[(The)-403.1(authors)-406.2(of)-405.3(the)]TJ
-16.5131 -1.1174 TD
[(American)-314(College)-310.8(of)-307.4(Chest)-307.1(Physicians)-312.6(guidelines)-313(expanded)]TJ
0 -1.1116 TD
[(on)-203.8(this)-200.3(idea)-202.7(and)-206.1(suggested)-202.1(that)-201.7(for)-204.8(lung)-200.4(cancer)-201.3(patients)-207.2(whose)]TJ
T*
[(anxie)-8(ty)-209.7(or)-215.3(pain)-213(is)-209.5(not)-216.5(adequately)-217.5(controlled)-215.3(by)-209.5(usual)-214(care,)-218.6(the)]TJ
0 -1.1174 TD
[(addition)-425.1(of)-422.6(massage)-426.7(therapy)-424.8(performed)-428.1(by)-422.7(trained)-425(profes-)]TJ
0 -1.1116 TD
[(sional)-7.8(s)-427.1(can)-431.8(be)-435.3(helpful)-429.6(in)-434.3(reducing)-431.7(anxiety)-430.8(and)-436.4(improving)]TJ
T*
[(well-being,)-236.9(as)-233.6(part)-230.3(of)-232.6(a)-226.9(multimodality)-237.6(cancer)-230.1(supportive)-236.8(care)]TJ
0 -1.1174 TD
(program.)Tj
7.3823 0 0 6.5614 349.0015 247.3511 Tm
(54)Tj
/F4 1 Tf
8.9663 0 0 8.9663 313.0582 215.4897 Tm
[(Enhancing)-339.1(Immunotherapy)]TJ
/F5 1 Tf
9.843 0 0 9.843 323.0361 199.0488 Tm
[(Immunotherapy)-485.7(is)-474.4(the)-476.9(use)-482.3(of)-474.5(medicines)-487(to)-474.6(stimulate)-480.3(a)]TJ
-1.0137 -1.1174 TD
[(patients)-571.1(own)-568.6(immune)-563.3(system)-567.4(to)-566.8(recognize)-573.4(and)-563.2(destroy)]TJ
0 -1.1116 TD
[(cancer)-328(cells.)-322.4(Immunothe)-7.9(rapy)-322.3(has)-321.1(moved)-324.7(to)-319.1(the)-321.4(center)-327(stage)]TJ
T*
[(of)-255.6(cancer)-253.1(treatment)-251.1(with)-253.2(the)-252.3(recent)-252.1(success)-252.5(of)-249.8(trials)-255.6(of)-249.8(PD-1/)]TJ
T*
[(PD-L1)-289.6(axis)-282(blockade)-288.9(in)-284.6(solid)-282(tumors.)-287.6(This)-282(type)-287.9(of)-278.6(approach)]TJ
0 -1.1174 TD
[(is)-445.6(becoming)-450.2(one)-442.2(of)-445.7(the)-448.1(leading)-442.3(new)-448.8(advances)-451(in)-440.1(treating)]TJ
0 -1.1116 TD
[(some)-386.7(forms)-380.9(of)-382.3(NSCLC.)]TJ
7.3823 0 0 6.5614 410.4566 137.6504 Tm
(65)Tj
9.843 0 0 9.843 421.6251 133.285 Tm
[(However,)-383.8(despite)-384.5(improvements)]TJ
-11.0298 -1.1116 TD
[(in)-457.3(tumor)-456.1(response)-460(leading)-459.5(to)-457.3(the)-453.9(initial)-458.8(excitement)-460.8(about)]TJ
0 -1.1174 TD
[(immunothe)-8(rapy,)-383.4(these)-387.9(therapies)-387.8(also)-391.4(induce)-383.4(a)-388.2(range)-387.9(of)-382.3(re-)]TJ
0 -1.1116 TD
[(sponses)-307.8(that)-299.6(are)-305.1(hard)-299.3(to)-301.8(predict,)-301.7(accompanied)-307.3(with)-305(multiple)]TJ
T*
[(toxic)-456.2(effects)-460.3(in)-457.3(the)-453.8(skin,)-451.3(gastrointest)-9.9(inal)-455.1(tract,)-455(lungs,)-458.1(and)]TJ
0 -1.1174 TD
[(endoc)-7.8(rine)-334(system.)]TJ
7.3823 0 0 6.5614 385.1716 82.885 Tm
(66)Tj
9.843 0 0 9.843 323.0361 67.5212 Tm
[(Information)-435.1(about)-427.3(the)-430.8(benets)-436(of)-428.4(incorporating)-431.7(CIM)-431.4(to)]TJ
-1.0137 -1.1116 TD
[(reduce)-286.5(these)-290(toxic)-283.4(effects)-281.8(and)-286.7(improve)-286.7(therapeutic)-287.8(coverage)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(866)Tj
46.3849 0 TD
[(FRENKEL)-338(ET)-338.7(AL.)]TJ
ET
endstream
endobj
65 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 59.7543 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(is)-284.4(limited)-281.3(because)-282.9(this)-280.9(eld)-276.2(is)-284.4(still)-276.5(in)-284.5(its)-279.8(infancy.)-278.5(One)-281.8(recent)]TJ
0 -1.1174 TD
[(study)-316.5(examined)-313.2(the)-315.6(safety)-314.1(of)-313.2(adding)-313.2(treatment)-320.3(with)]TJ
/F13 1 Tf
21.3455 0 TD
(Viscum)Tj
-21.3455 -1.1116 TD
[(album)-311.8(\(European)-305.8(Mistletoe\))]TJ
/F5 1 Tf
11.4676 0 TD
[(,)-308.7(a)-307.5(botanical)-307.5(commonly)-312.1(used)-304.9(in)]TJ
-11.4676 -1.1116 TD
[(Europe)-250.8(to)-250(improve)-246.4(quality)-251.2(of)-249.8(life)-247.7(during)-248.6(cancer)-253.1(treatment,)-248.8(to)]TJ
T*
[(immune)-402(checkpoint)-406.4(inhibitors.)-406.4(This)-397.2(herbal)-406.5(therapy)-401.8(neither)]TJ
0 -1.1174 TD
[(al)25.3(t)16.1(e)15(r)16.2(e)15(d)-346.7(n)16.2(o)16.2(r)-346.6(i)16.1(n)16.2(cr)25.5(e)15(a)15(s)16.4(ed)-331.7(t)16.1(h)0(e)-331.7(t)16.1(ox)26.6(i)16.1(c)-342.1(ef)25.5(f)16.2(e)15(c)15(t)0(s)-330.4(o)16.2(f)-346.6(t)16.1(h)16.2(e)-347.8(i)16.1(m)15(m)15(u)16.2(ne)-331.7(c)15(h)0(e)25.4(c)15(k)16.2(-)]TJ
0 -1.1116 TD
-.0162 Tc
[(p)-16.2(o)10.4(int)-334.2(i)-.1(n)-16.2(h)10.4(ibit)-16.2(o)10.3(r)0(s.)]TJ
7.3823 0 0 6.5614 121.2661 663.7605 Tm
(67)Tj
9.843 0 0 9.843 69.7323 648.4534 Tm
0 Tc
[(Another)-390(CIM)-391.1(treatment)-389.4(of)-388.1(interest)-391.4(in)-388.2(immunothe)-8(rapy)-385.7(is)]TJ
-1.0137 -1.1174 TD
[(probiotics.)-344.1(According)-341.5(to)-342.1(mouse)-341.8(studies)-342.8(and)-338.5(some)-340.7(early)-342(hu-)]TJ
0 -1.1116 TD
[(man)-345.5(studies,)-346.2(the)-344.4(gut)-343.3(microbiome)-344.3(helps)-346.4(to)-342.1(enhance)-346.4(the)-338.7(ef-)]TJ
T*
[(cacy)-434.1(of)-434.1(immunotherapy.)-437.5(Two)-431.6(recent)-430.7(studies)-435(revealed)-439.8(that)]TJ
0 -1.1174 TD
[(gut)-585.2(microbiota)-590.9(may)-587.4(enhance)-588.3(the)-586.3(antitumor)-582.9(immune)-586.3(re-)]TJ
0 -1.1116 TD
[(sponses)-353.9(to)-347.9(checkpoint)-348.8(inhibitors,)-354.6(resulting)-351.1(in)-347.9(tumor)-346.7(regres-)]TJ
T*
(sions.)Tj
7.3823 0 0 6.5614 82.4315 587.0549 Tm
(68)Tj
9.843 0 0 9.843 92.1826 582.6896 Tm
[(In)-232.6(patients)-241.7(who)-234.6(were)-238(treated)-241.8(with)-235.9(antibiotics)-239.5(or)-238.3(were)]TJ
-3.2946 -1.1116 TD
[(germ)-467.5(free,)-465.1(immune)-465.4(checkpoint)-464(inhibitors)-466.3(lost)-459.5(their)-467.7(thera-)]TJ
0 -1.1174 TD
[(peutic)-337.5(efcacy.)]TJ
7.3823 0 0 6.5614 120.9826 565.1148 Tm
(69)Tj
9.843 0 0 9.843 69.7323 549.8077 Tm
.0132 Tc
[(Re)5.2(se)5.2(ar)6.4(che)5.2(r).6(s)-241.1(h)6.3(av)6.3(e)-242.5(f).6(o)6.3(u).6(n)6.3(d)-241.3(th)6.3(at)-241.5(c)5.2(e)-.6(r)6.4(t).5(a)5.2(i).5(n)-241.3(g)6.3(ut)-241.5(b)6.3(a)-.6(c)5.2(t).5(e)5.2(r).6(i)6.2(a)-242.5(in)6.3(cr)6.4(ea)5.2(se)]TJ
-1.0137 -1.1116 TD
.0117 Tc
[(the)-341.9(t)4.7(her)4.9(a)-2.1(p)4.8(e)-2.1(u)4.8(t)-1(i)4.7(c)-347.7(b)4.8(e)-2.1(n)4.8(e)-2.1(t)-340.9(of)-340.7(CTLA-4)-340.7(bl)4.7(ockade)-341.9(\(Bacter)4.9(o)-.9(i)4.7(d)-.9(es\))]TJ
0 -1.1174 TD
.0107 Tc
[(in)-456.9(melanoma,)]TJ
7.3823 0 0 6.5614 116.7874 532.2329 Tm
.0145 Tc
(69)Tj
9.843 0 0 9.843 128.9196 527.8676 Tm
.0133 Tc
[(w)5.6(h).7(e)5.3(r).7(e)5.3(a)-.5(s)-454.1(o).7(t)6.3(h).7(er)6.5(s)-459.9(e)5.3(nh)6.4(an)6.4(ce)-455.5(the)-455.5(e)-.5(f)6.5(f).7(e)5.3(c)-.5(t)-454.5(P).8(D)5.6(-).7(1)]TJ
-7.0268 -1.1116 TD
.0072 Tc
[(b)-5.4(l)-5.5(oc)-6.6(ka)-6.6(de)-553.7(\()-5.4(C)-.7(l)-5.5(o).3(s)-5.2(t)-5.5(ri)-5.5(di)-5.5(al)-5.5(es)-5.2(\))]TJ
7.3823 0 0 6.5614 159.6472 521.2912 Tm
.0145 Tc
(70)Tj
9.843 0 0 9.843 172.6299 516.9258 Tm
.011 Tc
[(and)-548.8(P)4.3(D-L1)-548.8(bl)4(ockade)-549.9(\()4.2(B)-2.6(i)4()-1.5(d)4.1(o)-1.6(-)]TJ
-11.4676 -1.1116 TD
0 Tc
[(b)-6.9(a)-8(ct)-9.3(e)-8(r)0(i)-8.1(u)-6.9(m\))-9.2(.)]TJ
7.3823 0 0 6.5614 105.6189 510.3495 Tm
.0145 Tc
(68)Tj
9.843 0 0 9.843 117.2976 505.9841 Tm
0 Tc
[(T)-8(h)-6.9(es)-8.9(e)-428.5(i)-7(n)-6.9(d)0(i)-8.1(v)-6.9(id)-8.1(u)-6.9(a)0(l)-435.5(d)-6.9(if)-8.1(f)-6.8(e)0(r)-9.1(e)-8(nc)-9.1(e)-8(s)-427.1(i)-7(n)-427.3(m)-8.1(i)0(c)-9.2(r)-6.8(ob)-8(i)-7(o)-6.9(me)]TJ
-5.8461 -1.1174 TD
.0075 Tc
[(com)7.5(p)-1.7(os)7.5(itio)7.5(n)-179(m)7.5(ay)-172.1(be)-173.3(one)-173.3(of)-177.9(t)7.5(h)-.6(e)-173.3(r).7(ea)7.5(sons)-172(tha)7.5(t)-180.3(i)7.5(m)-1.8(m)7.5(u)-1.7(not)7.5(her)7.5(a)-1.6(pi)7.5(es)]TJ
0 -1.1116 TD
0 Tc
[(w)-7.7(o)-6.9(rk)-244.1(b)-6.9(e)-8(tt)-8.2(e)-8(r)-243(in)-244.2(s)-6.7(o)-6.9(me)-246.5(p)-6.9(a)-8(ti)-8.2(e)-8(n)0(t)-8.1(s)-242.8(t)-7(h)0(a)-9.1(n)-243(o)-6.9(t)0(h)-8.1(e)-8(rs)-7.7(.)-245.3(U)0(n)-8.8(d)-6.9(er)-9.1(s)-6.7(t)-7(an)-9.1(d)-6.9(i)0(n)-8.1(g)-243(t)-7(h)0(i)-8.1(s)]TJ
T*
[(principle)-196.9(can)-195.7(lead)-191.2(to)-192.4(innovative)-192.3(approaches)-194(that)-195.9(may)-190(improve)]TJ
0 -1.1174 TD
[(the)-263.8(efcacy)-265.6(of)-261.4(immunotherapy.)]TJ
1.0137 -1.1116 TD
[(Current)-280.7(evidence)-278.5(already)-276.2(suggests)-280.2(that)-276.5(optimizing)-273.1(the)-275.3(gut)]TJ
-1.0137 -1.1116 TD
[(microbiome)-603.5(might)-600.2(improve)-603.5(the)-597.8(therapeutic)-604.6(coverage)-600.9(of)]TJ
T*
[(immune)-350.2(checkpoint)-343.1(inhibitors.)]TJ
7.3823 0 0 6.5614 182.6078 433.644 Tm
(71)Tj
9.843 0 0 9.843 193.3795 429.2786 Tm
[(These)-348.7(studies)-342.8(suggest)-348.4(that)]TJ
-13.5756 -1.1174 TD
[(manipulating)-299.5(the)-292.6(microbiome)-292.5(by)-290.2(adding)-295.9(a)-290.2(specic)-293.2(probiotic)]TJ
0 -1.1116 TD
[(might)-358.3(lead)-358.2(to)-353.7(improvement)-362.7(in)-353.7(immunotherapy)-359.2(but)-354.8(requires)]TJ
T*
[(further)-371.8(research,)-373.7(specically)-368.1(in)-370.9(the)-367.5(context)-367.4(of)-370.8(lung)-367.4(cancer.)]TJ
0 -1.1174 TD
[(Additional)-249.7(research)-249.4(is)-244(needed)-246.2(to)-238.5(provide)-245.1(an)-245.3(educated)-249.7(answer)]TJ
0 -1.1116 TD
[(to)-336.4(this)-332.8(question.)]TJ
/F4 1 Tf
8.9663 0 0 8.9663 59.7543 352.5164 Tm
[(Complementary)-339.6(Therapies)]TJ
/F5 1 Tf
9.843 0 0 9.843 69.7323 336.0755 Tm
[(In)-365(a)-365.1(recent)-373.1(guideline)-369.7(document)-363.8(from)-368.4(the)-367.5(American)-371.6(Col-)]TJ
-1.0137 -1.1174 TD
[(lege)-346.7(of)-342(Chest)-341.7(Physicians)-341.4(on)-342(the)-344.4(use)-338.3(of)-342(CIM)-345(in)-342.1(lung)-338.6(cancer)]TJ
0 -1.1116 TD
[(patients,)-291.2(the)-286.8(reviewed)-295.5(evidence)-290.1(revealed)-290(that)-288.1(CIM)-287.4(therapies)]TJ
T*
[(can)-339.7(be)-331.7(benecial)-337.2(to)-336.4(patients)-333.9(during)-335(and)-332.8(after)-336.2(treatments.)]TJ
7.3823 0 0 6.5614 287.8298 307.559 Tm
(54)Tj
/F12 1 Tf
8.9663 0 0 8.9663 59.7543 281.2535 Tm
(Acupuncture)Tj
/F5 1 Tf
9.843 0 0 9.843 69.7323 264.8125 Tm
[(In)-583.9(acupuncture,)-590.5(a)-584(technique)-589.6(derived)-586.1(from)-587.3(Traditional)]TJ
-1.0137 -1.1174 TD
[(Chinese)-494.8(Medicine,)-495(trained)-494.1(practitioners)-501.9(stimulate)-491.8(specic)]TJ
0 -1.1116 TD
[(points)-386.8(on)-382.3(the)-379(body)-384.5(by)-382.3(inserting)-385.6(thin)-384.8(needles)-385.5(into)-379(the)-384.7(skin.)]TJ
T*
[(Acupuncture)-281.5(has)-275(been)-277.4(in)-278.8(use)-275(in)-273(various)-279.5(forms)-277.2(for)-273.9(more)-277.5(than)]TJ
0 -1.1174 TD
[(3000)-269.4(years.)-270.2(In)-261.4(the)-269.5(past)-270.4(decade,)-268.1(acupuncture)-270.3(has)-269.2(become)-264.8(one)]TJ
0 -1.1116 TD
[(of)-468.7(the)-465.4(most)-466.3(common)-465.3(CIM)-466(therapies)-474.2(used)-466.1(by)-463(patients)-466.3(af-)]TJ
T*
[(fected)-240.6(by)-238.3(cancer.)-239.3(This)-235.9(technique)-244.1(is)-238.3(considered)-239(safe)-236.9(for)-239.4(use)-234.7(in)]TJ
0 -1.1174 TD
[(the)-453.8(general)-454.8(population)-450.3(when)-455.7(practiced)-452.5(by)-451.5(an)-452.6(experienced)]TJ
0 -1.1116 TD
(practitioner.)Tj
7.3823 0 0 6.5614 107.8866 181.474 Tm
(52,7274)Tj
9.843 0 0 9.843 69.7323 166.1669 Tm
[(In)-365(response)-367.8(to)-359.4(the)-367.5(severity)-362.5(and)-367.3(persistence)-367.9(of)-359.3(symptoms)]TJ
-1.0137 -1.1116 TD
[(related)-431.9(to)-422.8(cancer)-425.9(care,)-431.8(patients)-426(usually)-423.6(try)-429.6(acupuncture)-425.8(in)]TJ
0 -1.1174 TD
[(conjunction)-348.9(with)-345.4(standard)-350.9(treatments.)-347.6(This)-351.1(use)-344.1(is)-347.7(generally)]TJ
0 -1.1116 TD
[(considered)-475.2(safe)-473(when)-467.2(conventional)-472.1(treatment)-475.8(fails)-467.5(or)-468.7(has)]TJ
T*
[(intolerable)-275.3(side)-270.4(effects.)]TJ
7.3823 0 0 6.5614 152.107 126.7086 Tm
(7274)Tj
9.843 0 0 9.843 173.2535 122.3433 Tm
[(In)-272.9(a)-267.2(set)-269.3(of)-272.9(American)-273.7(College)-270.5(of)]TJ
-11.5309 -1.1174 TD
[(Chest)-410.8(Physic)-7.5(ians)-408.7(guidelines,)-414.4(which)-410.9(are)-408.8(backed)-413.3(by)-405.4(clinical)]TJ
0 -1.1116 TD
[(evidence,)-460.5(acupuncture)-466.1(was)-454.4(suggested)-461.2(as)-458.2(an)-458.4(adjunct)-459.6(treat-)]TJ
T*
[(ment)-352.5(option)-346.7(for)-348.8(patients)-351.2(experiencing)-352.2(nausea)-355.5(and)-344.3(vomiting)]TJ
0 -1.1174 TD
[(caused)-522.5(by)-520.6(chemotherapy)-526.1(or)-520.5(radiotherapy,)-521.4(as)-521.5(well)-519.3(as)-521.5(for)]TJ
0 -1.1116 TD
[(patients)-328.1(with)-322.3(cancer-related)-329(pain)-322.5(and)-321.2(peripheral)-325.7(neuropathy)]TJ
T*
[(that)-334.1(are)-339.7(poorly)-335(controlled.)]TJ
7.3823 0 0 6.5614 164.8629 60.9449 Tm
(54)Tj
9.843 0 0 9.843 320.8251 725.1588 Tm
[(A)-405.1(more)-415.7(recent)-413.4(article,)-412.4(summarizing)-414.4(the)-407.8(current)-413.3(state)-416.8(of)]TJ
-1.0137 -1.1174 TD
[(knowledge)-381.9(related)-380(to)-376.7(acupuncture)-379.7(use)-378.7(in)-382.5(cancer)-379.8(care,)-379.9(con-)]TJ
0 -1.1116 TD
[(cluded)-302.8(that)-311.1(research)-306.9(has)-303.8(yielded)-309.8(promising)-304.9(evidence)-307.3(for)-308.5(the)]TJ
T*
[(role)-518.3(of)-520.5(acupuncture)-523.7(in)-520.7(the)-523(management)-519.4(of)-520.5(several)-523.7(chal-)]TJ
T*
[(lenging)-418.1(symptoms)-420(for)-412.2(which)-422.4(existing)-419.1(standard)-420(options)-416.7(re-)]TJ
0 -1.1174 TD
[(main)-485(limited.)-492.1(These)-486.9(symptoms)-489.1(include)-488.4(pain,)-487.2(fatigue,)-491.7(hot)]TJ
0 -1.1116 TD
[(ashes,)-305.6(nausea/vomiting,)-313(and)-304(xerostomia.)]TJ
7.3823 0 0 6.5614 477.4676 663.7605 Tm
(74)Tj
9.843 0 0 9.843 487.8424 659.3951 Tm
[(To)-302.9(evalu)-8(ate)-305.3(the)]TJ
-17.9818 -1.1116 TD
[(effectiveness)-446.2(of)-445.7(acupuncture)-443.1(as)-446.7(a)-440(potential)-444.7(treatment)-447(mo-)]TJ
0 -1.1174 TD
[(dality)-342.2(in)-336.4(symptomatic)-345.4(lung)-338.6(cancer)-345.3(patients,)-343.1(a)-342.1(cancer)-339.5(center)]TJ
0 -1.1116 TD
[(in)-578.3(Canada)-581.3(conducted)-583.7(a)-584(prospective)-580.1(observational)-588.2(study.)]TJ
T*
[(Researchers)-485.1(combined)-479(acupuncture)-477.6(with)-477.8(the)-476.9(conve)-7.8(ntional)]TJ
0 -1.1174 TD
[(best)-253.2(care)-261.3(for)-256.7(that)-253.5(center)-257.9(and)-257.9(observed)-258.6(statistically)-260.2(signicant)]TJ
0 -1.1116 TD
[(improvement)-437.6(in)-434.3(pain,)-435.4(appetite,)-436.6(nausea,)-439.6(anxiety,)-434.2(and)-436.4(well-)]TJ
T*
[(being.)-355.8(These)-360.2(effects)-356.6(were)-358.9(obtained)-357(with)-356.9(a)-353.6(minimum)-357.3(of)-359.3(six)]TJ
T*
[(acupuncture)-408.5(sessions.)-404.4(The)-408.8(researchers)-409.1(concluded)-411(that)-403.2(acu-)]TJ
0 -1.1174 TD
[(puncture)-662.1(may)-656.5(be)-660(an)-660(effective)-665.6(approach)-663.1(for)-659.8(improving)]TJ
0 -1.1116 TD
[(symptoms,)-429.1(especially)-436.3(pain)-426.2(and)-430.7(well-being,)-432.7(in)-428.5(lung)-425(cancer)]TJ
T*
(patients.)Tj
7.3823 0 0 6.5614 344.0692 543.2313 Tm
(75)Tj
9.843 0 0 9.843 320.8251 527.8676 Tm
[(Since)-439.8(then,)-435.4(additional)-445.8(studies)-440.7(have)-438.7(emerged)-444.4(suggesting)]TJ
-1.0137 -1.1116 TD
[(that)-518.4(acupuncture)-523.7(might)-519.6(have)-519.3(a)-520.6(benecial)-521.5(effect)-522.8(in)-514.9(other)]TJ
T*
[(situations)-450(in)-451.6(cancer)-454.7(care.)-454.8(In)-451.4(a)-451.5(small)-451.5(randomized,)-451.3(double-)]TJ
0 -1.1174 TD
[(blind,)-412.4(placebo-controlled)-417.8(pilot)-409.1(trial)-410.2(that)-414.8(aimed)-412.4(to)-411.3(evaluate)]TJ
0 -1.1116 TD
[(the)-367.5(clinical)-369.9(effect)-373(of)-365(acupuncture)-374(on)-365.1(cancer-related)-380.8(fatigue)]TJ
T*
[(in)-284.5(lung)-292.5(cancer)-287.7(patients,)-291.2(researchers)-293.9(found)-287.7(that)-293.8(Brief)-290(Fatigue)]TJ
0 -1.1174 TD
[(Inventory)-391.3(scores)-394.4(were)-393.5(signicantly)-395.8(reduced)-391.3(in)-388.2(participants)]TJ
0 -1.1116 TD
[(who)-413.1(received)-416.7(active)-413.5(acupuncture)-414.3(compared)-416.7(with)-414.5(those)-415.5(re-)]TJ
T*
[(ceiving)-332.8(the)-338.7(placebo.)]TJ
7.3823 0 0 6.5614 391.8613 444.5857 Tm
(76)Tj
9.843 0 0 9.843 320.8251 429.2786 Tm
[(In)-509(another)-517(study)-518.1(that)-518.4(investigated)-518.1(acupuncture)-518(for)-515.8(the)]TJ
-1.0137 -1.1174 TD
[(relief)-579.3(of)-578.1(breathlessness)-584(in)-578.3(lung)-574.7(cancer,)-584.9(researchers)-581.9(per-)]TJ
0 -1.1116 TD
[(formed)-417.9(a)-411.2(single)-7.8(-center,)-417.9(randomized)-419(phase)-416.6(II)-416.8(study)-414.4(of)-416.9(173)]TJ
T*
[(patients)-259(with)-264.7(NSCLC)-257.2(or)-261.4(mesothelioma)-261.3(with)-264.7(a)-255.7(dyspnea)-263.3(score)]TJ
0 -1.1174 TD
(of)Tj
/F10 1 Tf
1.1059 0 TD
(>)Tj
/F5 1 Tf
.5529 0 TD
[(4)-271.8(o)0(n)-272.9(the)-275.3(visual)-278.5(analog)-274(scale.)-277.3(In)-272.9(that)-276.5(study,)-273.8(patients)-276.3(were)]TJ
-1.6588 -1.1116 TD
[(randomized)-378.7(to)-376.7(receive)-381.1(acupuncture)-379.7(alone,)-380(morphine)-379.9(alone,)]TJ
T*
[(or)-307.4(both.)-307.5(Acupuncture)-310.3(was)-304.6(found)-310.7(to)-307.6(be)-302.9(effective)-314.3(in)-307.6(relieving)]TJ
0 -1.1174 TD
[(dyspnea,)-284(and)-280.9(the)-286.8(changes)-281.7(in)-284.6(visual)-284.3(analog)-285.5(scale)-285.4(scores)-285(were)]TJ
0 -1.1116 TD
[(not)-337.5(signicantly)-338.3(different)-340.7(between)-340.5(treatment)-337.5(arms.)-338.3(In)-336.2(addi-)]TJ
T*
[(tion,)-394(acupuncture,)-394.7(alone)-393.9(and)-396.1(combined)-392.6(with)-397.2(morphine,)-394.9(re-)]TJ
T*
[(duced)-537.7(anxiety,)-537.9(with)-535.4(a)-537.9(signicant)-537.5(improvement)-541.3(in)-532.2(visual)]TJ
0 -1.1174 TD
[(analog)-487.1(scale)-487(relaxation)-492.9(scores.)-490(Morphine)-489(alone)-486(increased)]TJ
0 -1.1116 TD
[(anxiety.)-342(The)-345.5(effects)-345.1(of)-342(acupuncture)-350.9(were)-341.6(evident)-344.4(at)-343.3(90)-169.2(min)]TJ
T*
[(and)-240.6(maximal)-237.4(at)-239.6(4)-168.1(h)0(,)-240.7(but)-239.6(the)-240.7(effects)-241.5(were)-238(sustained)-242.5(for)-239.4(up)-238.4(to)-244.2(2)]TJ
0 -1.1174 TD
(weeks.)Tj
7.3823 0 0 6.5614 337.8897 280.1763 Tm
(77)Tj
/F12 1 Tf
8.9663 0 0 8.9663 310.8472 248.3716 Tm
(Homeopathy)Tj
/F5 1 Tf
9.843 0 0 9.843 320.8251 231.9306 Tm
.0115 Tc
[(Homeo)4.6(p)-1.1(ath)4.6(y)-260.3(i)4.5(s)-260.1(a)-255.7(h)-1.1(eal)4.5(t)-1.2(h)-254.5(s)-.9(ys)4.8(tem)-261.5(o)4.6(f)-260.3(c)3.5(ar)4.7(e)-261.5(t)4.5(hat)-260.4(i)4.5(s)-260.1(c)3.5(ommo)4.6(nl)4.5(y)]TJ
-1.0137 -1.1174 TD
.3522 Tc
[(p)345.3(r)339.6(a)344.2(c)338.4(t)339.5(i)345.2(c)338.4(e)344.2(di)339.5(nE)344.2(u)339.6(r)345.4(o)339.6(p)345.3(e)338.4(,)3.2(A)338.7(s)339.8(i)345.2(a)338.4(,a)338.4(n)345.3(d)-.2(S)339.7(o)345.3(u)339.6(t)345.2(hA)338.7(m)344.1(e)338.4(r)345.4(i)339.5(c)338.4(a)344.2(,m)344.1(o)345.3(s)339.8(t)339.5(l)345.2(yf)339.6(o)345.3(r)]TJ
0 -1.1116 TD
.012 Tc
[(min)5.1(o)-.6(r)-403.8(a)-1.8(i)5(l)-.7(men)5.1(t)-.7(s.)-400.4(Ho)5.1(meopath)5.1(ic)-405(remedi)5(es)-403.6(have)-405(app)5.1(ear)5.2(ed)-403.8(t)5(o)]TJ
T*
.0114 Tc
[(b)4.5(e)-509.2(safe)-509.2(and)-508.1(f)4.6(ree)-503.5(o)-1.2(f)-508(a)3.4(dvers)4.7(e)-509.2(e)-2.4(f)4.6(f)-1.2(ect)4.4(s)-507.9(in)-508.1(mul)4.4(tip)4.5(le)-509.2(cli)4.4(n)-1.2(i)4.4(c)-2.4(al)]TJ
0 -1.1174 TD
[(t)4.5(r)-1.1(ials)4.8(.)]TJ
7.3823 0 0 6.5614 333.7511 192.4724 Tm
.015 Tc
(73,7881)Tj
9.843 0 0 9.843 365.0456 188.0503 Tm
.0086 Tc
[(H)-4.9(o)1.7(w)-4.9(e).6(ve)-5.2(r,)-282.8(it)-286.4(is)-286(unclea)-5.2(r)-280.5(i)-4.1(f)-280.4(h)-4(om)-5.2(eopa)-5.2(thy)-280.5(h)-4(as)-280.3(a)-5.2(n)1.7(y)]TJ
-5.5063 -1.1116 TD
.0131 Tc
[(c)5.1(l).4(i)6.1(n).5(ic)5.1(al)-448.9(ef)6.3(fe)5.1(ct)-448.9(in)-448.8(ca)5.1(nc)5.1(er)-448.7(pa)5.1(ti)6.1(ent)6.1(s).7(,)-451.1(a)5.1(nd)-448.8(un)6.2(ti)6.1(l)-454.7(r)6.3(ece)5.1(nt)6.1(ly)6.2(,)-451.1(h).5(o)6.2(-)]TJ
T*
.0073 Tc
[(me)-6.5(op)-5.3(at)-5.4(hy)-402.7(h)-5.3(a)-.7(s)-402.5(n)-5.3(ot)-402.9(r)-5.3(e)-.7(c)-6.5(e)-6.5(i).3(v)-5.3(e)-.7(d)-402.7(a)-6.5(tt)-5.4(en)-5.3(ti)-5.4(on)-402.7(a)-6.5(s)-402.5(a)-403.9(p).4(o)-5.3(s).6(s)-5.1(i)-5.4(bl)-5.4(e)-403.9(o).4(p)-5.3(t).3(i)-5.4(o).4(n)]TJ
T*
[(fo)-5.2(r)-333.5(c)-6.4(ar)-5.2(e)-6.4(.)]TJ
1.0137 -1.1174 TD
0 Tc
[(In)-244.1(a)-249.9(survey)-243.7(of)-249.8(123)-245.2(cancer)-253.1(centers)-247.3(across)-250.4(Europe,)-248.5(47.5%)-250.8(of)]TJ
-1.0137 -1.1116 TD
[(the)-563.3(centers)-564(provided)-563(CIM)-558.1(treatments.)-566.5(The)-564.4(leading)-563.2(CIM)]TJ
T*
[(treatments)-407.6(in)-399.7(those)-404(centers)-402.8(were)-405(acupuncture)-408.5(\(55.3%\))-402.7(and)]TJ
0 -1.1174 TD
[(homeopathy)-521.6(\(40.4%\).)]TJ
7.3823 0 0 6.5614 399.2314 115.7102 Tm
(73)Tj
9.843 0 0 9.843 411.7605 111.3448 Tm
[(In)-526.3(another)-522.8(cross-sectional)-527.8(survey)]TJ
-10.2523 -1.1116 TD
[(across)-492.3(eight)-490.7(European)-490.4(countries)-496.1(that)-489.6(specically)-494.9(targeted)]TJ
T*
[(lung)-402(cancer)-402.9(patients)-408.8(who)-401.6(use)-401.7(CIM,)-406.1(researchers)-409.1(found)-402.9(that)]TJ
0 -1.1174 TD
[(homeopathy)-337.2(was)-333.4(also)-333.8(one)-332.8(of)-336.2(the)-332.9(leading)-338.6(CIM)-333.5(treatments.)]TJ
7.3823 0 0 6.5614 542.9479 82.885 Tm
(5)Tj
9.843 0 0 9.843 320.8251 67.5212 Tm
[(Data)-531.9(from)-529.7(multiple)-535.9(research)-531.6(disciplines,)-536.4(ranging)-533.1(from)]TJ
-1.0137 -1.1116 TD
[(studies)-452.2(evaluating)-452.6(the)-453.8(effect)-453.7(of)-451.4(homeopathic)-454.8(remedies)-456.9(on)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(INTEGRATIVE)-339.7(MEDICINE)-335.4(IN)-335.1(LUNG)-336.8(CANCER)-31974.3(867)]TJ
ET
endstream
endobj
69 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 62.022 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(cancer)-408.6(cell)-404.4(lines)-404.2(to)-405.5(scientically)-410.9(valid)-404.3(animal)-407.8(and)-401.9(clinical)]TJ
0 -1.1174 TD
[(studies,)-444.2(suggest)-446.4(that)-443.6(homeopathy)-440.9(may)-443.4(have)-444.5(a)-445.8(role)-443.4(in)-440.1(im-)]TJ
0 -1.1116 TD
[(proving)-169.1(quality)-170.5(of)-175(life)-167.1(in)-169.4(selected)-174.8(cancer)-178.3(patients.)]TJ
7.3823 0 0 6.5614 251.9432 707.5841 Tm
(78)Tj
9.843 0 0 9.843 260.9574 703.2188 Tm
[(In)-175(a)-169.3(recent)]TJ
-20.2108 -1.1116 TD
[(study)-322.2(of)-318.9(an)-320.1(integrative)-327.1(oncology)-321.1(service)-327.9(in)-319.1(a)-319(large)-324.7(compre-)]TJ
T*
[(hensive)-257.6(cancer)-264.7(center)-257.9(in)-255.8(Israel,)-259.9(homeopathy)-262.4(was)-258.6(found)-258.9(to)-255.8(be)]TJ
0 -1.1174 TD
[(successfully)-269.8(incorporated)-270.3(as)-268.1(a)-267.2(supportive)-271.4(care)-267(modality.)-268.5(Re-)]TJ
0 -1.1116 TD
[(view)-190.9(of)-186.5(124)-181.9(les)-189.7(of)-186.5(cancer)-189.8(patients)-189.9(who)-188.5(received)-192.1(homeopathy)]TJ
T*
[(for)-170.3(symptom)-177.1(relief)-176.2(revealed)-174.8(that)-172.9(nearly)-176.1(three-quarters)-175.5(of)-169.2(these)]TJ
0 -1.1174 TD
[(patients)-299.3(reported)-304.9(a)-296(benecial)-302.7(effect)-303.9(when)-300.2(they)-299.4(used)-299.1(homeo-)]TJ
0 -1.1116 TD
[(pathic)-262.6(treatment)-262.7(for)-262.4(symptom)-263.5(relief.)]TJ
7.3823 0 0 6.5614 205.455 630.8786 Tm
(79)Tj
9.843 0 0 9.843 72 615.5715 Tm
[(In)-532.1(another)-540(pragmatic)-539(randomized)-540(controlled)-537.8(trial)-536.9(in)-538(a)]TJ
-1.0137 -1.1174 TD
[(comprehensive)-469.4(cancer)-472(center)-465.2(in)-463.1(Austria,)-468.2(with)-466.3(410)-464.1(cancer)]TJ
0 -1.1116 TD
[(patients)-512.4(who)-505.3(were)-508.7(randomized)-511.2(to)-503.4(receive)-513.5(or)-509(not)-504.5(receive)]TJ
T*
[(classic)-350.9(homeopathic)-351.2(adjunctive)-349(therapy)-350(in)-347.9(addition)-350.2(to)-342.1(stan-)]TJ
T*
[(dard)-506.6(therapy,)-508.9(researchers)-507(found)-506.6(that)-506.9(the)-505.7(subjective)-504.3(well-)]TJ
0 -1.1174 TD
[(being)-479.1(of)-480.2(these)-480.1(patients)-477.9(improved)-477.8(signicantly)-482.2(when)-478.7(they)]TJ
0 -1.1116 TD
[(received)-370.7(adjunct)-367.4(classic)-368.2(homeopathic)-368.4(treatment)-366.3(in)-365.2(addition)]TJ
T*
[(to)-336.4(conventional)-333.9(therapy.)]TJ
7.3823 0 0 6.5614 159.4204 543.2313 Tm
(80)Tj
9.843 0 0 9.843 72 527.8676 Tm
[(Some)-386.8(might)-387.1(argue)-382.2(that)-386(the)-390.5(intensive)-386.8(homeopathic)-391.5(inter-)]TJ
-1.0137 -1.1116 TD
[(view)-213.9(conducted)-215.1(at)-216.6(baseline)-214(may)-213(have)-214.1(inuenced)-215(the)-211.9(ndings.)]TJ
1.0137 -1.1116 TD
[(Most)-241.4(researchers)-253.6(seem)-243.9(to)-244.2(agree)-245.1(that)-242(given)-242.9(its)-245.3(low)-246.2(toxicity,)]TJ
-1.0137 -1.1174 TD
[(homeopathy)-337.3(is)-336.2(a)-336.3(possible)-338.2(option)-335.2(for)-331.5(symptom)-338.4(management)]TJ
0 -1.1116 TD
[(and)-482.5(supportive)-478.8(care.)-483.6(Whether)-478.9(these)-485.8(remedies)-480(have)-484.8(direct)]TJ
T*
[(effects)-299.1(on)-290.2(the)-292.6(tumor)-289.1(or)-295.9(survival)-292.2(is)-290.1(a)-296(more)-294.8(complex)-293.6(issue.)-292.1(In)]TJ
0 -1.1174 TD
[(Austria,)-312.7(researchers)-311.2(from)-310.8(the)-309.9(Medical)-311.9(University)-312.7(of)-307.4(Vienna)]TJ
0 -1.1116 TD
[(collected)-251.1(survival)-246.2(data)-248.8(on)-244.1(538)-245.2(patients)-247.5(with)-247.4(fatal)-250(disease)-247.1(and)]TJ
T*
[(poor)-430.6(prognosis)-430.1(who)-424.6(used)-431.6(homeopathy)-429.4(in)-428.5(addition)-430.8(to)-428.5(con-)]TJ
T*
[(ventional)-559.8(cancer)-564.2(care.)-558.5(The)-558.6(study)-558.4(included)-564.3(patients)-558.5(with)]TJ
0 -1.1174 TD
[(glioblastoma,)-394.9(lung)-390.4(cancer)-397.1(\(both)-391.5(SCLC)-393.4(and)-390.4(NSCLC\),)-394.1(met-)]TJ
0 -1.1116 TD
[(astatic)-443.4(renal)-439.9(cell)-439(carcinoma,)-439.8(and)-436.4(others.)]TJ
7.3823 0 0 6.5614 227.5086 411.7038 Tm
(82)Tj
9.843 0 0 9.843 239.1873 407.3385 Tm
[(Median)-441.9(overall)]TJ
-17.9991 -1.1116 TD
[(survival)-292.2(was)-287.4(compared)-295.7(with)-287.8(experts)-293.2(predictions)-291.1(of)-290.1(survival)]TJ
0 -1.1174 TD
[(outcomes)-484.6(by)-480.3(specic)-489(cancer)-483.5(type.)-487.2(The)-483.7(researchers)-484(found)]TJ
0 -1.1116 TD
[(that)-265(patients)-264.8(who)-263.4(received)-261.2(homeopathy)-268.1(survived)-263.3(longer)-261.3(than)]TJ
T*
[(the)-465.4(expected)-468.6(prognosis,)-462.3(across)-463.5(all)-465.5(observed)-465.9(cancer)-466.2(types.)]TJ
0 -1.1174 TD
[(Patients)-276.1(with)-276.2(SCLC)-278.2(and)-275.2(metastatic)-282.2(renal)-278.6(cell)-271.9(carcinoma)-280.8(had)]TJ
0 -1.1116 TD
[(the)-367.5(best)-362.6(results.)-369.2(The)-368.5(expected)-364.9(median)-367.4(overall)-367.4(survival)-367.1(was)]TJ
T*
[(11.3)-283.2(months)-278.5(for)-279.7(SCLC)-284(and)-280.9(26.4)-277.4(months)-284.2(for)-279.7(metastatic)-287.9(renal)]TJ
T*
[(cell)-473.5(carcinoma,)-474.3(but)-470(the)-471.1(observed)-471.7(median)-476.8(overall)-471(survival)]TJ
0 -1.1174 TD
[(was)-419.8(47)-416.9(months)-422.5(for)-417.9(patients)-420.3(with)-420.2(SCLC)-416.4(who)-418.9(received)-422.5(ho-)]TJ
0 -1.1116 TD
[(meopathy)-254.4(and)-252.1(61.4)-254.4(months)-255.4(for)-250.9(patients)-259(with)-253.2(metastatic)-259.1(renal)]TJ
T*
[(cell)-415.9(carcinoma)-413.3(who)-413.1(received)-416.7(homeopathy.)-409.8(Although)-413.1(these)]TJ
0 -1.1174 TD
[(results)-475.2(were)-474.1(promising,)-475.4(the)-476.9(authors)-475.3(stressed)-471.4(the)-476.9(need)-473.3(for)]TJ
0 -1.1116 TD
[(further)-596.4(study)-598.7(of)-595.4(homeopathic)-598.8(care)-595.3(in)-595.6(cancer)-598.7(patients.)]TJ
7.3823 0 0 6.5614 293.7259 269.2346 Tm
(82)Tj
9.843 0 0 9.843 62.022 253.9275 Tm
[(These)-302.6(European)-300.3(studies)-296.7(suggest)-302.4(that)-299.6(there)-295.9(is)-301.6(an)-297.1(urgent)-295.9(need)]TJ
0 -1.1174 TD
[(for)-331.5(homeopathi)-9.1(c)-330.6(clinical)-335.4(trials)-336.2(in)-336.4(lung)-332.8(cancer.)]TJ
/F4 1 Tf
8.9663 0 0 8.9663 62.022 215.4897 Tm
(Summary)Tj
/F5 1 Tf
9.843 0 0 9.843 72 199.0488 Tm
[(Most)-281.7(patients)-287.8(with)-282(lung)-281(cancer)-287.7(are)-282.1(diagnosed)-288.6(late)-283.4(in)-278.8(their)]TJ
-1.0137 -1.1174 TD
[(disease)-523.6(process)-516.5(and)-522.8(thus)-517(have)-519.3(a)-514.9(poor)-517(prognosis)-522.2(and)-517.1(in-)]TJ
0 -1.1116 TD
[(creased)-484.4(distress.)-479.6(As)-475.2(a)-480.3(result,)-477.8(a)-474.6(large)-480.2(percentage)-483.5(of)-474.5(these)]TJ
T*
[(patients)-489.4(tend)-489.5(to)-486.1(use)-488.1(CIM.)-492.5(Patients)-489.2(use)-488.1(CIM)-489(therapies)-491.5(to)]TJ
T*
[(reduce)-396(symptoms,)-394.6(lower)-393.5(the)-396.3(toxicity)-396.4(of)-388.1(conve)-7.8(ntional)-389.4(ther-)]TJ
0 -1.1174 TD
[(apies,)-310.7(improve)-309.7(their)-306.4(ability)-308.9(to)-307.6(heal,)-309.8(and)-304(increase)-312.9(their)-306.4(sense)]TJ
0 -1.1116 TD
[(of)-267.1(autonomy)-270.5(and)-263.7(control.)-266(Communicating)-274(openly)-267.1(with)-264.7(these)]TJ
T*
[(patients)-259(and)-257.9(their)-254.6(families)-260.2(about)-254.5(the)-258(use)-257.7(of)-255.6(CIM)-252.9(is)-255.6(important)]TJ
0 -1.1174 TD
[(for)-256.7(improving)-259(patients)-260.1(quality)-256.9(of)-255.6(life)-259.2(and)-257.9(empowering)-263.2(them)]TJ
0 -1.1116 TD
[(during)-340.8(the)-338.7(disease)-345(trajectory.)-346.6(A)-341.8(growing)-337(number)-343(of)-342(studies)]TJ
T*
[(support)-359(the)-355.9(use)-355.6(of)-353.5(CIM)-356.5(interventions)-362.5(such)-356.7(as)-354.5(nutrition)-356(and)]TJ
0 -1.1174 TD
[(dietary)-586.2(supplements,)-589.2(exercise,)-587(acupuncture,)-584.8(homeopathy,)]TJ
0 -1.1116 TD
[(and)-332.8(mindbody)-328.1(approaches.)-335.7(These)-331.4(interventions)-333.7(reduce)-332.6(the)]TJ
T*
[(severity)-569.9(of)-572.4(symptoms)-569.7(that)-570.3(relate)-569(to)-566.8(the)-574.8(disease)-569.6(and)-568.9(its)]TJ
25.504 67.9242 TD
[(treatment,)-346.7(increase)-347.4(well-being,)-346.3(improve)-344.3(quality)-343.3(of)-342(life,)-349(and)]TJ
0 -1.1174 TD
[(may)-339.8(even)-335(improve)-332.7(the)-332.9(survival)-338.3(of)-330.5(these)-336.1(patients.)]TJ
/F4 1 Tf
8.9663 0 0 8.9663 313.0582 689.6124 Tm
(Acknowledgment)Tj
/F5 1 Tf
9.843 0 0 9.843 323.0361 673.1715 Tm
[(The)-282.1(authors)-285.2(acknowledge)-288.5(Ms.)-282.8(Erica)-285.6(A)-284.2(Goodof,)-281.6(from)-282(MD)]TJ
-1.0137 -1.1116 TD
[(Anders)-8.4(on)-560.9(Department)-569.8(of)-560.9(Scientic)-572.2(Publications,)-566.3(for)-567.7(her)]TJ
T*
[(editorial)-421.7(review)-413.1(of)-416.9(the)-413.5(articles)-421.4(and)-413.4(helpful)-418(comments)-416.7(that)]TJ
0 -1.1174 TD
[(increased)-342.8(the)-332.9(quality)-337.6(of)-330.5(this)-332.8(article.)]TJ
/F4 1 Tf
8.9663 0 0 8.9663 313.0582 615.7416 Tm
[(Author)-338.3(Disclosure)-338.2(Statement)]TJ
/F5 1 Tf
9.843 0 0 9.843 323.0361 599.3007 Tm
[(No)-337.1(competing)-336.3(nancial)-334.9(interests)-334.7(exist.)]TJ
/F4 1 Tf
8.9663 0 0 8.9663 313.0582 574.7526 Tm
(References)Tj
/F5 1 Tf
9.2951 0 0 9.2951 317.707 558.7085 Tm
[(1.)-500.4(Ferlay)-434.8(J,)-432.4(Soerjomataram)-432.9(I,)-429.5(Ervik)-437.4(M,)-426.4(et)-430.9(al.)-430.9(GLOBOCAN)]TJ
1.2503 -1.1284 TD
[(2012)-537.3(v1.1,)-531.2(Cancer)-532.9(Incidence)-538.3(and)-535.3(Mortality)-529.3(Worldwide:)]TJ
T*
[(IARC)-386.1(CancerBase)-393.3(No.)-380.1(11)-384.5([Internet].)-390.1(Lyon,)-380.7(France:)-390.3(Inter-)]TJ
0 -1.1223 TD
[(national)-532.4(Agency)-535.4(for)-529.6(Research)-530.4(on)-530.9(Cancer,)-533(2014.)-531.3(Online)]TJ
0 -1.1284 TD
[(document)-527(at:)-528(www.globocan.iarc.fr,)-530.3(accessed)-526.7(January)-529.3(1,)]TJ
0 -1.1223 TD
(2018.)Tj
-1.2503 -1.1284 TD
.0098 Tc
[(2)9.8(.)-490.6(Wo)9.8(rl)9.8(d)-374.2(C)9.8(a)-5.6(n)3.6(c)9.8(e)1.1(r)-370.8(R)9.8(e)-5.6(s)9.8(ea)9.8(rc)9.8(h)-372.8(F).7(un)9.8(d)-374.7(I)9.8(nt)9.8(erna)9.8(ti)9.8(on)9.8(al)9.8(.)-374.1(C)9.8(ance)9.8(r)-375.2(F)9.8(ac)9.8(ts)]TJ
1.2503 -1.1223 TD
.0082 Tc
[(an)8.2(d)-358(F)8.2(igur)8.2(e)-4.7(s)8.2(:)-362.7(W)8.2(or)8.2(ldw)8.2(i).8(de)-356(Da)8.2(ta)8.2(.)-362.2(O).4(nl)8.2(i)8.2(n)-3.3(e)-356(doc)8.2(um)8.2(ent)-357.3(a)8.2(t:)-357.3(ww)8.2(w)]TJ
0 -1.1284 TD
0 Tc
[(.)-6.2(w)-7.8(cr)-12.9(f.)-8.6(o)-6.2(r)0(g)-8.7(/)0(i)-11.3(n)-6.2(t/c)-15.7(an)-10.6(ce)-8.7(r)-8.6(-)0(f)-11(a)0(c)-8.7(t)0(s)-11(-)0()-11.6(g)-6.2(ur)-8.7(es)-9.7(/w)-13.5(or)-8.7(ld)-11.9(wi)-7.4(d)-6.2(e)0(-)-12.9(d)0(a)-10.6(t)0(a)-10(,)-170.8(ac)-8.7(c)-10.4(e)0(s)-9.7(s)0(e)-9.7(d)]TJ
0 -1.1223 TD
[(Ja)-15.8(nu)-6.4(ar)-12.9(y)-262.4(1)-6.2(,)-268.4(2)0(0)-6.4(1)-6.2(8)-6.2(.)]TJ
-1.2503 -1.1284 TD
[(3.)-500.4(SEER)-353.6(Cancer)-349.9(Stat)-348.1(Facts:)-351.7(Lung)-350.1(and)-352.3(Bronchus)-347(Cancer.)-356.1(Be-)]TJ
1.2503 -1.1223 TD
.0114 Tc
[(thesda,)-372.9(M)-.2(D:)-372.4(National)-372.4(C).4(ancer)-375.3(Institu)5.2(te.)-372.9(O)-2.5(nlin)5.2(e)-377.2(d)5.2(ocument)]TJ
0 -1.1284 TD
0 Tc
[(at)20.5(:)-396(w)0(w)21(w)0(.)22.6(s)0(e)20.8(e)0(r)17.6(.)0(c)20(a)14(nc)19.9(er)17.6(.g)24.2(ov)18(/)12.6(s)0(t)19.5(a)0(t)20.5(f)0(a)17.6(c)13.9(ts)19.5(/)12.6(h)0(t)18.6(m)12.5(l/)19.2(l)12.6(u)0(n)18(g)0(b)24.1(.)0(h)18.1(t)12.6(m)12.5(l)0(,)-383.9(a)14(cc)15.7(e)14(s)0(s)19.8(e)0(d)]TJ
0 -1.1223 TD
[(Ja)14.7(nu)24.1(ar)17.6(y)-317.3(1)0(,)-311.3(2)0(0)18(1)0(8)24.1(.)]TJ
-1.2503 -1.1284 TD
[(4.)-500.4(Yates)-393.5(JS,)-392.7(Mustian)-392.8(KM,)-391.6(Morrow)-396.7(GR,)-391(et)-388.2(al.)-394.3(Prevalence)-393.1(of)]TJ
1.2503 -1.1223 TD
[(complementary)-604.6(and)-602.4(alternative)-604(medicine)-603.8(use)-601.5(in)-603.5(cancer)]TJ
0 -1.1284 TD
[(patients)-458.3(during)-454(treatment.)-453.3(Support)-457(Care)-455.2(Cancer)-453.6(2005;13:)]TJ
0 -1.1223 TD
(806811.)Tj
-1.2503 -1.1284 TD
[(5.)-500.4(Molassiotis)-311.2(A,)-312.9(Panteli)-309.5(V,)-306.8(Patiraki)-311.9(E,)-307.1(et)-308.9(al.)-309(Complementary)]TJ
1.2503 -1.1223 TD
[(and)-242.5(alternative)-244.1(medicine)-244(use)-241.6(in)-237.6(lung)-237.9(cancer)-245.7(patients)-238.7(in)-237.6(eight)]TJ
0 -1.1284 TD
[(European)-300.4(countries.)-296.7(Complement)-299.3(Ther)-295.7(Clin)-297(Pract)-294.3(2006;12:)]TJ
0 -1.1223 TD
(3439.)Tj
-1.2503 -1.1284 TD
.0114 Tc
[(6)11.4(.)-489(Wel)11.4(l)-6(s)-494.1(M)11.4(,)-500.4(S)2.3(arna)-493.1(L,)-494.9(Co)5.2(oley)-488.9(ME,)-494.9(e)1(t)-488.3(a)1(l.)-494.9(Use)-493.1(o)5.2(f)-497.3(c)1(o)5.2(m)-.5(pl)11.4(e-)]TJ
1.2503 -1.1223 TD
.0101 Tc
[(mentary)-600(a)-.3(nd)-600(alt)10.1(e)-12.1(rna)-6.4(t)10.1(i)-7.3(v)-2.2(e)-598.1(m)10.1(e)-12.3(d)3.9(icine)-598.1(t)-1.7(herapies)-599.1(t)10.1(o)-605.6(control)]TJ
0 -1.1284 TD
.0115 Tc
[(symp)5.3(tom)11.5(s)-268(in)-263.1(wo)5.3(men)-263.1(liv)5.3(ing)-263.1(w)3.7(ith)-263.1(l)11.5(u)-6.5(ng)-263.1(can)5.3(cer.)-263(Cancer)-259.3(Nurs)]TJ
0 -1.1223 TD
.0122 Tc
[(200)6(7;3)6(0)-.1(:4)6(5)6(55.)]TJ
-1.2503 -1.1284 TD
0 Tc
[(7.)-500.4(Micke)-367.7(O,)-361.6(Buntzel)-366.8(J,)-359.2(Kisters)-366.1(K,)-361.6(et)-363.8(al.)-363.8(Complementary)-367.3(and)]TJ
1.2503 -1.1223 TD
[(alternative)-414.9(medicine)-414.8(in)-414.5(lung)-408.7(cancer)-410.4(patients:)-415.2(A)-410.4(neglected)]TJ
0 -1.1284 TD
[(phenomenon?)-337.1(Front)-334.7(Radiat)-336.2(Ther)-338.4(Oncol)-335.3(2010;42:198205.)]TJ
-1.2503 -1.1223 TD
[(8.)-500.4(Bauml)-271(J,)-273.8(Langer)-269.7(CJ,)-272.6(Evans)-268.2(T,)-270.5(et)-272.3(al.)-272.4(Does)-267.7(perceived)-276(control)]TJ
1.2503 -1.1284 TD
[(predict)-529(complementary)-525.3(and)-523.1(alternative)-524.7(medicine)-524.5(\(CAM\))]TJ
0 -1.1223 TD
[(use)-497.8(among)-498.5(patients)-501(with)-495(lung)-500.1(cancer?)-500.1(A)-495.8(cross-sectional)]TJ
0 -1.1284 TD
[(survey.)-335.9(Support)-335(Care)-333.3(Cancer)-337.8(2014;22:24652472.)]TJ
-1.2503 -1.1223 TD
[(9.)-500.4(Sierpina)-391.8(V,)-392.1(Levine)-388.7(L,)-392.5(McKee)-392.3(J,)-383.6(et)-394.3(al.)-388.2(Nutrition,)-387.2(metabo-)]TJ
1.2503 -1.1284 TD
[(lism,)-443.4(and)-437.7(integrative)-441.2(approaches)-446.7(in)-432.8(cancer.)-447(Semin)-439.9(Oncol)]TJ
T*
[(Nurs)-339.1(2015;31:4252.)]TJ
-1.7505 -1.1223 TD
[(10.)-500.5(Mao)-491.8(JJ,)-492.6(Cohen)-491.6(L.)-490(Advancing)-492.6(the)-492(science)-498.2(of)-490.5(integrative)]TJ
1.7505 -1.1284 TD
[(oncology)-352.5(to)-353.5(inform)-352.2(patient-centered)-353.2(care)-357.1(for)-352.7(cancer)-349.4(survi-)]TJ
0 -1.1223 TD
[(vors.)-337.5(J)-334.7(Natl)-334.6(Cancer)-337.8(Inst)-330.8(Monogr)-337.9(2014;2014:283284.)]TJ
-1.7505 -1.1284 TD
[(11.)-500.5(World)-366.7(Cancer)-374.3(Research)-365.8(Fund/American)-373.5(Institute)-364.5(for)-371(Can-)]TJ
1.7505 -1.1223 TD
[(cer)-511.3(Research.)-518.3(Continuous)-510.4(Update)-510.4(Project)-513.6(Expert)-515(Report)]TJ
0 -1.1284 TD
[(2018.)-384.9(Diet,)-389.5(Nutrition,)-387.2(Physical)-388.6(Activity)-382.8(and)-388.9(Lung)-386.7(cancer.)]TJ
0 -1.1223 TD
[(On)16.4(l)12.6(i)12.6(n)0(e)-315.6(d)0(o)18(c)14(um)18.4(en)19.9(t)-322.8(a)0(t)20.5(:)-328.9(di)24.7(et)20.5(an)19.9(dc)19.9(an)19.9(ce)21.8(rr)19.5(ep)19.9(or)21.8(t)12.6(.)0(o)18.1(r)0(g)21.8(,)-323.3(ac)15.7(c)14(e)0(s)20.8(s)0(e)20.8(d)-329.5(J)12.9(u)0(n)18(e)]TJ
0 -1.1284 TD
[(1,)-311.3(20)18(18)24.1(.)]TJ
-1.7505 -1.1223 TD
[(12.)-500.5(Vieira)-365.8(AR,)-360.5(Abar)-356.3(L,)-362(Vingeliene)-361.6(S,)-356.9(et)-357.7(al.)-363.8(Fruits,)-357.9(vegetables)]TJ
1.7505 -1.1284 TD
[(and)-614.6(lung)-616(cancer)-617.7(risk:)-617(A)-611.6(systematic)-620.1(review)-616.4(and)-614.6(meta-)]TJ
0 -1.1223 TD
[(analysis.)-336.1(Ann)-337.5(Oncol)-335.3(2015;27:8196.)]TJ
-1.7505 -1.1284 TD
[(13.)-500.5(Yu)-306.8(N,)-312.9(Su)-302(X,)-306.8(Wang)-308(Z,)-307.1(et)-308.9(al.)-309(Association)-307(of)-307.6(dietary)-309.5(vitamin)]TJ
1.7505 -1.1223 TD
[(A)-434.8(and)]TJ
/F14 1 Tf
3.0313 0 TD
(b)Tj
/F5 1 Tf
.5489 0 TD
[(-carotene)-436.9(intake)-435.1(with)-428(the)-437.1(risk)-428.4(of)-429.6(lung)-433(cancer:)-434.3(A)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(868)Tj
46.3849 0 TD
[(FRENKEL)-338(ET)-338.7(AL.)]TJ
ET
endstream
endobj
95 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.2951 0 0 9.2951 76.0252 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(meta-analysis)-444.1(of)-435.6(19)-433.3(publications.)-434(Nutrients)-439.8(2015;7:9309)]TJ
0 -1.1223 TD
(9324.)Tj
-1.7505 -1.1284 TD
[(14.)-500.5(Woo)-431.7(HD,)-430.5(Kim)-434(J.)-432.4(Dietary)-433(avonoid)-428.5(intake)-435.1(and)-431.6(smoking-)]TJ
1.7505 -1.1223 TD
[(related)-490.5(cancer)-489.7(risk:)-482.8(A)-483.5(meta-analysis.)-492.9(PLoS)-484(One)-488.1(2013;8:)]TJ
0 -1.1283 TD
(e75604.)Tj
-1.7505 -1.1223 TD
[(15.)-500.5(Tang)-403.1(NP,)-395.2(Zhou)-398.9(B,)-401.4(Wang)-399.5(B,)-401.5(et)-400.4(al.)-400.4(Flavonoids)-396.9(intake)-398.5(and)]TJ
1.7505 -1.1284 TD
[(risk)-257.6(of)-258.8(lung)-256.2(cancer:)-263.6(A)-257.9(m)12.5(et)20.5(a-)17.6(a)14(n)0(a)19.9(l)0(y)18.6(s)12.9(is)19.5(.)-244(J)0(p)18.9(n)-244.1(J)-249.3(C)13.4(li)19.2(n)-244.1(O)0(n)16.4(c)14(ol)-237.6(20)24.1(09)18(;)]TJ
0 -1.1223 TD
-.0241 Tc
[(3)-24.1(9)-6.1(:)-11.5(3)-24.1(5)-6.1(2)-24.1(3)-24.1(59)-24.1(.)]TJ
-1.7505 -1.1284 TD
0 Tc
[(16.)-500.5(Gnagnarella)-246.8(P,)-241(Maisonneuve)-243.8(P,)-241(Bellomi)-239.6(M,)-243.4(et)-241.8(al.)-241.9(Red)-241.2(meat,)]TJ
1.7505 -1.1223 TD
[(Mediterranean)-599(diet)-589.2(and)-590.2(lung)-591.6(cancer)-593.3(risk)-593.1(among)-590(heavy)]TJ
0 -1.1284 TD
[(smokers)-590.9(in)-585.2(the)-589.6(COSMOS)-593.3(screening)-588.1(study.)-584.9(Ann)-593.6(Oncol)]TJ
0 -1.1223 TD
(2013;24:26062611.)Tj
-1.7505 -1.1284 TD
[(17.)-500.5(Mart)]TJ
3.6778 .0427 TD
()Tj
.305 -.0427 TD
(nez-Gonza)Tj
3.9584 .0427 TD
()Tj
.3843 -.0427 TD
[(lez)-276.6(MA.)-281.8(Benets)-277.9(of)-277.1(the)-278.5(Mediterranean)-281.8(diet)]TJ
-6.575 -1.1284 TD
[(beyond)-407.6(the)-406.6(Mediterranean)-409.9(Sea)-408.2(and)-407.2(beyond)-407.6(food)-405.4(patterns.)]TJ
0 -1.1223 TD
[(BMC)-338.6(Med)-333.3(2016;14:157.)]TJ
-1.7505 -1.1284 TD
[(18.)-500.5(Maisonneuve)-359.7(P,)-363(Shivappa)-353.5(N,)-361.6(He)]TJ
14.8577 .0427 TD
()Tj
.3843 -.0427 TD
[(bert)-360.3(JR,)-358(et)-357.7(al.)-357.7(Dietary)-359.8(in-)]TJ
-13.4915 -1.1223 TD
[(ammatory)-355.1(index)-345.9(and)-352.3(risk)-349.1(of)-350.3(lung)-347.7(cancer)-355.5(and)-346.2(other)-354.3(respi-)]TJ
0 -1.1284 TD
[(ratory)-411.7(conditions)-405.6(among)-407.1(heavy)-405.6(smokers)-407.9(in)-408.4(the)-406.6(COSMOS)]TJ
0 -1.1223 TD
[(screening)-338(study.)-334.8(Eur)-334(J)-334.7(Nutr)-333.3(2016;55:10691079.)]TJ
-1.7505 -1.1284 TD
[(19.)-500.5(Fortes)-283.3(C,)-279.5(Forastiere)-287.9(F,)-277.6(Farchi)-282.3(S,)-277.6(et)-284.5(al.)-278.5(The)-281(protective)-283(effect)]TJ
1.7505 -1.1223 TD
[(of)-527.1(the)-528.6(Mediterranean)-531.9(diet)-528.2(on)-530.9(lung)-524.5(cancer.)-532.4(Nutr)-528.4(Cancer)]TJ
0 -1.1284 TD
(2003;46:3037.)Tj
-1.7505 -1.1223 TD
[(20.)-500.5(Frenkel)-392.2(M,)-383.7(Abrams)-391.9(D,)-386(Ladas)-388.3(E,)-386.4(et)-388.2(al.)-382.1(Integrating)-391.1(dietary)]TJ
1.7505 -1.1284 TD
[(supplements)-311.6(into)-310.5(cancer)-306.7(care.)-314.5(Integr)-308(Cancer)-313.4(Ther)-307.9(2013;12:)]TJ
0 -1.1223 TD
(369384.)Tj
-1.7505 -1.1284 TD
[(21.)-500.5(Frenkel)-434.9(M.)-432.5(Is)-434.8(there)-437.8(a)-431.3(role)-433.5(for)-432(nutritional)-432.2(supplements)-439.7(in)]TJ
1.7505 -1.1223 TD
[(cancer)-337.2(care?)-337(Future)-339.1(Oncol)-335.3(2015;11:901904.)]TJ
-1.7505 -1.1284 TD
[(22.)-500.5(Corte)]TJ
3.5985 .0427 TD
()Tj
.3843 -.0427 TD
(s-Jofre)Tj
2.3299 .0427 TD
()Tj
.738 -.0427 TD
[(M,)-347.1(Rueda)-355.5(JR,)-351.9(Corsini-Mun)]TJ
10.7956 .0122 TD
()Tj
.4208 -.0122 TD
[(oz)-346(G,)-355.5(et)-345.5(al.)-351.6(Drugs)]TJ
-16.5167 -1.1223 TD
[(for)-517.4(preventing)-517.3(lung)-512.3(cancer)-520.2(in)-512(healthy)-520.6(people.)-515(Cochrane)]TJ
0 -1.1284 TD
[(Database)-341.4(Syst)-331.4(Rev)-338.8(2012;10:CD002141.)]TJ
-1.7505 -1.1223 TD
[(23.)-500.5(Luo)-392.7(J,)-389.7(Shen)-391.9(L,)-392.5(Zheng)-391.1(D.)-392.1(Association)-392.3(between)-398.9(vitamin)-393.4(C)]TJ
1.7505 -1.1284 TD
[(intake)-282.6(and)-279.1(lung)-274.5(cancer:)-281.9(A)-282.3(dose-response)-278.8(meta-analysis.)-285.6(Sci)]TJ
0 -1.1223 TD
[(Rep)-338.8(2014;4:6161.)]TJ
-1.7505 -1.1284 TD
[(24.)-500.5(Zhu)-368.3(YJ,)-360.9(Bo)-364.9(YC,)-366.6(Liu)-361.6(XX,)-363.4(Qiu)-367.4(CG.)-360.5(Association)-367.9(of)-362.5(dietary)]TJ
1.7505 -1.1223 TD
[(vitamin)-295.8(E)-294.8(intake)-294.8(with)-293.8(risk)-294.2(of)-295.4(lung)-292.8(cancer:)-300.2(A)-294.5(dose-response)]TJ
0 -1.1284 TD
[(meta-analysis.)-340.4(Asia)-334.3(Pac)-335(J)-334.7(Clin)-333.6(Nutr)-333.3(2017;26:271277.)]TJ
-1.7505 -1.1223 TD
[(25.)-500.5(Yasueda)-307.1(A,)-306.8(Urushima)-306.2(H,)-306.8(Ito)-301(T.)-307.1(Efcacy)-307.4(and)-303.5(interaction)-307(of)]TJ
1.7505 -1.1284 TD
[(antioxidant)-629.8(supplements)-622.7(as)-625.7(adjuvant)-624.5(therapy)-621.1(in)-627.9(cancer)]TJ
0 -1.1223 TD
[(treatment:)-367.4(A)-361.6(systematic)-370(review.)-366.4(Integr)-362.9(Cancer)-368.2(Ther)-362.8(2016;)]TJ
0 -1.1284 TD
(15:1739.)Tj
-1.7505 -1.1223 TD
.012 Tc
[(2)12(6)12(.)-488.5(Jatoi)-335.2(A)-1.9(,)-341.8(W)1.4(i)12(l)-5.4(liam)12(s)-346.8(BA,)-335.7(M).4(arks)-341(R,)-341.8(et)-335.2(al)12(.)-347.5(E)3.9(xpl)12(o)-6(r)3.4(ing)-335.8(v)-.3(it)12(amin)]TJ
1.7505 -1.1284 TD
.0111 Tc
[(and)-483.1(m)-.8(ineral)-488.6(s)11.1(u)-6.6(pp)4.9(lemen)4.9(t)-.7(atio)4.9(n)-489.2(a).7(n)4.9(d)-489.2(pu)4.9(rported)-483.1(c).7(lin)4.9(ical)-488.6(ef-)]TJ
0 -1.1223 TD
.0108 Tc
[(fect)10.8(s)-305.2(i)-1(n)-294.3(p)-1.5(atients)-299.5(w)3(ith)-294.3(small)-293.7(cell)-299.8(l)10.8(u)-7.2(n)-1.5(g)-294.3(cancer:)-299.8(R)-.2(esults)-299.5(from)]TJ
0 -1.1284 TD
.0103 Tc
[(the)-250.2(M)-1.3(ayo)-252.1(C)-.7(li)10.3(n)-7.7(i)-1.5(c)-250.2(l)-1.5(ung)-252.1(c)-.1(a)-6.2(n)4.1(cer)-254.4(cohort.)-252(N)-3.6(utr)-254.4(C)-.7(anc)-6.2(e)-.1(r)-248.3(2005;51:)]TJ
0 -1.1223 TD
.0123 Tc
[(71)6.1(2.)]TJ
-1.7505 -1.1284 TD
0 Tc
[(27.)-500.5(Jatoi)-326.2(A,)-325.1(Williams)-329.4(B,)-328.3(Nichols)-321.9(F,)-326.4(et)-327.2(al.)-327.3(Is)-325(voluntary)-323.8(vitamin)]TJ
1.7505 -1.1284 TD
[(and)-504.8(mineral)-504.2(supplementation)-505.2(associated)-503.3(with)-501.1(better)-504.5(out-)]TJ
0 -1.1223 TD
[(come)-337.9(in)-335.2(non-small)-334.7(cell)-337.2(lung)-335.5(cancer)-337.2(patients?)-334.6(Results)-342.5(from)]TJ
0 -1.1284 TD
[(the)-278.5(Mayo)-278.5(Clinic)-282.6(lung)-274.5(cancer)-282.3(cohort.)-275.3(Lung)-276.9(Cancer)-282.9(2005;49:)]TJ
0 -1.1223 TD
(7784.)Tj
-1.7505 -1.1284 TD
[(28.)-500.5(Jaakkola)-256.3(K,)-258(La)]TJ
7.4167 .0244 TD
()Tj
.3843 -.0244 TD
(hteenma)Tj
3.0252 .0244 TD
()Tj
.3843 -.0244 TD
[(ki)-249.8(P,)-259.3(Laakso)-254.3(J,)-255.5(et)-254(al.)-254.1(Treatment)-260.5(with)]TJ
-9.4599 -1.1223 TD
[(antioxidant)-453(and)-443.8(other)-445.8(nutrients)-450.5(in)-445(combination)-447(with)-446.2(che-)]TJ
0 -1.1284 TD
[(motherapy)-377(and)-376.7(irradiation)-372.2(in)-371.8(patients)-379(with)-373.1(small-cell)-378.7(lung)]TJ
0 -1.1223 TD
[(cancer.)-337.3(Anticancer)-338.2(Res)-337.9(1992;12:599606.)]TJ
-1.7505 -1.1284 TD
[(29.)-500.5(Pathak)-469(AK,)-461(Bhutani)-466.3(M,)-463(Guleria)-463.5(R,)-468.5(et)-461.4(al.)-467.5(Chemotherapy)]TJ
1.7505 -1.1223 TD
[(alone)-466(vs.)-456.9(chemotherapy)-465.1(plus)-456.6(high)-463.5(dose)-455.2(multiple)-466.2(antioxi-)]TJ
0 -1.1284 TD
[(dants)-290.1(in)-286.4(patients)-293.6(with)-287.7(advanced)-292.5(non)-287.1(small)-289.1(cell)-288.4(lung)-292.8(cancer.)]TJ
0 -1.1223 TD
[(J)-334.7(A)0(m)-336.9(Coll)-333.6(Nutr)-333.3(2005;24:1621.)]TJ
-1.7505 -1.1284 TD
[(30.)-500.5(Feng)-764(Q,)-758.1(Zhang)-757(H,)-764.2(Dong)-758.5(Z,)-758.4(et)-760.2(al.)-760.3(Circulating)-758.9(25-)]TJ
1.7505 -1.1223 TD
[(hydroxyvitamin)-482.2(D)-477.5(and)-480.4(lung)-475.7(cancer)-477.5(risk)-483.3(and)-474.3(survival:)-481(A)]TJ
0 -1.1284 TD
[(dose-response)-352(meta-analysis)-352.6(of)-350.3(prospective)-350(cohort)-348.4(studies.)]TJ
0 -1.1223 TD
[(Medicine)-341.3(\(Baltimore\))-336.8(2017;96:e8613.)]TJ
-1.7505 -1.1284 TD
[(31.)-500.5(Huang)-537.1(JD,)-531.7(Dong)-532.8(CH,)-531.3(Shao)-532.2(SW,)-532.1(et)-534.6(al.)-534.6(Circulating)-533.3(25-)]TJ
1.7505 -1.1223 TD
[(hydroxyvitamin)-384.6(D)-379.9(level)-380(and)-382.8(prognosis)-379.4(of)-380.8(lung)-378.2(cancer)-386(pa-)]TJ
27.0135 70.8975 TD
[(tients:)-288.7(A)-294.5(systematic)-296.8(review)-293.2(and)-291.3(meta-analysis.)-297.8(Bull)-290.9(Cancer)]TJ
0 -1.1223 TD
(2017;104:675682.)Tj
-1.7505 -1.1284 TD
[(32.)-500.5(Liu)-270.1(J,)-267.7(Dong)-270.5(Y,)-276.3(Lu)-270.5(C,)-267.3(et)-272.3(al.)-272.4(Meta-analysis)-279.1(of)-271(the)-266.3(correlation)]TJ
1.7505 -1.1223 TD
[(between)-496.5(vitamin)-491(D)-495.8(and)-492.6(lung)-494(cancer)-495.8(risk)-495.5(and)-492.6(outcomes.)]TJ
0 -1.1283 TD
[(Oncotarget)-334(2017;8:8104081051.)]TJ
-1.7505 -1.1223 TD
[(33.)-500.5(Zhou)-295.2(W,)-291.2(Suk)-296.1(R,)-297.8(Liu)-294.5(G,)-294.6(et)-296.7(al.)-296.8(Vitamin)-297.4(D)-294.5(i)0(s)-297.7(associated)-295.9(with)]TJ
1.7505 -1.1284 TD
[(improved)-269(survival)-274(in)-274.2(early)-273.1(stage)-276(non-small)-273.7(cell)-270.1(lung)-274.5(cancer)]TJ
0 -1.1223 TD
[(patients.)-702.4(Cancer)-697.6(Epidemiol)-706.7(Biomarkers)-700.5(Prev)-699.2(2005;14:)]TJ
0 -1.1284 TD
(23032309.)Tj
-1.7505 -1.1223 TD
[(34.)-500.5(Zhou)-795.4(W,)-791.4(Heist)-797.4(RS,)-794.8(Liu)-794.6(G,)-800.8(et)-790.7(al.)-796.9(Circulating)-801.6(25-)]TJ
1.7505 -1.1284 TD
[(hydroxyvitamin)-518.8(D)-520.1(levels)-519.6(predict)-522.9(survival)-518(in)-518.1(early)-523.2(stage)]TJ
0 -1.1223 TD
[(non-small)-322.5(cell)-331.1(lung)-323.3(cancer)-331.1(patients.)-324.2(J)-328.6(Clin)-327.5(Oncol)-323.1(2007;25:)]TJ
0 -1.1284 TD
(479485.)Tj
-1.7505 -1.1284 TD
[(35.)-500.5(Heist)-693.7(RS,)-697.3(Zhou)-697.8(W,)-693.8(Wang)-698.3(Z,)-697.4(et)-693.1(al.)-699.3(Circulating)-697.9(25-)]TJ
1.7505 -1.1223 TD
[(hydroxyvitamin)-427.3(D,)-428.7(VDR)-423.1(polymorphisms,)-433.6(and)-425.5(survival)-426.5(in)]TJ
0 -1.1284 TD
[(advanced)-414.4(non-small-cell)-418.2(lung)-408.7(cancer.)-416.5(J)-414(Clin)-406.8(Oncol)-414.6(2008;)]TJ
0 -1.1223 TD
(26:55965602.)Tj
-1.7505 -1.1284 TD
[(36.)-500.5(Yang)-268.6(P,)-271.5(Cartwright)-271.1(C,)-267.3(Chan)-271.8(D,)-270.2(et)-272.3(al.)-272.4(Anticancer)-271.1(activity)-275.6(of)]TJ
1.7505 -1.1223 TD
[(sh)-563.6(oils)-571.9(against)-568.5(human)-565.6(lung)-567.2(cancer)-575(is)-566.1(associated)-570.4(with)]TJ
0 -1.1284 TD
[(changes)-317.7(in)-323(formation)-319.6(of)-319.8(PGE2)-318(and)-321.8(PGE3)-318(and)-321.8(alteration)-325.2(of)]TJ
0 -1.1223 TD
[(Akt)-330.8(phosphorylation.)-335.5(Mol)-334.6(Carcinog)-339.4(2014;53:566577.)]TJ
9.2951 0 0 9.2951 310.8472 505.4739 Tm
[(37.)-500.5(Deliseo)-316.4(D,)-319(Velotti)-321.7(F.)-314.2(Omega-3)-317.9(fatty)-323.3(acids)-318.7(and)-315.7(cancer)-318.9(cell)]TJ
1.7505 -1.1223 TD
[(cytotoxicity:)-500.9(Implications)-496.8(for)-499.1(multi-targeted)-503.9(cancer)-495.8(ther-)]TJ
0 -1.1284 TD
[(apy.)-334.1(J)-334.7(Clin)-333.6(Med)-333.3(2016;5)-335.8(pii:)-328.2(E15.)]TJ
-1.7505 -1.1223 TD
[(38.)-500.5(Yin)-294.2(Y,)-294.6(Sui)-289.4(C,)-297.8(Meng)-290.7(F,)-295.9(et)-296.7(al.)-290.7(The)-293.2(omega-3)-298(polyunsaturated)]TJ
1.7505 -1.1284 TD
[(fatty)-408.6(acid)-404.9(docosahexaenoic)-416.3(acid)-411(inhibits)-406.6(proliferation)-411.4(and)]TJ
0 -1.1223 TD
[(progression)-300.9(of)-301.5(non-small)-304.2(cell)-306.7(lung)-298.9(cancer)-306.7(cells)-306(through)-301.6(the)]TJ
0 -1.1284 TD
[(reactive)-287.5(oxygen)-291.7(species-mediated)-294.3(inactivation)-292(of)-289.3(the)-284.6(PI3K/)]TJ
0 -1.1223 TD
[(Akt)-330.8(pathway.)-339.9(Lipids)-330.1(Health)-339.1(Dis)-336(2017;16:87.)]TJ
-1.7505 -1.1284 TD
[(39.)-500.5(Murphy)-331.8(RA,)-336.1(Mourtzakis)-338.8(M,)-334.9(Chu)-334.6(QS,)-334.2(et)-333.3(al.)-333.4(Nutritional)-342.3(in-)]TJ
1.7505 -1.1223 TD
[(tervention)-333.7(with)-330.4(sh)-331.8(oil)-334.7(provides)-335.6(a)-327.6(benet)-334.9(over)-336.5(standard)-333.7(of)]TJ
0 -1.1284 TD
[(care)-375.4(for)-371(weight)-371.5(and)-376.7(skeletal)-377.1(muscle)-373.3(mass)-374.6(in)-371.8(patients)-372.9(with)]TJ
0 -1.1223 TD
[(nonsmall)-320.1(cell)-318.9(lung)-317.2(cancer)-325(receiving)-320.1(chemotherapy.)-324.9(Cancer)]TJ
0 -1.1284 TD
(2011;117:17751782.)Tj
-1.7505 -1.1223 TD
[(40.)-500.5(van)-388.9(der)-385.1(Meij)-393.2(BS,)-386.2(Langius)-389.9(JA,)-391.4(Smit)-386.2(EF,)-389.4(et)-388.2(al.)-388.2(Oral)-392.4(nutri-)]TJ
1.7505 -1.1284 TD
[(tional)-436.4(supplements)-439.7(containing)-441.2(\(n-3\))-434.6(polyunsaturated)-441.5(fatty)]TJ
0 -1.1223 TD
[(acids)-349.2(affect)-346.9(the)-351.7(nutritional)-346.8(status)-349.8(of)-344.2(patients)-348.5(with)-348.7(stage)-349.2(III)]TJ
0 -1.1284 TD
[(non-small)-292(cell)-288.4(lung)-292.8(cancer)-288.4(during)-289.3(multimodality)-294.6(treatment.)]TJ
0 -1.1223 TD
[(J)-334.7(Nutr)-333.3(2010;140:17741780.)]TJ
-1.7505 -1.1284 TD
[(41.)-500.5(Finocchiaro)-298.9(C,)-297.8(Segre)-294.9(O,)-294.6(Fadda)-298.7(M,)-298.3(et)-296.7(al.)-296.8(Effect)-301.9(of)-295.4(n-3)-295.5(fatty)]TJ
1.7505 -1.1223 TD
[(acids)-471.2(on)-463.8(patients)-470.5(with)-470.6(advanced)-475.4(lung)-463.5(cancer:)-477(A)-465.3(double-)]TJ
0 -1.1284 TD
[(blind,)-402.2(placebo-controlled)-416.4(study.)-401.9(Br)-409.9(J)-401.8(Nutr)-406.5(2012;108:327)]TJ
0 -1.1223 TD
(333.)Tj
-1.7505 -1.1284 TD
[(42.)-500.5(Yun)-288.7(M,)-286.1(Kim)-287.7(EO,)-290.5(Lee)-291.3(D,)-288.5(et)-290.6(al.)-290.7(Melatonin)-287.8(sensitizes)-296.4(H1975)]TJ
1.7505 -1.1223 TD
[(non-small-cell)-680.5(lung)-683.1(cancer)-684.8(cells)-678(harboring)-686.6(a)-675.3(T790)-167.1(M-)]TJ
0 -1.1284 TD
[(targeted)-380.9(epidermal)-386.7(growth)-382.3(factor)-379.3(receptor)-383.8(mutation)-381.4(to)-384(the)]TJ
T*
[(tyrosine)-469.2(kinase)-477.5(inhibitor)-471(getinib.)-476.3(Cell)-472(Physiol)-471.5(Biochem)]TJ
0 -1.1223 TD
(2014;34:865872.)Tj
-1.7505 -1.1284 TD
[(43.)-500.5(Zhou)-374.5(Q,)-379.9(Gui)-379.6(S,)-375.2(Zhou)-380.6(Q,)-379.9(Wang)-375.1(Y.)-379.9(Melatonin)-379.3(inhibits)-382.2(the)]TJ
1.7505 -1.1223 TD
[(migration)-365.5(of)-368.6(human)-370.5(lung)-366(adenocarcinoma)-370.2(A549)-368.1(cell)-367.7(lines)]TJ
0 -1.1284 TD
[(involving)-908.4(JNK/MAPK)-917(pathway.)-913.2(PLoS)-910.9(One)-915(2014;9:)]TJ
0 -1.1223 TD
(e101132.)Tj
-1.7505 -1.1284 TD
[(44.)-500.5(Plaimee)-588.3(P,)-588.6(Weerapreeyakul)-596.8(N,)-587.3(Barusrux)-593.3(S,)-588.6(Johns)-590.6(NP.)]TJ
1.7505 -1.1223 TD
[(Melatonin)-379.3(potentiates)-383.1(cisplatin-induced)-383.8(apoptosis)-380.8(and)-376.7(cell)]TJ
0 -1.1284 TD
[(cycle)-567.8(arrest)-573.6(in)-566.9(human)-565.6(lung)-573.3(adenocarcinoma)-571.4(cells.)-568.3(Cell)]TJ
0 -1.1223 TD
[(Prolif)-330.5(2015;48:6777.)]TJ
-1.7505 -1.1284 TD
[(45.)-500.5(Lissoni)-329.3(P,)-332.5(Chilelli)-336.6(M,)-328.8(Villa)-334.1(S,)-332.5(et)-327.2(al.)-333.4(Five)-336.5(years)-333.8(survival)-328.9(in)]TJ
1.7505 -1.1223 TD
[(metastatic)-344(non-small)-340.8(cell)-337.2(lung)-341.6(cancer)-343.3(patients)-342.4(treated)-338.1(with)]TJ
0 -1.1284 TD
[(chemotherapy)-520(alone)-527(or)-514.9(chemotherapy)-526.1(and)-523.1(melatonin:)-519.5(A)]TJ
0 -1.1223 TD
[(randomized)-332.6(trial.)-335(J)-334.7(Pineal)-334.3(Res)-337.9(2003;35:1215.)]TJ
-1.7505 -1.1284 TD
[(46.)-500.5(Sookprasert)-241.8(A,)-245.8(Johns)-236.8(NP,)-242.7(Phunmanee)-248.2(A,)-239.7(et)-241.8(al.)-241.9(Melatonin)-245.1(in)]TJ
1.7505 -1.1223 TD
[(patients)-440(with)-434(cancer)-440.9(receiving)-442(chemotherapy:)-440.3(A)-440.9(random-)]TJ
0 -1.1284 TD
[(ized,)-270.8(double-blind,)-275(placebo-controlled)-276.1(trial.)-274(Anticancer)-277.2(Res)]TJ
0 -1.1223 TD
(2014;34:73277337.)Tj
/F11 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(INTEGRATIVE)-339.7(MEDICINE)-335.4(IN)-335.1(LUNG)-336.8(CANCER)-31974.3(869)]TJ
ET
endstream
endobj
169 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.2951 0 0 9.2951 62.022 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(47.)-500.5(Upton)-300.6(R,)-297.8(ed.)-297.3(Astragalus)-303.6(Root:)-303.2(Analytical,)-300.1(Quality)-303.9(Control,)]TJ
1.7505 -1.1223 TD
[(and)-462.1(Therapeutic)-460.6(Monograph.)-464.6(Santa)-456.7(Cruz,)-463.3(CA:)-463.7(American)]TJ
0 -1.1284 TD
[(Herbal)-335.9(Pharmacopoeia,)-338.3(1999:125.)]TJ
-1.7505 -1.1223 TD
[(48.)-500.5(Wang)-430(SF,)-433.1(Wang)-430(Q,)-428.7(Jiao)-430.3(LJ,)-428.3(et)-430.9(al.)-430.9(Astragalus-containing)]TJ
1.7505 -1.1283 TD
[(traditional)-265.6(Chinese)-268.9(medicine,)-268.4(with)-269.4(and)-266.9(without)-263.1(prescription)]TJ
0 -1.1223 TD
[(based)-551.1(on)-543.1(syndrome)-549.2(differentiation,)-549.6(combined)-551.4(with)-543.8(che-)]TJ
0 -1.1284 TD
[(motherapy)-590.5(for)-584.5(advanced)-591.3(non-small-cell)-589(lung)-585.5(cancer:)-592.9(A)]TJ
0 -1.1223 TD
[(systemic)-451.5(review)-445.6(and)-443.8(meta-analysis.)-456.3(Curr)-443(Oncol)-451.2(2016;23:)]TJ
0 -1.1284 TD
(e188e195.)Tj
-1.7505 -1.1223 TD
[(49.)-500.5(Hayakawa)-240.7(K,)-239.7(Mitsuhashi)-245.4(N,)-233.6(Saito)-244.5(Y,)-233.6(et)-241.8(al.)-241.9(Effect)-240.9(of)-234.4(Krestin)]TJ
1.7505 -1.1284 TD
[(as)-564.7(adjuvant)-569.6(treatment)-569.1(following)-564.6(radical)-569.8(radiotherapy)-572.9(in)]TJ
0 -1.1223 TD
[(non-small)-493.3(cell)-489.7(lung)-487.9(cancer)-495.8(patients.)-488.9(Cancer)-490.2(Detect)-495.8(Prev)]TJ
0 -1.1284 TD
(1997;21:7177.)Tj
-1.7505 -1.1284 TD
[(50.)-500.5(Fritz)-295.7(H,)-294.6(Kennedy)-297.7(DA,)-296.3(Ishii)-293.8(M,)-298.3(et)-290.6(al.)-296.8(Polysaccharide)-300.7(K)-294.5(and)]TJ
/F13 1 Tf
1.7505 -1.1223 TD
[(Coriolus)-356.8(versicolor)]TJ
/F5 1 Tf
8.2706 0 TD
[(extracts)-355.6(for)-352.7(lung)-353.8(cancer:)-361.1(A)-355.5(systematic)]TJ
-8.2706 -1.1284 TD
[(review.)-335.9(Integr)-338.5(Cancer)-331.7(Ther)-338.4(2015;14:201211.)]TJ
-1.7505 -1.1223 TD
[(51.)-500.5(Brown)-509.5(JC,)-510.5(Ligibel)-511.6(JA.)-513.4(The)-512.8(role)-512.8(of)-508.8(physical)-513.8(activity)-513.5(in)]TJ
1.7505 -1.1284 TD
[(oncology)-584.2(care.)-582.8(J)-584.8(Natl)-584.6(Cancer)-587.8(Inst)-580.9(Monogr)-588(2017;2017:)]TJ
0 -1.1223 TD
(lgx017.)Tj
-1.7505 -1.1284 TD
[(52.)-500.5(Yun)-343.6(H,)-337.3(Sun)-344.9(L,)-343.7(Mao)-339.4(JJ.)-340.1(Growth)-347.3(of)-338.1(integrative)-349.7(medicine)-341.6(at)]TJ
1.7505 -1.1223 TD
[(leading)-520.6(cancer)-526.3(centers)-520.7(between)-520.9(2009)-519(and)-523.1(2016:)-518.6(A)-520.1(sys-)]TJ
0 -1.1284 TD
[(tematic)-383.5(analysis)-384.8(of)-380.8(NCI-designated)-383.5(comprehensive)-385.1(cancer)]TJ
0 -1.1223 TD
[(center)-515.4(websites.)-514.5(J)-511.6(Natl)-511.4(Cancer)-514.6(Inst)-513.8(Monogr)-514.8(2017;2017:)]TJ
0 -1.1284 TD
(lgx004.)Tj
-1.7505 -1.1223 TD
[(53.)-500.5(Holmes)-401.2(MD,)-403.7(Chen)-406(WY,)-402.7(Feskanich)-399.6(D,)-404.3(et)-400.4(al.)-406.5(Physical)-400.8(ac-)]TJ
1.7505 -1.1284 TD
[(tivity)-510.9(and)-510.9(survival)-511.9(after)-513.3(breast)-510.3(cancer)-514.1(diagnosis.)-515(JAMA)]TJ
0 -1.1223 TD
(2005;293:24792486.)Tj
-1.7505 -1.1284 TD
[(54.)-500.5(Deng)-427.2(GE,)-418.6(Rausch)-427.9(SM,)-423.4(Jones)-424(LW,)-421.4(et)-424.8(al.)-424.8(Complementary)]TJ
1.7505 -1.1223 TD
[(therapies)-453.4(and)-456(integrative)-453.4(medicine)-457.4(in)-451(lung)-451.3(cancer:)-458.7(Diag-)]TJ
0 -1.1284 TD
[(nosis)-419.2(and)-413.3(management)-419.4(of)-417.4(lung)-420.9(cancer,)-416.5(3rd)-417.5(ed:)-418.8(American)]TJ
0 -1.1223 TD
[(College)-372.9(of)-374.7(Chest)-374.2(Physicians)-375.8(evidence-based)-381.9(clinical)-371.3(prac-)]TJ
0 -1.1284 TD
[(tice)-337.2(guidelines.)-336.7(Chest)-331.5(2013;143\(5)-338.7(Suppl\):e420Se436S.)]TJ
-1.7505 -1.1223 TD
[(55.)-500.5(Chen)-381.6(HM,)-379.4(Tsai)-377.3(CM,)-382.6(Wu)-376.7(YC,)-378.8(et)-382.1(al.)-376(Effect)-387.3(of)-374.7(walking)-383.8(on)]TJ
1.7505 -1.1284 TD
[(circadian)-403.6(rhythms)-397.9(and)-401.1(sleep)-398(quality)-399.9(of)-399.1(patients)-397.3(with)-403.6(lung)]TJ
0 -1.1223 TD
[(cancer:)-403.8(A)-404.3(randomised)-406.7(controlled)-400.8(trial.)-408.1(Br)-397.7(J)-401.8(Cancer)-410.9(2016;)]TJ
0 -1.1284 TD
(115:13041312.)Tj
-1.7505 -1.1223 TD
[(56.)-500.5(Cole)-301.8(SW,)-306.5(Nagaraja)-308(AS,)-303.7(Lutgendorf)-304.4(SK,)-303.7(et)-302.8(al.)-302.9(Sympathetic)]TJ
1.7505 -1.1284 TD
[(nervous)-543.4(system)-545.1(regulation)-547.2(of)-539.3(the)-546.9(tumour)-545(microenviron-)]TJ
0 -1.1223 TD
[(ment.)-333.2(Nat)-335(Rev)-338.8(Cancer)-331.7(2015;15:563572.)]TJ
-1.7505 -1.1284 TD
[(57.)-500.5(Blanc-Lapierre)-346.6(A,)-337.3(Rousseau)-335.8(MC,)-339.9(Weiss)-336.3(D,)-337.2(et)-339.4(al.)-339.5(Lifetime)]TJ
1.7505 -1.1223 TD
[(report)-338.5(of)-338.1(perceived)-337(stress)-339.6(at)-339.4(work)-333.8(and)-340.1(cancer)-337.2(among)-340(men:)]TJ
0 -1.1284 TD
[(A)-282.3(case-control)-289.5(study)-285.9(in)-280.3(Montreal,)-290.6(Canada.)-286.7(Prev)-284.5(Med)-284.5(2017;)]TJ
0 -1.1223 TD
(96:2835.)Tj
-1.7505 -1.1284 TD
[(58.)-500.5(Holland)-280.1(JC.)-272.6(Psycho-Oncology,)-278.3(Second)-280.5(Edition.)-275.7(New)-276.2(York:)]TJ
1.7505 -1.1223 TD
[(Oxford)-336.4(University)-336.3(Press,)-331.7(2010.)]TJ
-1.7505 -1.1284 TD
[(59.)-500.5(Giese-Davis)-370.5(J,)-359.2(Collie)-368(K,)-361.7(Rancourt)-369.9(KM,)-361.1(et)-363.8(al.)-363.8(Decrease)-372.9(in)]TJ
1.7505 -1.1284 TD
[(depression)-351.4(symptoms)-345.6(is)-352.6(associated)-350.8(with)-348.7(longer)-348.4(survival)-353.3(in)]TJ
0 -1.1223 TD
[(patients)-342.4(with)-342.6(metastatic)-350.1(breast)-345.6(cancer:)-342.8(A)-343.3(secondary)-344.7(analy-)]TJ
0 -1.1284 TD
[(sis.)-333.6(J)-334.7(Clin)-333.6(Oncol)-335.3(2011;29:413420.)]TJ
-1.7505 -1.1223 TD
[(60.)-500.5(Spiegel)-377.1(D.)-373.8(Mind)-377.4(matters)-375.2(in)-377.9(cancer)-373.8(survival.)-377.8(JAMA)-380.3(2011;)]TJ
1.7505 -1.1284 TD
(305:502503.)Tj
-1.7505 -1.1223 TD
[(61.)-500.5(Thaker)-538(PH,)-541.6(Han)-536.8(LY,)-540.6(Kamat)-540.3(AA,)-540.3(et)-540.6(al.)-534.6(Chronic)-542.4(stress)]TJ
1.7505 -1.1284 TD
[(promotes)-255.9(tumor)-258.2(growth)-254.3(and)-254.7(angiogenesis)-261.5(in)-249.8(a)-260.5(mouse)-253.7(model)]TJ
0 -1.1223 TD
[(of)-332(ovarian)-334.4(carcinoma.)-342.8(Nat)-335(Med)-333.3(2006;12:939944.)]TJ
-1.7505 -1.1284 TD
[(62.)-500.5(Sloan)-434.2(EK,)-430.8(Priceman)-432.7(SJ,)-429.3(Cox)-432.2(BF,)-428.9(et)-430.9(al.)-430.9(The)-433.5(sympathetic)]TJ
1.7505 -1.1223 TD
[(nervous)-555.6(system)-551.2(induces)-550.8(a)-553.3(metastatic)-557.5(switch)-553.5(in)-554.7(primary)]TJ
0 -1.1284 TD
[(breast)-333.4(cancer.)-337.2(Cancer)-337.8(Res)-337.9(2010;70:70427052.)]TJ
-1.7505 -1.1223 TD
[(63.)-500.5(Ben-Arye)-374.3(E,)-374.2(Schiff)-371.9(E,)-374.2(Zollman)-377.6(C,)-371(et)-369.9(al.)-376(Integrating)-372.8(com-)]TJ
1.7505 -1.1284 TD
[(plementary)-594.2(medicine)-597.7(in)-591.3(supportive)-597.6(cancer)-599.4(care)-594.9(models)]TJ
0 -1.1223 TD
[(across)-339.2(four)-328.5(continents.)-336.7(Med)-339.4(Oncol)-335.3(2013;30:511.)]TJ
-1.7505 -1.1284 TD
[(64.)-500.5(Frenkel)-239.7(M,)-237.3(Cohen)-235.4(L,)-240(Peterson)-239(N,)-239.7(et)-235.7(al.)-235.8(Integrative)-242.8(medicine)]TJ
1.7505 -1.1223 TD
[(consultation)-598.6(service)-593.9(in)-591.3(a)-596(comprehensive)-598.6(cancer)-593.3(center:)]TJ
27.0074 68.6469 TD
[(Findings)-459.5(and)-456(outcomes.)-459.1(Integr)-454.4(Cancer)-459.7(Ther)-460.3(2010;9:276)]TJ
0 -1.1223 TD
(283.)Tj
-1.7505 -1.1284 TD
[(65.)-500.5(Balar)-247.4(AV,)-241.4(Weber)-241.5(JS.)-240.2(PD-1)-239.1(and)-242.5(PD-L1)-241.2(antibodies)-245.1(in)-243.7(cancer:)]TJ
1.7505 -1.1223 TD
[(Current)-380(status)-374.2(and)-370.6(future)-375.1(directions.)-375.6(Cancer)-380.4(Immunol)-374(Im-)]TJ
0 -1.1283 TD
[(munother)-336(2017;66:551564.)]TJ
-1.7505 -1.1223 TD
[(66.)-500.5(Rapoport)-444.9(BL,)-446.2(van)-443.8(Eeden)-444.1(R,)-444.1(Sibaud)-446.5(V,)-440.9(et)-443.1(al.)-443.1(Supportive)]TJ
1.7505 -1.1284 TD
[(care)-302.2(for)-297.8(patients)-299.7(undergoing)-294.1(immunotherapy.)-297.4(Support)-298.4(Care)]TJ
0 -1.1223 TD
[(Cancer)-337.7(2017;25:30173030.)]TJ
-1.7505 -1.1284 TD
[(67.)-500.5(Thronicke)-367.1(A,)-367.8(Steele)-362.9(ML,)-367.5(Grah)-362.4(C,)-364.9(et)-363.8(al.)-363.8(Clinical)-365.8(safety)-363.9(of)]TJ
1.7505 -1.1223 TD
[(combined)-533.1(therapy)-535.7(of)-527.1(immune)-534.3(checkpoint)-531.4(inhibitors)-537.3(and)]TJ
/F13 1 Tf
0 -1.1284 TD
[(Viscum)-549.9(album)]TJ
/F5 1 Tf
6.5323 0 TD
[(L.)-544.9(therapy)-547.9(in)-542.5(patients)-543.7(with)-543.8(advanced)-542.5(or)]TJ
-6.5323 -1.1223 TD
[(metastatic)-283(cancer.)-276.3(BMC)-277.6(Complement)-281(Altern)-276.2(Med)-278.4(2017;17:)]TJ
0 -1.1284 TD
(534.)Tj
-1.7505 -1.1284 TD
[(68.)-500.5(Sivan)-379.3(A,)-373.8(Corrales)-383.5(L,)-374.2(Hubert)-380.5(N,)-373.8(et)-376(al.)-376(Commensal)-378.1(Bido-)]TJ
1.7505 -1.1223 TD
[(bacterium)-618.5(promotes)-609.6(antitumor)-609.5(immunity)-614.6(and)-608.5(facilitates)]TJ
0 -1.1284 TD
[(anti-PD-L1)-338.8(efcacy.)-340.3(Science)-337.3(2015;350:10841089.)]TJ
-1.7505 -1.1223 TD
[(69.)-500.5(Vetizou)-424.6(M,)-426.4(Pitt)-422.6(JM,)-419.6(Daillere)-430.7(R,)-419.7(et)-424.8(al.)-418.7(Anticancer)-429.7(immu-)]TJ
1.7505 -1.1284 TD
[(notherapy)-444.5(by)-439.4(CTLA-4)-446.4(blockade)-446.3(relies)-442.6(on)-439.4(the)-443.2(gut)-439(micro-)]TJ
0 -1.1223 TD
[(biota.)-339.3(Science)-337.3(2015;350:10791084.)]TJ
-1.7505 -1.1284 TD
[(70.)-500.5(Gopalakrishnan)-358.1(V,)-349.4(Spencer)-354.3(CN,)-348.3(Nezi)-357.7(L,)-349.8(et)-351.6(al.)-351.6(Gut)-349.1(micro-)]TJ
1.7505 -1.1223 TD
[(biome)-333.3(modulates)-330.5(response)-333.4(to)-329.1(anti-PD-1)-330.6(immunotherapy)-333.9(in)]TJ
0 -1.1284 TD
[(melanoma)-341.7(patients.)-336.4(Science)-337.3(2018;359:97103.)]TJ
-1.7505 -1.1223 TD
[(71.)-500.5(Pitt)-532.4(JM,)-535.5(Vetizou)-534.4(M,)-530.1(Waldschmitt)-541.4(N,)-532.4(et)-528.5(al.)-534.6(Fine-tuning)]TJ
1.7505 -1.1284 TD
[(cancer)-556.7(immunotherapy:)-553(optimizing)-551.9(the)-546.9(gut)-548.8(microbiome.)]TJ
0 -1.1223 TD
[(Cancer)-337.7(Res)-337.9(2016;76:46024607.)]TJ
-1.7505 -1.1284 TD
[(72.)-500.5(Sierpina)-300.3(VS,)-297.6(Frenkel)-294.6(MA.)-300.1(Acupuncture:)-297.7(A)-294.5(clinical)-304.3(review.)]TJ
1.7505 -1.1223 TD
[(Southern)-339.4(Med)-333.3(J)-334.7(2005;98:330337.)]TJ
-1.7505 -1.1284 TD
[(73.)-500.5(Rossi)-497.2(E,)-502.2(Vita)-493.1(A,)-495.8(Baccetti)-502.9(S,)-497.1(et)-498(al.)-498(Complementary)-501.5(and)]TJ
1.7505 -1.1223 TD
[(alternative)-555.2(medicine)-548.9(for)-547.9(cancer)-550.6(patients:)-549.4(Results)-549.9(of)-545.4(the)]TJ
0 -1.1284 TD
[(EPAAC)-324.5(survey)-323.7(on)-317.4(integrative)-319.2(oncology)-322(centres)-325.6(in)-316.9(Europe.)]TJ
0 -1.1223 TD
[(Support)-335(Care)-339.4(Cancer)-337.8(2015;23:17951806.)]TJ
-1.7505 -1.1284 TD
[(74.)-500.5(Zia)-420.7(FZ,)-413.8(Olaku)-420.7(O,)-416.5(Bao)-418.1(T,)-416.9(et)-418.7(al.)-418.7(The)-415.2(National)-418.1(Cancer)-423.1(In-)]TJ
1.7505 -1.1223 TD
[(stitutes)-467.3(Conference)-466.8(on)-457.7(Acupuncture)-468.9(for)-456.4(Symptom)-466(Man-)]TJ
0 -1.1284 TD
[(agement)-342(in)-329.1(Oncology:)-341.4(State)-334.1(of)-332(the)-339.5(Science,)-337.4(Evidence,)-338.4(and)]TJ
0 -1.1223 TD
[(Research)-542.6(Gaps.)-542.3(J)-536(Natl)-535.8(Cancer)-539(Inst)-538.2(Monogr)-539.2(2017;2017:)]TJ
0 -1.1284 TD
(lgx005.)Tj
-1.7505 -1.1223 TD
[(75.)-500.5(Kasymjanova)-312.8(G,)-306.8(Grossman)-312(M,)-304.4(Tran)-307.9(T,)-307.1(et)-308.9(al.)-302.9(The)-311.5(potential)]TJ
9.2951 0 0 9.2951 329.329 338.1165 Tm
[(role)-342(for)-334.4(acupuncture)-337.3(in)-335.2(treating)-339.5(symptoms)-339.5(in)-335.2(patients)-336.3(with)]TJ
T*
[(lung)-597.7(cancer:)-592.9(An)-593.5(observational)-599.8(longitudinal)-594.7(study.)-591(Curr)]TJ
0 -1.1284 TD
[(Oncol)-335.3(2013;20:152157.)]TJ
-1.7505 -1.1223 TD
[(76.)-500.5(Cheng)-509.9(CS,)-508.2(Chen)-509.7(LY,)-504(Ning)-507.8(ZY,)-510.1(et)-504.1(al.)-510.2(Acupuncture)-511.6(for)]TJ
1.7505 -1.1284 TD
[(cancer-related)-409.3(fatigue)-394.9(in)-396.2(lung)-402.6(cancer)-398.2(patients:)-396.9(A)-398.2(random-)]TJ
0 -1.1223 TD
[(ized,)-435.4(double)-431.5(blind,)-432.7(placebo-controlled)-440.7(pilot)-432(trial.)-432.5(Support)]TJ
0 -1.1284 TD
[(Care)-339.4(Cancer)-337.8(2017;25:38073814.)]TJ
-1.7505 -1.1223 TD
[(77.)-500.5(Minchom)-473.1(A,)-471.4(Punwani)-472.7(R,)-468.5(Filshie)-469(J,)-469(et)-473.6(al.)-467.5(A)-471.4(randomised)]TJ
1.7505 -1.1284 TD
[(study)-365.2(comparing)-364.8(the)-357.8(effectiveness)-366.2(of)-362.5(acupuncture)-367.8(or)-362.5(mor-)]TJ
T*
[(phine)-339.8(versus)-341.1(the)-333.4(combination)-337.2(for)-340.5(the)-339.5(relief)-336(of)-338.1(dyspnoea)-338.1(in)]TJ
0 -1.1223 TD
[(patients)-568.1(with)-568.2(advanced)-566.9(non-small)-566.5(cell)-569(lung)-567.2(cancer)-568.9(and)]TJ
0 -1.1284 TD
[(mesothelioma.)-340.3(Eur)-334(J)-334.7(Cancer)-337.8(2016;61:102110.)]TJ
-1.7505 -1.1223 TD
[(78.)-500.5(Frenkel)-343.4(M.)-334.9(Is)-343.3(there)-340.2(a)-339.8(role)-335.9(for)-340.5(homeopathy)-338.2(in)-341.3(cancer)-343.3(care?)]TJ
1.7505 -1.1284 TD
[(Questions)-339.6(and)-334(challenges.)-339.6(Curr)-333.3(Oncol)-335.3(Rep)-332.7(2015;17:467.)]TJ
-1.7505 -1.1223 TD
.0121 Tc
[(7)12.1(9)12.1(.)-488.4(Samuels)-340.9(N)-1.8(,)-341.7(F)-3.1(reed)-341.8(Y,)-347.8(Weitzen)-341.8(R)-5(,)-341.7(et)-347.3(al.)-347.8(F)3(easibility)-347.9(o)5.9(f)-350.2(h)5.9(o)-.2(-)]TJ
1.7505 -1.1284 TD
[(meopathic)-455.9(treatment)-457.2(f)3.4(or)-460.1(sympto)5.8(m)-457.3(r)-2.7(educti)-5.9(o)5.8(n)-457.8(in)-457.8(an)-457.8(inte-)]TJ
0 -1.1223 TD
.0125 Tc
[(grative)-522.5(oncology)-518.3(service.)-518.2(Integr)-520.6(Cancer)-520.6(Ther)-514.5(2017;17:)]TJ
0 -1.1284 TD
.0123 Tc
(486492.)Tj
-1.7505 -1.1223 TD
0 Tc
[(80.)-500.5(Frass)-465.8(M,)-463(Friehs)-460.2(H,)-465.3(Thallinger)-463.7(C,)-456.3(et)-467.5(al.)-461.4(Inuence)-464.2(of)-460.1(ad-)]TJ
1.7505 -1.1284 TD
[(junctive)-386(classical)-386.7(homeopathy)-387(on)-378.4(global)-382.1(health)-386.3(status)-386.4(and)]TJ
0 -1.1223 TD
[(subjective)-346.9(wellbeing)-351.1(in)-341.3(cancer)-343.3(patientsA)-350.5(pragmatic)-344(ran-)]TJ
0 -1.1284 TD
[(domized)-350(controlled)-352(trial.)-353.3(Complement)-348.1(Ther)-350.6(Med)-351.6(2015;23:)]TJ
0 -1.1223 TD
(309317.)Tj
-1.7505 -1.1284 TD
[(81.)-500.5(Banerji)-283.7(P,)-271.5(Campbell)-281.2(DR,)-275.1(Banerji)-277.7(P.)-277.6(Cancer)-276.8(patients)-281.4(treated)]TJ
1.7505 -1.1223 TD
[(with)-482.8(the)-485.9(Banerji)-485(protocols)-481.5(utilizing)-484.5(homoeopathic)-488.5(medi-)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(870)Tj
46.3849 0 TD
[(FRENKEL)-338(ET)-338.7(AL.)]TJ
ET
endstream
endobj
245 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.2951 0 0 9.2951 76.0252 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(cine:)-373.9(A)-367.7(Best)-368(Case)-372.7(Series)-366.8(Program)-372.2(of)-368.6(the)-363.9(National)-375.4(Cancer)]TJ
0 -1.1223 TD
[(Institute)-340.1(USA.)-329.8(Oncology)-335.7(Rep)-338.8(2008;20:6974.)]TJ
-1.7505 -1.1284 TD
[(82.)-500.5(Gaertner)-440.3(K,)-428.7(Mu)]TJ
8.0632 .0122 TD
()Tj
.4147 -.0122 TD
[(llner)-433(M,)-432.5(Friehs)-435.8(H,)-428.7(et)-430.9(al.)-437(Additive)-432.2(home-)]TJ
-6.7275 -1.1223 TD
[(opathy)-297.3(in)-292.5(cancer)-300.6(patients:)-293.2(Retrospective)-303.8(survival)-292.3(data)-301.2(from)]TJ
0 -1.1283 TD
[(a)-309.3(homeopathic)-305.4(outpatient)-312.5(unit)-304.4(at)-308.9(the)-302.9(Medical)-310.6(University)-305.8(of)]TJ
0 -1.1223 TD
[(Vienna.)-339.7(Complement)-335.9(Ther)-332.3(Med)-333.3(2014;22:320332.)]TJ
-1.7505 -1.1284 TD
.0222 Tc
[(8)22.2(3)22.2(.)-478.3(Arts)-440.6(IC.)-441.4(A)-437(review)-437(of)-437.7(the)-439.6(e)-.4(pidemiological)-434.8(evidence)-439.6(on)]TJ
1.7505 -1.1223 TD
.0237 Tc
[(tea,)-238.6(av)5.3(o)-.8(n)5.3(o)-.8(i)5.8(d)-.8(s,)-238.6(a)7.2(n)-.8(d)-238.7(l)-.3(u)5.3(n)-.8(g)-238.7(c)7.2(ancer.)-238.6(J)-237.8(Nu)5.3(tr)-234.9(20)5.3(08)5.3(;1)5.3(38)5.3(:1)5.3(56)5.3(1S)]TJ
0 -1.1284 TD
.0234 Tc
[(15)5(66)5(S.)]TJ
-1.7505 -1.1223 TD
0 Tc
[(84.)-500.5(Howells)-299.1(LM,)-294.3(Mahale)-298.8(J,)-292.1(Sale)-291.9(S,)-295.9(et)-296.7(al.)-290.7(Translating)-298.3(curcumin)]TJ
1.7505 -1.1284 TD
[(to)-353.5(the)-351.7(clinic)-355.2(for)-352.7(lung)-347.7(cancer)-355.5(prevention:)-358.3(Evaluation)-351.6(of)-350.3(the)]TJ
0 -1.1223 TD
[(preclinical)-451.5(evidence)-450.5(for)-444.2(its)-443.6(utility)-443.4(in)-445(primary,)-448.1(secondary,)]TJ
0 -1.1284 TD
[(and)-443.8(tertiary)-445.5(prevention)-450.2(strategies.)-446(J)-444.5(Pharmacol)-445.1(Exp)-441.5(Ther)]TJ
T*
(2014;350:483494.)Tj
-1.7505 -1.1223 TD
[(85.)-500.5(Attoub)-281.9(S,)-271.5(Sperandio)-282.7(O,)-276.3(Raza)-280.2(H,)-276.3(et)-278.4(al.)-278.5(Thymoquinone)-281.3(as)-278.1(an)]TJ
1.7505 -1.1284 TD
[(anticancer)-359.1(agent:)-361.9(Evidence)-356.7(from)-358.5(inhibition)-352.3(of)-356.4(cancer)-361.6(cells)]TJ
0 -1.1223 TD
[(viability)-405.2(and)-401.1(invasion)-405.9(in)-396.2(vitro)-404.4(and)-401.1(tumor)-404.6(growth)-400.6(in)-402.3(vivo.)]TJ
0 -1.1284 TD
[(Fundam)-336.9(Clin)-333.6(Pharmacol)-335.3(2013;27:557569.)]TJ
-1.7505 -1.1223 TD
[(86.)-500.5(Wu)-254.7(SH,)-261(Liu)-251.8(Z.)-258.3(Soy)-253.4(food)-253(consumption)-259.5(and)-254.7(lung)-256.2(cancer)-257.9(risk:)]TJ
1.7505 -1.1284 TD
[(A)-392.1(meta-analysis)-395.3(using)-395.7(a)-388.6(common)-394.6(measure)-392.8(across)-394.1(studies.)]TJ
0 -1.1223 TD
[(Nutr)-339.4(Cancer)-331.7(2013;65:625632.)]TJ
-1.7505 -1.1284 TD
[(87.)-500.5(Myneni)-510(AA,)-503.7(Chang)-509.9(SC,)-508.2(Niu)-507.7(R,)-505.1(et)-504.1(al.)-510.2(Raw)-505(garlic)-510.6(con-)]TJ
1.7505 -1.1223 TD
[(sumption)-315.9(and)-309.6(lung)-317.2(cancer)-312.8(in)-310.8(a)-315.4(Chinese)-311.6(Population.)-318(Cancer)]TJ
0 -1.1284 TD
[(Epidemiol)-334.6(Biomarkers)-340.7(Prev)-333.3(2016;25:624633.)]TJ
25.263 25.8851 TD
[(88.)-500.5(Turrini)-482.1(E,)-490(Ferruzzi)-484.3(L,)-490(Fimognari)-484.9(C.)-486.8(Potential)-486.1(effects)-492.6(of)]TJ
1.7505 -1.1223 TD
[(pomegranate)-251.5(polyphenols)-247.7(in)-249.8(cancer)-251.8(prevention)-248.9(and)-248.6(therapy.)]TJ
0 -1.1284 TD
[(Oxid)-330.9(Med)-333.3(Cell)-337.8(Longev)-336.3(2015;2015:938475.)]TJ
-1.7505 -1.1223 TD
[(89.)-500.5(Melkonian)-404.3(SC,)-404.5(Daniel)-400.1(CR,)-406.4(Ye)-402.5(Y,)-404.3(et)-400.4(al.)-406.5(Glycemic)-404.1(Index,)]TJ
1.7505 -1.1283 TD
[(Glycemic)-446.8(Load,)-445.9(and)-449.9(Lung)-447.7(Cancer)-447.5(Risk)-449.1(in)-445(Non-Hispanic)]TJ
0 -1.1223 TD
[(Whites.)-355.1(Cancer)-362.1(Epidemiol)-352.9(Biomarkers)-359(Prev)-357.7(2016;25:532)]TJ
0 -1.1284 TD
(539.)Tj
-1.7505 -1.1223 TD
[(90.)-500.5(Majeed)-542.8(F,)-545.9(Malik)-539.8(FZ,)-541.9(Ahmed)-548.9(Z,)-538.8(et)-546.8(al.)-540.7(Ginseng)-548.2(phyto-)]TJ
1.7505 -1.1284 TD
[(chemicals)-247.4(as)-247.6(therapeutics)-250.1(in)-249.8(oncology:)-242.2(Recent)-249.5(perspectives.)]TJ
0 -1.1223 TD
[(Biomed)-332.1(Pharmacother)-342.3(2018;100:5263.)]TJ
-1.7505 -1.1284 TD
[(91.)-500.5(Sun)-424.2(AS,)-425.7(Ostadal)-429.8(O,)-428.7(Ryznar)-425(V,)-428.7(et)-424.8(al.)-424.8(Phase)-432(I/II)-427.8(study)-426.2(of)]TJ
1.7505 -1.1223 TD
[(stage)-245.5(III)-245.3(and)-248.6(IV)-248.1(non-small)-243.2(cell)-251.8(lung)-244(cancer)-251.8(patients)-244.8(taking)-247.9(a)]TJ
0 -1.1284 TD
[(specic)-332.2(dietary)-340(supplement.)-336.8(Nutr)-333.3(Cancer)-337.8(1999;34:6269.)]TJ
9.843 0 0 9.843 435.0046 571.2377 Tm
[(Address)-331.9(for)-337.3(correspondence:)]TJ
/F13 1 Tf
3.4155 -1.1116 TD
[(Moshe)-335.9(Frenkel,)-338.3(MD)]TJ
-4.8842 -1.1116 TD
[(Department)-337.7(of)-330.6(Family)-338.4(Medicine)]TJ
-9.0658 -1.1174 TD
[(The)-332.6(University)-343.7(of)-330.6(Texas)-335.8(Medical)-339.7(Branch)-331.3(at)-336.4(Galveston)]TJ
16.4267 -1.1116 TD
[(Hashoftim)-340.2(1)-168.1(B)]TJ
-6.1629 -1.1116 TD
[(Zichron)-331.2(Yaacov)-337.1(30900)-333.8(Israel)]TJ
6.1341 -1.1174 TD
[(Galveston,)-339.2(TX)]TJ
-8.0924 -2.1253 TD
(E-mail:)Tj
/F5 1 Tf
3.3925 0 TD
(frenkelm@netvision.net.il)Tj
/F11 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(INTEGRATIVE)-339.7(MEDICINE)-335.4(IN)-335.1(LUNG)-336.8(CANCER)-31974.3(871)]TJ
ET
endstream
endobj
275 0 obj
<>stream
8;X]O>EqN@%''O_@%e@?J;%+8(9e>X=MR6S?i^YgA3=].HDXF.R$lIL@"pJ+EP(%0
b]6ajmNZn*!='OQZeQ^Y*,=]?C.B+\Ulg9dhD*"iC[;*=3`oP1[!S^)?1)IZ4dup`
E1r!/,*0[*9.aFIR2&b-C#soRZ7Dl%MLY\.?d>Mn
6%Q2oYfNRF$$+ON<+]RUJmC0InDZ4OTs0S!saG>GGKUlQ*Q?45:CI&4J'_2j$XKrcYp0n+Xl_nU*O(
l[$6Nn+Z_Nq0]s7hs]`XX1nZ8&94a\~>
endstream
endobj
278 0 obj
<>stream
hބU
PT~{/@؋C$
GQ@,*
,"*D]@ğT#&VE[ AScQab28K4M:tޛ;sϹwFҺIĔEAE)sb]2_iT߉o#`y^}uQޒFSc.Yr֬-T˚̚>;صs]ܙJt9Ӥڬ31!c)9fB
_
!0@չӓv2nՓmAw:FlI*6γ2H
|3*WҗTDA#Nߧj@G[8VVl-i6n[l*ݬ.ߝxgQWd߽ۻIeYYVf+m!_:#CyF:zr8帒e E}=
tz3/xw 8I%xJ~vUuaIeKwx;x
&|P^Xت#P]Nf2 AU
94rU)V
__аƸ\?&Zؾ.1)!@
0/:jZC(
ldef<ƑNeA B]8M5]\t2&bO`6~TG:\_/Er=,W_E/玞8«jD2*6Bc0+xsMTtBJ
ӎ`ai+֭<4>m94'ތb>b,PDT$s<"7k<揼?dxWGϰK*/C|BzݽʾbCB<$~SYqMz?Tn;B&-d}? ??+G~p`}_xg2Ө@$QPs`2#F232:Ή{y\24w5[lp\\"jqr}OH<Ĝ W/uMCz[EUKXRj.iQ'ȭa~+ʋc:V؆->}uKK,b?U}shIJ- Y&;:}5XFw~{Uںm\'`T].;>%aLiũ$'}4AKkWbkqGɥovD]mFI6/eS`#WD:'psg#]gxU("xAyY {E(Z]tcb(.Zvl"{g@x߇W'&3cv D)8
endstream
endobj
280 0 obj
<>stream
h\WyTSg轉ERWuVT[jETٕ-$KX} vE*.բTVNgnl眙99}}>\OϾ#o]+.;Xz@+ ǟr,rQE}(_TrEZãuOzR*NL"VX-u+gOUѮScJ<>U&:v:].ǭvI$ w((^/Db(V$ŧJSD qZ\/(6-n}T$澓eıRqlyp?#=x/xxM